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Abstract 
Tuberculosis is primarily a pulmonary condition caused by Mycobacterium tuberculosis, 
which causes a serious threat to human health. In 2016 more than 1.3 million people died of 
tuberculosis, meanwhile there were 10.4 million new infections worldwide. Treatment for 
tuberculosis currently takes a minimum of 6 months with a combination of four different 
antibiotics, but there is increasing resistance to the first line antibiotics. The second line 
antibiotics include the fluoroquinolones (moxifloxacin, levofloxacin and gatifloxacin), which 
target DNA gyrase, the only Type IIA topoisomerase in M. tuberculosis, of which there is 
limited structural and biochemical information available within the literature. 
 
To address these problems, we sought to increase our knowledge of mycobacterial DNA 
gyrase through biochemical mechanistic studies, inhibition studies of known and novel 
inhibitors of DNA gyrase alongside structural studies by X-ray crystallography. This led us to 
determine that a fusion of the GyrB and GyrA subunits was fully active and, in some cases, 
potentially more active than using the individual subunits. In particular, we determined that a 
detectable and greater rate of ATPase activity was present in Mtb DNA gyrase than previously 
suggested. We found this rate to be highly DNA-dependent requiring a topologically 
unconstrained DNA substrate (linear or nicked plasmid) for the highest rates. In addition, we 
cloned, expressed, purified and partially characterised DNA gyrase from the thermophilic M. 
thermoresistibile for use in structural studies. 
 
In investigating the novel tricyclic group of compounds optimised by Redx AntiInfectives, we 
determined that they act in a similar mechanism of action to novobiocin through biochemical 
studies. They differ in their binding pocket, as determined by X-ray crystallography, and 
mechanism of resistance, as determined by bacterial mutagenesis.  
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1. Introduction 
1.1 Tuberculosis 
In 2017 tuberculosis was the 9th biggest killer worldwide, and the biggest killer via an 
infectious agent (WHO, 2018a). In 2016 there were an estimated 10.4 million new cases of 
tuberculosis causing approximately 1.3 million deaths in HIV-negative patients. Within these 
cases an estimated 558,000 new cases were classified as drug-resistant with approximately 
82% of these being multidrug-resistant (resistant to 2 or more of the first line drugs). These 
were most prevalent in China, India and the Russian federation (WHO, 2018a) (Figure 1.1.1). 
 
 
Figure 1.1.1: World map of the estimated new tuberculosis cases recorded per 100,000 population in 
2017, indicating the worst affected areas to be south-east Asia and sub-Saharan Africa. Figure 
reproduced from Figure 3.4 (WHO, 2018a). 
 
Tuberculosis is caused by the bacterium Mycobacterium tuberculosis (Mtb). Primarily it 
causes a pulmonary disease which spreads as an airborne pathogen. The difficulty with Mtb 
is that it commonly infects without resulting in an active infection (Styblo, 1980, Comstock, 
1982). This non-active latent disease state is formed when the bacteria become encased in an 
immune response causing a granuloma to form in the lower respiratory tract. In this latent state 
of infection, the patient is unable to spread the disease, nor do they experience any symptoms. 
There are several different known pathologies of the granuloma but the classical caseous 
granuloma is the most widely studied. In this case the Mtb is surrounded by immune cells 
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including macrophages and dendritic cells, which are encased by both B and T cells. It is 
thought that fibroblasts encase the whole structure (Barry et al., 2009) (Figure 1.1.2). 
 
 
Figure 1.1.2: Cartoon representation of a representation of a classical granuloma containing M. 
tuberculosis typically found in the lungs. The M. tuberculosis cells are encased within or surrounded 
by macrophages which are surrounded by foam cells and dendritic cells. This layer of immune cells is 
then encapsulated by T and B cells. The M. tuberculosis inside the granuloma appear to enter a dormant 
state where they are not actively replicating, nor have they been killed. Adapted from (Ramakrishnan, 
2012) and (Cadena et al., 2017). 
 
In many cases the patient will die from other causes unaware that they were infected with 
latent tuberculosis, however, in a percentage of cases the infection will progress into an active 
disease state causing tuberculosis (Saunders and Britton, 2007). It is more common for the 
infection to progress to an active disease state in patients that become immuno-compromised, 
and especially those who are co-infected with HIV/AIDS (Selwyn et al., 1989). Currently, 
there is no clear evidence as to what causes the progression of the disease from a latent to an 
active disease state. For the most part even if a latent disease is discovered it is left untreated 
until an active infection is detected. This is largely because there is a major issue with 
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incomplete treatment of latent infections causing resistance, and complications treating any 
subsequent infections. 
 
1.2 Current treatments 
The current BCG vaccination programme was introduced in 1921, and is generally accepted 
to be only between 60-80% effective against the most severe forms of childhood meningitis 
tuberculosis infections, and less effective in pulmonary infections (Trunz et al., 2006, 
Rodrigues et al., 2011, Roy et al., 2014). As the disease burden cannot be fully prevented even 
through complete vaccination, it is important to have effective treatments for those cases that 
are able to occur. At present there is only one approved standard course of treatment against 
tuberculosis – this is known as DOTS (directly observed treatment, short course) which 
consists of treatment via isoniazid and rifampicin for 6 months and additional treatment with 
pyrazinamide and ethambutol for the first 2 months (or longer as removal requires the 
pathogenic strain to be first identified as fully drug-sensitive) (WHO, 2010). Where a person 
is deemed to have drug-resistant TB they are treated using second line anti-tuberculosis 
treatments including a fluoroquinolone such as moxifloxacin or levofloxacin (WHO, 2010). 
It is recommended wherever possible to use different drugs from unique drug classes 
depending on the sensitivity of the infection (Table 1.2.1). Where the susceptibility of a drug 
is unknown it should be assumed that the strain is susceptible, but once resistance has been 
confirmed, drugs should not be used if there is a possibility of cross-resistance (WHO, 2010). 
 
1.2.1 Treatment for co-infection with HIV/AIDS 
With an estimated 374,000 tuberculosis deaths being in the patient group that were co-infected 
with HIV/AIDS in 2016, it is highly important to keep developing new strategies for treating 
these patients (WHO, 2017). However, there are additional challenges faced when treating 
patients who are co-infected with both tuberculosis and HIV/AIDS. This is primarily due to 
drug interactions between the anti-tuberculosis and anti-viral treatments leading to decreased 
efficiency of the drugs alongside increased toxicity (Zumla et al., 2013). Currently, it is 
recommended that all patients begin a course of the DOTS tuberculosis treatments as above, 
alongside a treatment program of co-trimoxazole and anti-retroviral treatment to treat the HIV 
infection (WHO, 2010). This has led to a drive to create a novel treatment plan for those co-
infected to treat susceptible strains in this patient group. 
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Table 1.2.1: Treatment groups of drugs against tuberculosis defined to be drug-resistant. Table adapted 
from Table 2 (WHO, 2018c). 
Group Drug 
A: Include all three medicines Levofloxacin OR Moxifloxacin 
Bedaquiline 
Linezolid 
B: Add one or both medicines Clofazimine 
Cycloserine OR Terizidone 
C: Add to complete the regimen and when 
medicines from Groups A and B cannot be 
used 
Ethambutol 
Delamanid 
Pyrazinamide 
Imienem-Cilastatin OR Meropenem 
Amikacin (OR Streptomycin) 
Ethionamide OR Prothionamide 
p-aminosalicyclic acid 
 
1.2.2 Treatment of latent tuberculosis 
Recent estimates predict that approximately 23% of the world population is currently infected 
with latent tuberculosis (LBTI) (Houben and Dodd, 2016). As discussed in section 1.1, LBTI 
is an asymptomatic state where the infective agent (M. tuberculosis) is encased and non-
transmissible. In this state there is no immediate risk to the patient therefore treatment is not 
imperative. It is only recommended to treat a fraction of LTBI cases where there is a greater 
risk of developing the active disease, these include those with a HIV infection and those in 
low burden countries who are currently in prison, homeless or are illicit drug users (WHO, 
2015). The currently used programme to treat LTBI is currently a 6-9 month course of 
isoniazid or a shorter 3-month course using a combination of rifampicin or rifapentine 
alongside isoniazid (Esmail et al., 2012, Esmail et al., 2014, WHO, 2015). The major issue 
with these treatment programmes is that because isoniazid mainly kills only replicated bacilli, 
it therefore may not kill the potentially non-replicating bacteria in the granuloma (Fox et al., 
1999). 
 
1.3 Mycobacterial infections 
Apart from tuberculosis there are several other infectious species within the Mycobacteria 
genus. These include infections such as bovine tuberculosis (M. bovis) and marine tuberculosis 
(M. marinum) alongside less infective environmental mycobacteria such as M. smegmatis. 
This gives the opportunity to study less infective bacteria in the laboratory in the place of M. 
tuberculosis as they contain several unusual properties as well as giving the option to look at 
homologues of proteins and enzymes. 
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1.3.1 Mycobacterial properties 
Amongst the unusual properties of Mycobacteria is the distinctly slower growth rate than 
typical laboratory bacteria such as Escherichia coli. Typically, the doubling time for 
Mycobacteria is in the range of several hours to several days rather than around half an hour 
for E. coli (Cole et al., 2001, Cox, 2003). This has been determined for M. tuberculosis to be 
about 72 times slower whilst in log-phase (Musuka et al., 2013). Many of the Mycobacterial 
enzymes are significantly slower in their functions and reduced in redundancy than those 
found in faster growing species, however, the debate remains of whether this is result or cause 
of the slower growth rate (Harshey and Ramakrishnan, 1977, Hiriyanna and Ramakrishnan, 
1986, Stephan et al., 2005). Additionally, several traditionally essential genes, which cause 
lethal knockouts in other bacteria are found not to be present at all within the Mycobacterial 
genome (Bercovier et al., 1986, Stephan et al., 2005). One particularly noticeable example is 
in the topoisomerases where only two have been functionally annotated within the genome 
although a third was at one point postulated (Cole et al., 1998, Jain and Nagaraja, 2005). 
 
Secondly, Mycobacteria are defined as Gram-intermediate (Reynolds et al., 2009) due to the 
presence of their unusual cell wall which is made of the very hydrophobic lipid – mycolic acid 
(Figure 1.3.1). This has an extensive synthesis mechanism which has been exploited as a drug 
target. The lipidic nature of the mycolic acid cell wall structure also makes mycobacterial cells 
very hydrophobic. This unique cell wall structure, like that of the outer membrane of Gram-
negative bacteria, also provides a useful function to the cell in modulating entry of potentially 
lethal compounds to the cells (Nikaido, 2001). Although, some molecules will still make it 
across the membrane the numbers are greatly decreased, and with an effective efflux system 
it means that although some molecules may effectively kill the function of an essential protein, 
they will not be active against whole cells unless they can actively cross the membrane. 
Limiting the range of effectiveness of several compounds against TB and other mycobacterial 
infections (Nikaido, 2001). This also means that there is the possibility of making a 
mycobacterial specific inhibitor which can permeate the mycolic acid cell wall efficiently but 
possibly with a lower degree of specificity to penetrate through other bacterial membranes. 
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Figure 1.3.1: Cartoon representation of the Mycobacterial cell membrane and wall. The cytoplasmic or 
cell membrane is covered by a layer of peptidoglycan as with many other bacteria. The mycobacterial 
membrane then differs as this peptidoglycan membrane is further covered with a layer of arabinan and 
galactan which is additionally decorated with mycolic acids. This combination makes it very 
hydrophobic and difficult to penetrate. 
 
1.3.2 Latent infections and granuloma formation 
Granuloma is described by the Merrium-Webster medical dictionary (2018) as the “mass or 
nodule of chronically infected tissue with granulations that is usually associated with an 
infective process”. Although traditionally granuloma are primarily associated with 
tuberculosis infections, a wide range of bacterial and fungal species can cause them in both 
the human lungs and in other organs and species. However, they are a significant feature of 
mycobacterial infections forming in multiple different organs. For example, a M. marinum 
human infection commonly causes granuloma below the skin in what is known as “swimming 
pool granuloma”, but also causes these formations in their native fish hosts (Zumla and James, 
1996). Typically, M. tuberculosis infections are initially isolated within granuloma most 
commonly within the lungs of infected patients long before any active infection may be 
discovered. This type of infection is difficult to identify in the lungs as a granuloma type 
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infection is commonly asymptomatic, with the current best method available for identifying 
the M. tuberculosis granuloma being the tuberculin skin test where a hypersensitivity response 
is observed in those with a latent infection (Esmail et al., 2012, Lardizabal and Reichman, 
2017). 
 
Over recent years there have been developments into increasing our understanding 
classification of the granuloma and disease progression, although this is still not fully 
understood. However, the major importance of the granuloma is to provide an immune state 
in which the bacteria are surrounded by immune cells to contain the infection, but not eradicate 
the infection meaning that the infection can be induced at a later time, for example if a patient 
becomes immunocompromised in later life (Flynn and Chan, 2001). Furthermore, while the 
bacteria are contained within a granuloma it is thought that they have a significantly lower 
metabolic rate, which significantly decreases the effect of many antibiotics on them (Norton 
and Holland, 2012). Currently the preferred treatment for LBTI is a monotherapy course of 
isoniazid for 6 months, although shorter 3 months treatment courses of rifampicin or 
rifapentine with isoniazid in high TB incidence countries may be considered. These additional 
options along with a 3-4 months course of rifampicin monotherapy may be considered in low 
TB incidence countries (WHO, 2018b). 
 
1.3.3 Mycobacterium smegmatis as a homologue 
M. smegmatis was first identified in 1884, it is a common environmental mycobacterium 
which is rarely found to be a human pathogen (Tsukamura, 1976). On the few occasions when 
it has been identified as a human pathogen, it has mostly been described as forming skin 
lesions around wound sites (Newton et al., 1993, Shimizu, 2012, Saffo and Ognjan, 2016). In 
only one case it was described to be like a typical M. tuberculosis lung infection (Vonmoos et 
al., 1986) and once described as a systemic infection leading to death of an immune-deficient 
child (Pierre-Audigier et al., 1997). Interestingly, there has also been a canine case described 
within the literature (Grooters et al., 1995), although it is not normally a human or animal 
pathogen. 
 
In addition to its potential to cause tuberculosis like infections, M. smegmatis has significant 
advantages as a laboratory bacterium as a surrogate. The major difference is that M. smegmatis 
is classed as a fast-growing Mycobacterium, which means that it has a doubling time in the 
order of hours not days (Cox, 2003), whilst maintaining a similar cell wall structure and having 
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a high degree of sequence homology within essential genes. This is underlined in the fact that 
M. smegmatis is classified within group 4 of the Runyon classification of mycobacteria with 
the other rapid growers (Runyon, 1959). The combination of the decreased pathogenicity, 
pathogenicity control and increased growth rate, makes M. smegmatis an ideal laboratory 
bacterium to use to study the effect of compounds on growing mycobacteria. 
 
1.3.4 Mycobacterium thermoresistibile as a homologue 
M. thermoresistibile is a thermophilic opportunistic pathogenic bacterium first described in 
1966 (Tsukamura, 1966). Although the infection is relatively unheard of, 6 human and 2 feline 
infection reports have been described in the literature. The first human infection was described 
in 1981, within a female patient suffering from a tuberculosis-like infection with Langhans 
type granulomas which were successfully treated with rifampicin, ethambutol, and 
streptomycin (Weitzman et al., 1981). As in many of the cases that have been described, the 
bacterial growth appears like that of M. tuberculosis except much faster with growth able to 
occur at 45°C, with viable growth recorded up to 52°C (Tsukamura, 1971, Weitzman et al., 
1981). Although, the initial case seemed to occur in a healthy individual several of the other 
case reports have occurred in individuals with significant health issues including diabetes 
mellitus. Furthermore, by no means is this disease limited to the lungs, as only two cases in 
humans and one in cats have been isolated as a pulmonary disease (Weitzman et al., 1981, Liu 
et al., 1984, Foster et al., 1999). The second feline case was described primarily as having 
granuloma dermatitis, with skin lesions containing the bacterium (Willemse et al., 1985). A 
similar case to this was found 3 months post-heart transplant near to the surgical scar, and 
importantly in this case the bacterium was found to be isoniazid-resistant (Neeley and 
Denning, 1989). The final three recorded cases were all associated with external implants with 
lesions or granuloma-type structures forming around the implant sites with the implants all 
being removed retrospectively. These were a mammoplasty implant (Wolfe and Moore, 1992), 
knee replacement (LaBombardi et al., 2005) and surgical pin post tibia fracture (Suy et al., 
2013). All of these infections were successfully identified and treated using long term 
combination therapies. 
 
Recently, the advantage of using thermophilic homologues to generate more stable enzymes 
has been routinely employed to gain improved structural and biochemical data. The use of M. 
thermoresistibile as a source of mycobacterial thermophilic homologues was first described 
in 2012 (Edwards et al., 2012). Their reason for suggesting it as a homologue was due to its 
increased thermal stability due to its ability to grow at a higher temperature range than M. 
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tuberculosis while exhibiting similar infection symptoms as described above. At present, there 
are 35 entries in the protein data bank of structures of proteins from M. thermoresistibile 
including the structures of alpha-1,4-glucan:maltose-1-phosphate maltosyltransferase (GlgE) 
(Mendes et al., 2015) and nitrilotriacetate monooxygenase component B (Zhang et al., 2011). 
 
Like M. smegmatis there is a high degree of conservation within the cell wall structure and 
good sequence homology in the essential genes with those from M. tuberculosis. Likewise, 
there is a high sequence homology between the gyrase genes with 91% identity in the GyrA 
and 88% in the GyrB protein sequences, as compared to 43% identity GyrA and 48% identity 
GyrB to the P. aeruginosa enzymes (Figure 1.3.2). This makes the M. thermoresistibile DNA 
gyrase homologues interesting candidates for both structural and mechanistic studies.  
 
 
Figure 1.3.2: Phylogenetic tree of DNA gyrase B based on sequence from M. tuberculosis H37Rv. 
Alignment and sequence comparison made using BLASTn function of NCBI webserver, with distances 
being estimated via the same server. Alignment shows very little divergence in the DNA gyrase B gene 
within the Mycobacterium genus. Gram-negative Pseudomonas aeruginosa is included as a reference 
point. 
 
1.3.5 Mycobacterial biofilms 
Although our modern understanding of biofilms was formed as recently as 1978 (Costerton et 
al., 1978), mycobacteria have been described for much longer as forming “aggregates” in 
solution, which are similar in nature to what we now think of as a biofilm (Löwenstein, 1920, 
Calmette, 1936). Furthermore, it has been known for a number of years that environmental 
mycobacteria are able to form biofilms, for example M. avium biofilms have been observed 
within the water pipes of large cities (Falkinham et al., 2001, Norton et al., 2004). Unusually, 
these mycobacterial biofilms form on both on surfaces as well as at the air-media boundary. 
This is in part due to the unique highly lipophilic mycolic acid cell wall that is present in all 
mycobacteria and allows mycobacteria to adhere to each other and surfaces (Ojha et al., 2008, 
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Richards and Ojha, 2014). These biofilms formed by mycobacteria must have different 
characteristics to biofilms produced by other bacterial species as they lack several of the key 
components that promote biofilms in other species. These include the pili and fimbriae, as 
well as exopolysaccharide components of the extracellular matrix (Menozzi et al., 1996, 
Zamora et al., 2007). 
 
The first known report of M. tuberculosis biofilms created within a laboratory system came in 
2008 (Ojha et al., 2008). There have also been historical cases presented in the literature where 
M. tuberculosis has been attributed as the cause for biofilm-like structures on implants 
(Spinner et al., 1996, Sendi and Brent, 2016). However, only recently it has been demonstrated 
that within an in vitro granuloma model, that M. tuberculosis is capable of forming biofilms 
with a requirement for the presence of MmpL (mycobacterial membrane protein large). 
Although this has not been demonstrated in vivo, it suggests that mycobacterial biofilms may 
be important in the granuloma state. Indeed, there have been reports of non-tuberculosis 
mycobacterial species colonising the lungs sights of scarring caused by previous infections in 
a biofilm type infection (Wolinsky, 1979). These infections first form a biofilm then can 
colonise the host causing repeated infections. These repeat infections are likely to be because 
of increased resistance of the biofilm phenotype to antibiotics, which has been reported to be 
up to >100,000-fold increase in the MBEC (minimum biofilm eradication concentration) value 
compared to the MIC100 value in four rapidly growing mycobacterial species (Munoz-Egea et 
al., 2015). Overall, this makes the phenomena of mycobacterial biofilms a highly interesting 
and clinically relevant target to study to find new antimycobacterial agents that can effectively 
kill biofilms in addition to whole cells. 
 
1.4 DNA topology 
DNA topology is the three-dimensional geometry of DNA, typically this is thought of on the 
level of supercoiling within the cells – the ability of DNA to over or under-wind to produce 
more compact structures. However, the topic also covers knotting and catenation – how 
different pieces of DNA are intertwined. These topics are highly relevant when considering 
repilication, transcription, and recombination of DNA, where the three-dimensional shape of 
the DNA is highly relevant in the initiation and propagation of all three processes. 
 
In the absence of topoisomerases, the process of DNA replication would not be able to occur 
as positive supercoils would build up ahead of the replication fork. As replication approaches 
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the terminus there is a decreased amount of space for the positive supercoils to form, and 
hence a build-up of precatenanes occurs after the replication fork (Figure 1.4.1) (Postow et 
al., 2001). Both of these features are highly dangerous for the cell if not resolved. In bacteria 
the relaxation of positive supercoils is processed mainly by DNA gyrase, which subsequently 
introduces negative supercoils into the DNA (Baker et al., 1986), although topo IV is also able 
to remove positive supercoils (Khodursky et al., 2000). In the absence of topo IV, DNA gyrase 
is solely responsible for this process in mycobacteria (Figure 1.4.1) (Manjunatha et al., 2002, 
Aubry et al., 2006a). On the other hand the precatenanes that are formed after the replication 
fork are commonly resolved by the type I topoisomerase topo III if there are nicks present in 
the DNA (Hiasa and Marians, 1994, Nurse et al., 2003) or alternatively by topo IV 
(Zechiedrich and Cozzarelli, 1995), but, as neither of these enzymes are present in 
mycobacteria, it is DNA gyrase and topo I that must instead work together to resolve these 
structures (Figure 1.4.1). The daughter chromosomes produced by bacterial transcription are 
often found to be catenated, and hence must be decatenated before completion of cell division 
can occur (Wasserman and Cozzarelli, 1986). These catenanes are thought to be most 
commonly decatenated by topo IV (Adams et al., 1992, Zechiedrich and Cozzarelli, 1995), 
although there is evidence that DNA gyrase is also capable of doing this as well (Steck and 
Drlica, 1984).  
 
 
Figure 1.4.1: Topology diagram at the replication fork indicating the need for topoisomerases to remove 
the positive supercoils that accumulate before the replication fork and the precatenanes that associate 
after the replication fork. As M. tuberculosis does not have topo III or topo IV it relies on its remaining 
two topoisomerases, DNA gyrase and topo I, to remove the precatenanes and solely on DNA gyrase to 
remove the positive supercoils. Figure adapted from (Postow et al., 2001) and (Higgins, 2007). 
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The second process where topoisomerases are crucial is in that of transcription. This is the 
process by which double-stranded DNA is opened to allow binding of RNA polymerase which 
allows mRNA to be transcribed for processing by the ribosome (Figure 1.4.2). When the DNA 
is opened it creates positive supercoils ahead of transcription and negative supercoils behind 
transcription as the RNA polymerase complex is unable to move around the DNA, hence the 
DNA moves around RNA polymerase; this process is known as creating “Twin Supercoiled 
Domains” (Liu and Wang, 1987, Wu et al., 1988). The twinned supercoiled domains need to 
be resolved to ensure that the plasmid maintains an optimal negative supercoiled state. The 
positive supercoils ahead of transcription are relaxed by DNA gyrase and topo IV, meanwhile 
negative supercoils are introduced by DNA gyrase. The excess negative supercoils behind 
transcription are relaxed by topo I and topo IV (Zechiedrich et al., 2000). In the absence of 
both topo III and topo IV in mycobacteria the positive supercoils are resolved by DNA gyrase 
and the excess negative supercoils by topo I and to a lesser degree DNA gyrase (Cole et al., 
1998).  
 
 
Figure 1.4.2: Topology diagram at the site of transcription where the DNA is separated to give access 
to RNAP to allow mRNA to be transcribed and proteins to be made by the ribosomes. Separation of the 
DNA strands results in negative supercoils to accumulate before the site of transcription and positive 
supercoils to be introduced after the site of transcription. Figure adapted and redrawn from (Wu et al., 
1988) 
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Finally, the process of recombination by which the chromosomes are rearranged to maintain 
genetic diversity by general and site-specific methods has important implications on topology, 
as these processes can result in catenated or knotted DNA products (Abremski et al., 1983, 
Azaro and Landy, 2002). These interlinked and knotted products are resolved by the 
topoisomerase enzymes.  
 
1.5 DNA topoisomerases 
DNA topoisomerases are found in all domains of life and can be broadly split into two 
different classes which are known as type I and type II topoisomerases, depending on whether 
they cleave one or two stands of double stranded DNA in the process of altering DNA 
topology. These classes can be further split depending on structural and mechanistic features 
of the enzymes (Table 1.5.1). 
 
1.5.1 Type IA topoisomerases 
Type I topoisomerases cause transient single-stranded breaks in DNA. The type IA enzyme 
family have a 5' phosphate attachment to DNA during the process of single-strand breakage 
(Champoux, 2002). They do this with a preference for binding to a short single-stranded region 
of DNA within negatively supercoiled DNA (Wang, 2002). This group of topoisomerases 
share a common TOPRIM domain that is also found in type II topoisomerases and in the 
DnaG-type primases (Aravind et al., 1998). This family of topoisomerases are only able to 
relax negatively-supercoiled and not positively-supercoiled DNA as they are only able to 
unpair the helix of negatively supercoiled DNA to produce a single-stranded region 
(Kirkegaard and Wang, 1985). 
 
There are several enzymes classified into this group including bacterial topoisomerase I (topo 
I), and topoisomerase III (topo III) which is found in all three life kingdoms (Wang, 2002), as 
well as reverse gyrase which is exclusively found in thermophilic and hyperthermophilic 
eubacteria (Lulchev and Klostermeier, 2014). One point of note is that topo III, which 
traditionally is a relaxing and decatenation enzyme of DNA, has also been found to have the 
ability to cleave and relax RNA, making it one of the only known RNA topoisomerases (Wang 
et al., 1996). 
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Table 1.5.1: Classification of DNA topoisomerases, with reference to reactions that each group is 
known to carry out, and where each of the topoisomerases are known to be present. Classification is 
mainly based on structural and mechanistic features. 
Classification Reactions Enzymes Species 
Type IA Relax negative supercoil 
Decatenate ssDNA 
Topo I Bacterial 
Topo III Eukaryotic, 
Prokaryotic, 
Archaeal 
Reverse gyrase Thermophilic/ 
Hyperthermophilic 
archaea 
Type IB Relax negative and 
positive supercoils 
Topo I Eukaryotes, Virus 
Type IC Relax negative and 
positive supercoils 
Topo V Hyperthermophilic 
archaea 
Type IIA Relax negative and 
positive supercoils 
Decatenate DNA 
Topo IV Bacteria 
Topo II Eukaryotes, 
Bacteriophage 
Relax negative and 
positive supercoils 
Decatenate DNA 
Negative supercoil 
DNA gyrase Bacteria, plants and 
possibly plasmodia 
Type IIB Relax positive and 
negative supercoils 
Decatenate DNA 
Topo VI Archaea, plants and 
possibly plasmodia 
Topo VIII Bacteria, Archaea 
 
Bacterial topo I, including that from M. tuberculosis, has been described to be an efficient 
drug target, however, presently there are no clinically approved drugs against this target 
(Nagaraja et al., 2017). 
 
1.5.2 Type IB topoisomerases 
The type IB topoisomerases have major differences to the type IA topoisomerases in their 
mechanism whereby the IB enzymes attach to the 3' phosphate as opposed to the 5' phosphate 
while causing single-stranded breaks allowing for alteration in the topology of DNA 
(Champoux, 2002). The IB enzymes, in contrast to the IA enzymes prefer binding to duplex 
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DNA after the cleavage of the single strand. This has led to the conclusion that the mechanism 
of action is through “controlled rotation”, by which the protein provides a controlled 
environment where a nicked piece of DNA can rotate to alter the supercoiling number in steps 
of 1 before religation of the nick (Redinbo et al., 1998). Additionally, the structures of this 
group are unique from the IA enzymes (Redinbo et al., 1998). 
 
This group of enzymes is mainly confined to eukaryotic topo I – a relaxing enzyme which can 
relax both positive and negative supercoils in DNA (Wang, 2002). In addition to the 
eukaryotic topo I enzymes, this group also contains viral topoisomerase enzymes such as that 
from the vaccinia virus (Stivers et al., 1997). This means that therapeutically the inhibition of 
this group of topoisomerases is limited to just anticancer and antiviral treatments. Presently 
Camptothecin is clinically used to inhibit human topo I for anticancer treatments (Ulukan and 
Swaan, 2002, Wethington et al., 2008) 
 
1.5.3 Type IC topoisomerases 
To our current knowledge, the type IC topoisomerase group is unique to just topoisomerase V 
from the hyperthermophilic archaea Methanopyrus kandleri (Slesarev et al., 1993, Taneja et 
al., 2006, Rajan et al., 2010). This topoisomerase is unusual due to its additional role in DNA 
repair, and high proportion of (HhH)2 folds (Belova et al., 2002, Forterre, 2006). 
Topoisomerase V is able to relax both positive and negatively supercoiled DNA through use 
of a rotational and swivel mechanism of action, utilising a single-nicked strand with a 
phosphotyrosine bond at the 3' end between the enzyme and the DNA (Slesarev et al., 1993). 
It is known that the reaction of this enzyme is independent of ATP and magnesium ions like 
the type IA enzymes, and is also active in a wide range of salt conditions and temperatures 
above 65°C (Slesarev et al., 1993). Although the mechanism of this type of topoisomerase is 
very similar to the type IB enzymes they have distinct structural features determining 
topoisomerase V to be classed as a type IC enzyme (Forterre, 2006).  
 
Due to the limited species containing this class of topoisomerases, it has not investigated for 
medicinal use as; no known pathogenic species have currently been identified to encode a type 
IC topoisomerase. 
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1.5.4 Type IIA topoisomerases 
The type IIA topoisomerases was the first discovered class of topoisomerases which alter the 
topology DNA by using double-stranded breaks (Liu et al., 1980). Classified into the type IIA 
class is eukaryotic topoisomerase II (topo II), bacterial DNA gyrase and topoisomerase IV 
(topo IV) as well as bacteriophage topo II. Structurally, all three of these enzymes have a high 
degree of homology with all the enzymes in the classification containing the same domain 
arrangement, with several conserved featured including the TOPRIM (topoisomerase primase) 
domain, also found in type IA topoisomerases, and a catalytic tyrosine (Figure 1.5.1). The 
TOPRIM domain is structurally conserved consisting of around 100 amino acids found in 
some topoisomerases as well as DnaG-type primases and small primase-like proteins in 
bacteria and archaea (Aravind et al., 1998). Although eukaryotic topo II forms dimers, 
whereas heterotetramers are formed by bacterial DNA gyrase and topo IV. Bacteriophage topo 
II has been reported to contain three subunits arranged into a heterohexomeric arrangement 
(A2B2C2) (Liu et al., 1979, Seasholtz and Greenberg, 1983). There is significant evidence that 
all of these genes have a common ancestor, although from an evolutionary perspective they 
cluster into their respective groups of eukaryotic topo IIs including eukaryotic viral 
topoisomerases, T4 bacteriophage topo II, and the final group containing the bacterial type 
IIA topoisomerases sub-divided into topo IV and DNA gyrase (Forterre et al., 2007). 
 
The type IIA topoisomerases all form three major dimer interfaces, this results in the formation 
of two DNA gates, which is important in the conserved mechanisms of these enzymes (Berger 
et al., 1996, Roca et al., 1996). The mechanism of actions of all the enzymes causes a change 
in the linking number of DNA to change by 2 units per reaction cycle or to a 
knotting/unknotting reaction of DNA through the hydrolysis of two ATP molecules depending 
on the location of the two DNA segments (Brown and Cozzarelli, 1979, Bates et al., 2011). 
The reaction mechanism is initiated by the formation of a dimeric or tetrameric enzyme in 
complex with DNA. ATP binding allows for cleavage of a gate segment of DNA and transport 
of the transport DNA segment through the gate segment. After passage of the transport 
segment of DNA religation of the gate segment occurs and release of the DNA through the C-
gate with a change in the topology (Baird et al., 1999). In addition, in the reaction cycle both 
ATP molecules are hydrolysed, although the exact timing of this is unknown (Figure 1.5.2). 
The directionality of the change in linking number (positive vs negative) may be determined 
by the wrap of the DNA around the CTDs (Kampranis and Maxwell, 1996). Eukaryotic topo 
II, bacterial topo IV and bacteriophage topo II are all relaxing enzymes of both positive and 
negative supercoils, and can decatenate DNA (Goto and Wang, 1982, Kreuzer and Jongeneel, 
1983, Kato et al., 1990). DNA gyrase is able to relax positive supercoils and introduce 
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negative supercoils in relaxed DNA (Higgins et al., 1978, Mizuuchi et al., 1978). Additionally, 
DNA gyrase can relax negative supercoils in DNA in an ATP-independent fashion (Gellert et 
al., 1977, Sugino et al., 1977). All of the type IIA topoisomerases hydrolyse ATP in a DNA-
dependent fashion, and the free energy provided by this reaction enables these enzymes to 
relax and decatenate DNA past the distribution possible by ATP-independent enzymes in a 
process known as topology simplification (Rybenkov et al., 1997, Stuchinskaya et al., 2009). 
 
 
Figure 1.5.1: Domain alignment of eukaryotic and prokaryotic type II topoisomerases. The TOPRIM 
(topoisomerase-primase) domain is highlighted in pink, the catalytic tyrosine in purple and the C-
terminal wrapping domain in yellow. The N-terminal ATPase domain is in the region between the 
protein N-termini and the TOPRIM domains of all of the proteins. All domains are to scale. The 
eukaryotic topo II proteins form active dimers, meanwhile the bacterial DNA gyrase and topo IV form 
active heterotetramers. 
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Figure 1.5.2: The likely strand-passage mechanism of action of the type IIA topoisomerases. A) The 
mechanism is initiated through the formation of a complex of two of each of the subunits with 2 ATP 
molecules in the N-terminal domains (yellow), and two segments of DNA known as the gate (G-
segment) and transport (T-segments) segments. This is followed by cleavage of the G-segment of DNA 
(green) allowing passage of the T-segment of DNA (Pink/Red) through the G-segment. Subsequent 
hydrolysis of ATP allows for the complex to be reset ready for another reaction cycle. B) There is 
considerable evidence that DNA gyrase wraps a single piece of DNA around the CTDs in a positive 
supercoiled direction to allow for the introduction of negative supercoils. C) On the other hand, topo 
IV does not appear to wrap DNA around the CTDs, instead it preferentially decatenates and relaxes 
DNA. Figure adapted from (Neuman, 2010). 
 
There is homology between the type IIA topoisomerase enzymes which is greatest at the N-
terminals of the GyrA/ParC and GyrB/ParE subunits, including the ATPase domain 
(Hammonds and Maxwell, 1997). A substantial amount of work has been conducted on the 
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DNA gyrase ATPase domain from E. coli for the most part (see section 1.6.1). In addition, 
there has been a considerable effort to characterise this domain in yeast and human topo II(α) 
and a lesser effort in bacterial topo IV. Like DNA gyrase these enzymes all have significant 
stimulation of the ATPase activity by DNA, of between 4-fold for S. pneumoniae topo IV to 
19-fold for yeast topo II (Lindsley and Wang, 1991, Hammonds and Maxwell, 1997, 
Laponogov et al., 2018). This stimulation was found to be dependent on the presence of both 
ParC and DNA for topo IV. On the other hand, the eukaryotic topo II(α) could be stimulated 
by DNA in the absence of the C-terminal portion of the enzyme, although the length of DNA 
required was much shorter for the N-terminal domain on its own (Campbell and Maxwell, 
2002). The kinetics of this mechanism appear to follow Michaelis-Menton kinetics in the 
absence of DNA, but instead have cooperative binding in the presence of DNA (Lindsley and 
Wang, 1991). In the case of S. pneumoniae the first structures of the ATPase domain bound 
to DNA has recently been shown confirming the predictions previously made for DNA gyrase 
(Wigley et al., 1991, Laponogov et al., 2018). 
 
Although commonly bacteria have genes for both DNA gyrase and topo IV there are many 
occasions in nature when bacteria have been identified to only have DNA gyrase without topo 
IV. In single-cell eukaryotes such as S. cerevisiae only one copy of topo II is present whereas 
in higher eukaryotes such as Homo sapiens (humans) there are two copies identified labelled 
as topo IIα and IIβ (Burden and Osheroff, 1998). Although DNA gyrase previously was 
thought to be predominantly a bacterial enzyme it has been recently found in plants including 
Arabidopsis thaliana and potentially some plasmodia species (Aravind et al., 2003, Wall et 
al., 2004). 
 
This class of topoisomerases has been highly exploited in terms of medicinal use. This 
includes clinical use as an antibiotic target against both DNA gyrase and topoisomerase IV 
through the fluoroquinolones (Gellert et al., 1977, Khodursky et al., 1995) and as a target for 
anticancer treatments through inhibition of the human topo II enzymes by for example 
etoposide reviewed by Nitiss (2009). Recently, there have also been investigations into plant 
DNA gyrase in relation to generating novel herbicidal compounds (Wallace et al., 2018), as 
well as the identification of DNA gyrase and topo VI plasmodium parasites having the 
potential for being a future target for anti-malarial compounds (Aravind et al., 2003). 
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1.5.5 Type IIB topoisomerases 
The type IIB topoisomerases, like the type IIA topoisomerases, also alter the topology of DNA 
through the use of double-stranded DNA breaks. These enzymes can both decatenate and relax 
negatively supercoiled DNA in an ATP-dependent reaction (Bergerat et al., 1997). The main 
enzyme characterised within this class is that of the archaeal topoisomerase VI (topo VI) 
enzyme which is primarily found in archaea such as Methanosarcina mazei (Bergerat et al., 
1997), however more recently it has been discovered within the genomes of plants such as A. 
thaliana (Hartung and Puchta, 2000) and the Plasmodium parasites (Aravind et al., 2003). 
Like the type IIA enzymes, structurally topo VI forms heterotetramers (A2B2), however, 
uniquely it only has two dimer interfaces, forming a single DNA gate (Bush et al., 2015). A 
second topoisomerase VIII (topo VIII) has recently been added to this class of topoisomerases. 
It is the smallest known type IIB topoisomerase, and like human topo II it has the subunits 
fused to form a single subunit which dimerises. Presently topo VIII has only been identified 
in a small number of bacterial genomes and on plasmids from both bacteria and archaea 
(Gadelle et al., 2014). 
 
Currently, these enzymes are not used as drug targets although there have been recent attempts 
to utilise the plasmodium and plant topo VI enzymes as targets for antimalarial and herbicidal 
compounds (Bush et al., 2018). 
 
1.5.6 Topoisomerases in mycobacteria 
It has been the wonder of the topoisomerase community since the genome of M. tuberculosis 
was published in 1998 (Cole et al., 1998) that there were only two apparent topoisomerases 
identified – these being DNA gyrase and topoisomerase I, which is unusual but not unheard 
of in other species such as Aquifex aeolicus (Tretter et al., 2010) which contains just one type 
IIa topoisomerase. Hence, there has been some suspicion that the mycobacterial DNA gyrase 
may have enhanced catalytic activities in the reactions that are traditionally thought of as topo 
IV reactions; these being enhanced relaxation and decatenation. The decatenation activity of 
DNA gyrase in M. tuberculosis has been reported as being up to 10-times more efficient that 
E. coli DNA gyrase, but still 25-times less efficient than the activity of S. pneumoniae topo 
IV (Aubry et al., 2006a). This is somewhat like the results obtained by Manjunatha et al. 
(2002) who found that the M. smegmatis homologous gyrase has 7-times greater activity in 
decatenation than its E. coli homologue. In contrast the ATP-independent relaxation activities 
of both the M. smegmatis and E. coli gyrase enzymes were comparable needing a 10-fold 
increase in enzyme (Manjunatha et al., 2002). 
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While the DNA gyrase found in Mycobacteria may appear to be slightly special in its ability 
to more effectively decatenate substrates that its Gram-negative homologues, there has also 
been a suspicion that there may possibly be further uncharacterised topoisomerases in the 
genome of these bacteria that are yet to be characterised. One potential novel topoisomerase 
was identified and somewhat characterised in M. smegmatis as a heterotetramer of two TopoN 
and two TopoM subunits (Jain and Nagaraja, 2005). Although there was little homology to 
other characterised topoisomerases, it appeared to relax negative supercoils in the presence of 
either ATP or dATP at a 10 nM concentration, as well as exhibiting decatenation activity on 
a similar level to that of M. smegmatis DNA gyrase. However, since the initial report of this 
putative type II topoisomerase it appears that there has been no further work carried out on 
this enzyme and it does not appear to have a homologue in M. tuberculosis. 
 
1.6 DNA gyrase  
DNA gyrase is a heterotetrameric enzyme first discovered in 1976 for its ability to introduce 
negative supercoils into DNA in an ATP-dependent manner (Gellert et al., 1976), and has 
been studied in depth since. Initial studies revealed it to have a heterotetrameric active form 
consisting of two proteins – GyrA (97 kDa) and GyrB (90 kDa) for the E. coli enzymes 
(Higgins et al., 1978, Mizuuchi et al., 1978). The GyrA protein is largely associated with DNA 
binding and wrapping (Reece and Maxwell, 1991a, Reece and Maxwell, 1991b), while the 
GyrB protein has a role in ATP hydrolysis (Wigley et al., 1991). Although the full-length 
DNA gyrase complex has never been solved by X-ray diffraction there have been several 
lower resolution structural studies (Costenaro et al., 2005, Costenaro et al., 2007, Baker et al., 
2011) and a recent cryo-electron microscopy structure to around 17 Å (Papillon et al., 2013). 
These have somewhat confirmed the theorised structural arrangement proposed many years 
earlier, with a GyrB dimer sitting on top of the GyrA dimer, with DNA wrapping around the 
two GyrA CTD domains. 
 
1.6.1 ATP hydrolysis and the GyrB N-terminal domain 
One of the earliest observations indicated that DNA gyrase required ATP to insert negative 
supercoils into DNA (Gellert et al., 1976). Initially it was assumed to require ATP hydrolysis 
and hence studies were carried out to confirm this. In the presence of ADPNP (non-
hydrolysable ATP), DNA gyrase is only able to carry out one reaction cycle and is not able to 
be processive as it is in the presence of ATP (Sugino et al., 1978). This is thought to be a 
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consequence of not being able to hydrolyse and hence release ADP from the enzyme; ADPNP 
remains tightly bound (Tamura et al., 1992). This means that the enzyme is trapped in a DNA-
bound form, and only limited incomplete supercoiling of a relaxed DNA substrate can be 
observed. 
 
The first structure of any part of DNA gyrase to be solved was a 2.5 Å structure of the E. coli 
N-terminal 43 kDa domain of GyrB (GyrB43) (Wigley et al., 1991). This structure was of a 
domain already known to be an ATPase (Ali et al., 1993) and confirmed that ATP binding 
causes dimerization of GyrB, resulting in a 20 Å cavity for DNA binding. Although a cavity 
has been observed for DNA binding, no evidence for interaction of GyrB43 with DNA was 
initially determined, nor did it appear to form any interactions with the GyrA subunit (Ali et 
al., 1993). Regardless of this, there is considerable evidence that DNA binding is important in 
the stimulation of the ATPase activity of GyrB (Maxwell and Gellert, 1984). It is indicated 
that in the case of the E. coli DNA gyrase heterotetramers either a fragment of 85±15 bp of 
DNA or higher concentrations of shorter fragments are needed to stimulate the ATPase 
activity, and from the data suggesting a sigmoidal dependence of short DNA fragment binding, 
it was inferred that two cooperative DNA binding sites must be occupied to stimulate ATPase 
activity (Maxwell and Gellert, 1984). Although approximately 85 bp are required to bind ATP 
is should be noted that this may not indicate the full DNA binding footprint, instead only the 
section required to induce the ATP hydrolysis reaction. No sequence specificity for induction 
of ATPase activity has been observed (Maxwell and Gellert, 1984), rather a preference for a 
substrate that appears to be a relaxed, linear or nicked form of double stranded DNA as 
opposed to one that is negatively supercoiled (Mizuuchi et al., 1978, Sugino and Cozzarelli, 
1980). Likewise, it has been shown that DNA gyrase from M. tuberculosis has a higher affinity 
for positively supercoiled DNA than other topological forms (Ashley et al., 2017), and 
although this has not been demonstrated to induce ATPase activity it can be inferred. 
 
Additional structural studies focusing on the GyrB43 domain indicate probable 
conformational changes in hydrolysis of the ATPase reaction (Stanger et al., 2014). From 
solving a series of different crystal structures in the presence of different nucleotides and 
counter ions, they observed a 12° rotation opening the domain interface on hydrolysis of ATP. 
This appears to be independent of the tertiary ɣ-phosphate in ATP but appeared to be 
dependent on the presence of Pi as an intermediate structure was obtained when BeF3 replaced 
Pi as the counter ion with ADP (Stanger et al., 2014). This is important as it appears to suggest 
that a passage is opened for DNA to move through the GyrB molecule, assisting with the 
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mechanical role of the enzyme. Furthermore, from the structural and biochemical studies it 
was interpreted that DNA strand passage occurs prior to ATP hydrolysis and hence ATP 
hydrolysis is likely to be coupled to DNA release (Wigley et al., 1991). There is still however, 
considerable doubt about the timings of ATP hydrolysis and ADP release in the mechanism 
of DNA gyrase. 
 
Due to the dimerization of GyrB it is likely that two ATP molecules bind to the heterotetramer 
cooperatively (Maxwell and Gellert, 1986). The mechanism has been studied and it is 
hypothesised that the mechanism of DNA gyrase uses sequential hydrolysis of two ATPs, with 
the rate limiting step being the slow hydrolysis of the second ATP, with the second ATP 
hydrolysis resulting in a conformational change that allows for gate opening to release the 
DNA from the enzyme (Hartmann et al., 2017). This would agree with the proposed 
mechanism for yeast topo II (Baird et al., 1999), meanwhile the structural data presented above 
(Stanger et al., 2014) and data from the B. subtillus enzyme suggest that there is significant 
reason to believe that the hydrolysis of ATP is synchronous (Gottler and Klostermeier, 2007). 
 
It is known that there are several highly conserved residues in the ATPase domain. These 
include the aspartic acid at residue 46 (E. coli) which is required to coordinate magnesium 
binding (Wigley et al., 1991, Lewis et al., 1996), E50 and R76 which form an important salt 
bridge (Gross et al., 2003).  A second aspartic acid forms a direct hydrogen bond with the 
adenosine amino group of ATP (Gross et al., 2003) which is highly specific and can only be 
mutated to a glutamic acid to retain activity (Gross et al., 2003). Two further amino acids P79 
and K103 have been further described to couple the ATPase activity to the supercoiling 
function of the enzyme as mutation is permissive to ATPase activity but not to supercoiling 
(Gross et al., 2003). The catalytic active site of the ATPase reaction has been determined to 
contain the likely catalytic residues of E42 and H38 (Jackson and Maxwell, 1993). Finally, 
T165 is highly conserved within all type II topoisomerases. Mutation of this residue to serine 
is permissible although an alanine is not (Gross et al., 2003), this may be explained due to 
direct and indirect bonding (via an ordered water molecule) to ATP (Lewis et al., 1996).  
 
The E. coli model DNA gyrase system has been used for the most part to investigate the 
mechanism of action, and relationship between ATP hydrolysis and the change in topology. 
There is however a smaller amount of data on the mycobacterial DNA gyrase ATPase domain, 
including structures of the full domain (Agrawal et al., 2013). The data presented in the 
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literature suggests that M. tuberculosis does not have an appreciable rate of ATP hydrolysis 
that can be reliably tested (Agrawal et al., 2013, Karkare et al., 2013b, Shirude et al., 2013), 
meanwhile the initial data for the M. smegmatis DNA gyrase does not suggest it to be much 
better (Manjunatha et al., 2002), although other groups have been able to generate a high 
throughput ATPase assay system for this protein (Shirude et al., 2013). As with the E. coli 
enzyme there is significant stimulation of the ATPase activity when both GyrA and DNA were 
included in the reaction, and this activity is abolished on the addition of novobiocin indicating 
specificity to DNA gyrase (Manjunatha et al., 2002, Agrawal et al., 2013). Overall, it is 
suggested that the coupling of the ATPase activity to DNA supercoiling is greater in Mtb DNA 
gyrase than in other enzymes such as E. coli, where the ATPase activity can be uncoupled 
from strand passage (Sugino and Cozzarelli, 1980, Bates et al., 1996, Fu et al., 2009, Bates et 
al., 2011). 
 
1.6.2 DNA gyrase core: GyrB C-terminal domain and GyrA N-terminal domain 
The GyrA NTD includes the essential catalytic tyrosine (Y122 E. coli) (Horowitz and Wang, 
1987, Wilkinson and Wang, 1990), meanwhile the GyrB CTD contains the TOPRIM domain. 
Results of studies carried out to probe the role of the GyrA subunit have previously 
demonstrated that all the NTD of GyrA is required to support supercoiling and decatenation, 
however weak and non-processive supercoiling is possible in the presence of just the first 572 
amino acids (E. coli) and subsequently suggesting a role of residues 523-572 in active strand 
passage (Reece and Maxwell, 1991b).  
 
The GyrB CTD contains the TOPRIM domain which has been demonstrated to be conserved 
across a wide variety of DNA-binding proteins including bacterial DnaG-type primases, types 
IA and II topoisomerases as well as RecR/M bacterial repair proteins (Aravind et al., 1998), 
in addition to the tail domain (Costenaro et al., 2007). This 47 kDa domain has a predominant 
role in interactions with both the GyrA subunit and DNA (Brown et al., 1979, Chatterji et al., 
2000, Noble and Maxwell, 2002, Schoeffler et al., 2010). 
 
1.6.3 The GyrA C-terminal domain and DNA wrapping 
The CTDs of GyrA are implicated to be involved in stabilising the DNA-protein complex 
through a sequence-independent DNA binding and wrapping mechanism (Reece and 
Maxwell, 1991a), and are essential for the process of negative supercoiling (Kampranis and 
Maxwell, 1996), indeed in their absence the protein is converted into an ATP-dependent 
25 
 
relaxing enzyme. Although they have been shown to bind stretches of double stranded DNA 
greater than 35 bp long (Reece and Maxwell, 1991a), independently the CTD is catalytically 
inactive suggesting their role to be accessory (Reece and Maxwell, 1991b). It is implied that 
the CTD preferentially binds to positively supercoiled DNA over negatively-supercoiled DNA 
in the presence of nucleotide, suggesting a topological substrate preference (Kampranis et al., 
1999a). The structure of the CTD has been solved from several species including E. coli, M. 
tuberculosis and Xanthomanas campastris (Ruthenburg et al., 2005, Hsieh et al., 2010, Tretter 
and Berger, 2012) all showing a composition of 6 blades forming a beta-pinwheel structure, 
although other structures have been demonstrated to be possible (Corbett et al., 2004). 
 
1.6.4 DNA gyrase: a proposed mechanism of action 
There is a consensus within the field that there is one recognised mechanism of action for 
DNA gyrase. This was initially postulated by Brown and Cozzarelli (1979) who suggested 
that the reaction mechanism involved using a double-strand break to decrease the linking 
number of DNA by two on each reaction cycle. 
 
It is thought that dimeric GyrA assembles together with two GyrB subunits and wrapping a 
section of DNA of ca. 128 bp around the CTDs in a positive wrap (Orphanides and Maxwell, 
1994). The reaction cycle is then initiated through the binding of two ATP molecules causing 
the closure of the two GyrB N-terminal domains to trap a T-segment of DNA (Wigley et al., 
1991, Stanger et al., 2014). This also allows for ligation of the G-segment of DNA through 
stabilisation by the two active-site tyrosine residues (Tyr-122 in E. coli DNA gyrase) 
(Horowitz and Wang, 1987, Cabral et al., 1997). The T-segment is then able to pass through 
the G-segment before it is ligated possibly with the hydrolysis of one ATP molecule. However, 
this is unclear as there is some evidence to suggest that both ATP molecules are hydrolysed 
synchronously (Gottler and Klostermeier, 2007). However, more recently it has been 
suggested that the rate-limiting step of DNA supercoiling is the hydrolysis of the second ATP 
molecule within the reaction, as the DNA is only able to be released from the exit gate of DNA 
gyrase (interaction of the two N-terminal domains of GyrA) once hydrolysis of both of the 
ATP molecules has occurred (Wigley et al., 1991, Corbett et al., 2004, Hartmann et al., 2017). 
Although this is just theory, there is considerable evidence that the reaction of DNA gyrase 
can only alter the linking number of DNA by minus 2 (Brown and Cozzarelli, 1979) giving 
considerable evidence for this mechanism (Figure 1.6.1).  
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Figure 1.6.1: Mechanism of negative supercoiling by DNA gyrase. Domains coloured as follows: Dark 
blue GyrB-NTD, red GyrB-TOPRIM, green GyrB-tail, orange GyrA-NTD, light blue GyrA-CTD. The 
transport (T) segment is coloured purple and the gate (G) segment black. From their free solution state 
(i) the active state combines to form a complex with the G segment bound between the GyrB-TOPRIM 
and GyrA-NTD (ii) and with the addition of 2x ATP molecules the GyrB clamp can close capturing the 
T segment and allowing cleavage of the G segment (iii). Hydrolysis of the first ATP molecule allows 
for a conformation change allowing the T segment to be passed through the G segment (iv) this allows 
the G segment to be religated and the T segment to be released from the C-gate (v). Hydrolysis of the 
second ATP molecule then resets the enzyme allowing for subsequent cycles to proceed (i/ii). 
Reproduced from (Costenaro et al., 2007). 
 
However, although this is the generally accepted mechanism for DNA gyrase there has been 
some conflicting evidence against this mechanism as it has been observed that a DNA gyrase 
heterotetramer with one of its active-site tyrosine residues mutated to a phenylalanine is able 
to negatively supercoil DNA in steps of 2 (Gubaev et al., 2016). As it is thought that both 
active site tyrosine residues are required to ligate the G-segment of DNA allowing for 
transport of the T-segment the authors proposed an alternative nicking and closing mechanism 
by which a single DNA stand is cleaved allowing for relaxation by rotation of the single strand 
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break. There are however, significant issues with these experiments. The first arises from the 
question of purification efficiency from the tandem affinity purification mechanism. 
Meanwhile, the second arises from the question of possible higher order multimers and 
potential subunit exchange not being fully accounted for. 
 
1.6.5 DNA gyrase from M. tuberculosis 
M. tuberculosis gyrase is encoded by the Rv006 and the Rv005 genes which are located next 
to each other in the genome (Cole et al., 1998). It was first characterised as a recombinant 
enzyme purified with a His-tag by Aubry et al. (2006a). At this time, it was explained that it 
supercoils at a similar level of activity to other gyrases, but has enhanced activity in relaxation, 
cleavage and decatenation, although it is unable to decatenate to the same degree as a true topo 
IV enzyme. Of interest was that the cleavage specificity was compared across four more active 
quinolones (Aubry et al., 2006a) alongside the DNA gyrase and topo IV from S. pneumoniae. 
This analysis demonstrated that the cleavage pattern shared the greatest similarity to that of 
other DNA gyrase enzymes as opposed to topo IV, and hence along with the information that 
the enzyme from Mtb can negatively supercoil DNA it has been classified as a DNA gyrase 
enzyme as opposed to a topo IV. 
 
One of the most important problems scientists faced working on this enzyme early on was the 
confusion over the start codon. This came about because there were initially multiple possible 
start codons which were quickly reduced to two potential sites in the coding sequence leading 
to two different possibilities for GyrB, one starting with a valine start codon, the other with 
the more traditional methionine including an additional 40 amino acids (Madhusudan et al., 
1994, Karkare et al., 2013a). In vitro it was found that no significance in activity or inhibition 
was seen regardless of the position of the start codon (Karkare et al., 2013a). In addition, it 
was demonstrated that the promotor located upstream of the valine start codon gave a 
prominent level of promotor activity while the promotor upstream of the methionine start 
codon did not (Karkare et al., 2013a). It is for these reasons that it was decided to work solely 
with the valine start codon for the work within this thesis. 
 
1.6.6 Fusion proteins of DNA gyrase 
Fusion proteins are created when two individual genes are fused together to give one open 
reading frame, resulting in the transcription of a single protein. These have been observed 
under certain conditions in nature. Equally, since the development of modern molecular 
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biology techniques it has been possible to make unnatural fusion proteins such as those with 
affinity and solubility tags for purification purposes, fluorescent tags for imaging, and most 
interestingly in this instance the combination of two proteins that dimerise for structural 
studies (Beckwith, 2000). Previously in the field of topoisomerases there have been initial 
studies on some fusion constructs of some topoisomerases (Lavasani and Hiasa, 2001, 
Trigueros and Roca, 2002, Papillon et al., 2013). Additionally, many of the structural studies 
in the Klostermeier laboratory have been carried out using a fusion construct of B. subtilus 
DNA gyrase (Klostermeier, 2018). 
 
The first recorded fusion in this field is that of the ParE-ParC fusion which was characterised 
as an active protein although it did appear to require more protein to produce the same results 
of the individual subunits (Lavasani and Hiasa, 2001). Importantly, it was demonstrated in 
vivo to complement a ParE or ParC knockout in a temperature-sensitive strain at a non-
permissible temperature. Presently there has been much less work on GyrB-GyrA fusion 
proteins, but recently there have been several papers published utilising them (Gubaev and 
Klostermeier, 2011, Gubaev and Klostermeier, 2012, Lanz and Klostermeier, 2012, Gubaev 
and Klostermeier, 2014b, Gubaev and Klostermeier, 2014a, Lanz et al., 2014, Gubaev et al., 
2016, Hartmann et al., 2017, Stelljes et al., 2018).  
 
Structural studies often drive the development of fusion proteins and this is no different in 
terms of DNA gyrase. The core-fusion is a chimeric protein of the GyrA NTD and the GyrB 
CTD with DNA (see Figure 1.5.1 this section of DNA gyrase includes the TOPRIM domain 
and catalytic tyrosine but not the N-terminal ATPase domain or C-terminal domains of GyrA) 
(Schoeffler et al., 2010, Srikannathasan et al., 2015). This gave significant insight into the 
structure of this part of the enzyme. More recent advances have used a full-length gyrase 
fusion protein to obtain a low resolution cryoEM structure at 23 Å in the presence of a 155 bp 
DNA fragment (Papillon et al., 2013). In this study it was determined that the T. thermophilus 
fusion protein that they worked with was as active in supercoiling as the native protein.  
 
One of the most intriguing studies on a GyrBA fusion protein was carried out by Trigueros 
and Roca (2002) where they concluded that gyrase is unable to fully complement a yeast topo 
II knockout, but is able to remove positive supercoils in yeast cells. These results are not 
unsurprising considering the functional divergence between eukaryotic topo II and bacterial 
DNA gyrase. 
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A considerable amount of mechanistic studies on DNA gyrase have been carried out so far 
including several studies which for reasons of convenience have used fusion proteins. These 
appear to have been initiated by work carried out by (Gubaev and Klostermeier, 2011), where 
they utilised FRET labelling to help elucidate various parts of the DNA gyrase mechanism of 
action (Lanz and Klostermeier, 2012, Gubaev et al., 2016). It has been demonstrated through 
the use of this work that a B. subtillus DNA gyrase fusion protein has equivalent activity to 
unfused subunits; therefore, it is interesting to determine if an equivalent fusion of the 
mycobacterial DNA gyrase will give the same results. 
 
1.7 Structural biology of DNA gyrase 
At present there are no full-length high-resolution structures of DNA gyrase or other type IIA 
topoisomerase from any species. There have however been many structural studies carried out 
of DNA gyrase, including a full length low-resolution cryoEM structure of Thermus 
thermophiles GyrBA fusion at around 17 Å. This structure has a 3-amino acid linker between 
the GyrB and GyrA subunits and was bound to ADPNP in the absence of DNA. However, 
within this structure the GyrA CTDs were not visible (Papillon et al., 2013). Within the same 
paper there was a further structure obtained at 23 Å. This structure contained a DNA fragment 
and ciprofloxacin, and furthermore it was possible to observe the GyrA CTDs due to the 
stabilisation from the DNA wrapping (Figure 1.7.1A) (Papillon et al., 2013). 
 
The closest structure to the full-length DNA gyrase structure is the structure of the core fusion 
containing the GyrA NTD and GyrB CTD – there are several of these structures available in 
the PDB including that of the S. aureus (Srikannathasan et al., 2015) core fusion and more 
interestingly the M. tuberculosis fusion (Figure 1.7.1B) (Blower et al., 2016). There is also a 
fusion structure of the homologous topo IV containing full length ParE fused to ParC55 from 
S. pneumonia and additionally contains two DNA molecules bound at a resolution of 3.7 Å 
(Figure 1.7.1C) (Laponogov et al., 2013). Finally, there is a structure of the first 1177 amino 
acids from Saccharomyces cerevisiae topo II which has been solved at a resolution of 4.41 Å 
in complex with nucleotide and DNA (Figure 1.7.1D) (Schmidt et al., 2012). All together 
these structures give a good indication that DNA gyrase is arranged with the GyrB subunits 
sat on top of the GyrA dimer, with the G-segment of DNA being held between the GyrA and 
GyrB dimers. This indicates that the C-terminal domains of GyrA are likely to be flexible and 
external from the rest of the structure.  
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Figure 1.7.1: Comparison of the structures of type IIA topoisomerases demonstrating the most complete 
structural knowledge known to date with DNA highlighted in grey. A) Full-length fusion structure of 
T. thermophilus DNA gyrase solved by cryo-electron microscopy (23 Å) (Papillon et al., 2013). B) 
Crystal structure of the M. tuberculosis DNA gyrase core fusion structure (5BS8) (2.4 Å) (Blower et 
al., 2016). C) ParE-ParC55 crystal structure of topo IV from S. pneumoniae (4I3H) (3.7 Å) (Laponogov 
et al., 2013). D) Crystal structure of the first 1177 residues from S. cerevisiae (yeast) topo II (4GFH) 
(4.41 Å) (Schmidt et al., 2012). PDB accession codes are given in brackets. 
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There are more than 50 structures of the GyrB N-terminal ATPase domain or sub-domain 
within the PDB. Of particular note are three structures which contain novobiocin (1KIJ, 1AJ6, 
4URO) (Holdgate et al., 1997, Lamour et al., 2002, Lu et al., 2014), two structures of other 
aminocoumarins (1KZN, Chlorobiocin) (Lafitte et al., 2002) and 4URM (Kbdelomycin) (Lu 
et al., 2014), three structures of the full length M. tuberculosis ATPase domains 3ZKB, 3ZKD 
and 3ZM7 (Agrawal et al., 2013), and finally two M. smegmatis GyrB24 drug-bound 
structures 4B6C (Shirude et al., 2013) and 4BAE (Hameed et al., 2014). The M. tuberculosis 
structures are of moderate resolution (2.9 Å) and are from two different similar constructs 
bound to non-hydrolysable ATP analogues. Again the M. smegmatis structures are solved at 
resolutions of 2.35 Å and 2.2 Å, both missing at least one flexible loop, but they do have 
inhibitors bound. 
 
Overall, presently there is a considerable knowledge of the structural features of DNA gyrase 
from M. tuberculosis. This is represented by 18 structures being available within the PDB of 
sections from M. tuberculosis (Figure 1.7.2). There is a lot of redundancy within the region 
known as the core (C-terminal domain of GyrB and N-terminal domain of GyrA) as many of 
these structures are solved with marginally different compounds (Blower et al., 2016). 
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Figure 1.7.2: Coverage of current structures of DNA gyrase from M. tuberculosis solved by X-ray 
crystallography. Blue sections represent areas where structures have been solved, grey sections indicate 
where there is missing density and the structures have not been solved. The full-length protein 
arrangement and sizes are displayed at the top. For each structure, the PDB accession code, resolution 
and reference is shown. 
 
1.8 Inhibition of DNA gyrase 
As essential enzymes DNA topoisomerases, especially the type IIA enzymes, have been well-
utilised as drug targets, including human topoisomerase II as an anti-cancer chemotherapy 
target (Liu, 1989), and DNA gyrase / topo IV from bacteria as antibiotic targets. Importantly 
the properties of human topo II cannot be replaced by DNA gyrase, indicating that there is a 
significant difference between the catalytic activity and inhibition profile of the two different 
enzymes (Trigueros and Roca, 2002). Clinically, currently only the quinolone type drugs are 
licenced antibacterial, although other inhibitors of both DNA gyrase and topoisomerase IV 
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also exist. The quinolones moxifloxacin, gatifloxacin and levofloxacin are all current second 
line anti-mycobacterial agents (WHO, 2010). 
 
Other major classes of DNA gyrase inhibitors include the aminocoumarins (Maxwell and 
Lawson, 2003), the (flouro)quinolones (Van Bambeke et al., 2005), naphthoquinones 
(Karkare et al., 2013b), and the simocyclinones (Flatman et al., 2005) (Figure 1.8.1). In 
addition to the major classes of inhibitors there are additional natural products that are known 
to inhibit DNA gyrase including albicidins (Hashimi et al., 2007) and microcin B17 (Heddle 
et al., 2001). Recently there have been several reviews of the use of DNA gyrase as a target 
for antituberculosis chemotherapy including (Nagaraja et al., 2017, Kashyap et al., 2018). 
 
Figure 1.8.1: Model of full-length DNA gyrase from M. tuberculosis based on homology modelling to 
other known structures, indicating the binding sites of inhibitors. Each subdomain is indicated in 
different colours. Yellow: GyrB N-terminal B24 sub-domain including GHKL ATP-binding domain; 
orange transducer domain in the GyrB N-terminal domain; red GyrB C-terminal domain including 
TOPRIM domain, which binds the Mg2+ ion cofactor; teal is the winged helix domain (WHD) which 
is within the GyrA NTD and includes the catalytic tyrosine; purple is the tower domain (GyrA NTD); 
blue is the coiled-coil domain which forms the exit gate within the GyrA NTD; pink is the GyrA CTD 
which is thought to be responsible for DNA wrapping. Four groups of known DNA gyrase inhibitors 
and their known binding domains are indicated. Figure was reproduced from (Bush et al., 2018). 
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1.8.1 Inhibition of DNA gyrase by (fluoro)quinolones  
The quinolones are a class of inhibitors which act to stabilise the DNA cleavage complex 
inhibiting both the ATP-dependent negative supercoiling reaction and the ATP-independent 
relaxation reaction (Gellert et al., 1977). To date there have been three generations of 
quinolone antibiotics all of which have been used clinically, these have included 
advancements in the chemical structure including the fluoro-group in generation 2 (Figure 
1.8.2). 
 
 
Figure 1.8.2: Chemical structures of examples from each of the four generations of (fluoro)quinolone 
antibiotics. Fluoroquinolones are characterised by the addition of the fluoro-group at position 8 of the 
scaffold. 
 
Over the years there has been a considerable amount of work to determine the mechanism of 
action of quinolone, as well as optimisation to work to gain better clinical efficacy. To date 
there have been studies of the activity of multiple quinolones against TB gyrase (Onodera et 
al., 2001, Aubry et al., 2004), a crystal structure of the M. tuberculosis DNA gyrase core 
bound to DNA and moxifloxacin (Blower et al., 2016), as well as multiple clinical studies of 
M. tuberculosis mutagenesis resulting in clinical resistance (Kocagoz et al., 1996, Bozeman 
et al., 2005, Aubry et al., 2006b, Matrat et al., 2006, Agrawal et al., 2009, Avalos et al., 2015, 
Rigouts et al., 2016). 
 
35 
 
Two quinolone molecules bind to the DNA gyrase complex to stabilise the enzyme preventing 
religation of the DNA (Critchlow and Maxwell, 1996, Heddle et al., 2000). This causes 
damage as the DNA is locked in a cleavage complex causing the cells to utilise DNA repair 
mechanisms and induce cell death (Drlica and Zhao, 1997).  
 
1.8.2 Inhibition of DNA gyrase by aminocoumarins  
Aminocoumarins are a class of antibiotics with a contrasting mechanism that includes 
novobiocin, coumermycin A1 and clorobiocin (Figure 1.8.3). Instead of inhibiting at the DNA 
gate, instead they are competitive inhibitors of ATP and bind partially across the ATP-binding 
site. This means that they inhibit only the negative supercoiling reaction of the enzyme and 
leave the ATP-independent relaxation reaction unaffected (Sugino et al., 1978). Although the 
general mechanism of action for the coumarin antibiotics was quickly deciphered, the exact 
binding site took longer to determine through bacterial mutant isolation, with mutants being 
isolated in E. coli (del Castillo et al., 1991, Contreras and Maxwell, 1992) and in S. aureus 
(Stieger et al., 1996) (Table 1.8.1) (Kampranis et al., 1999b). A further systematic study of 
the effects of mutations surrounding the ATP- and novobiocin-binding sites has further 
confirmed the crystallographic binding site through use of the ATPase reaction (Gross et al., 
2003). 
 
The aminocoumarins have whole cell activity against Gram-positive bacteria only and 
clinically only novobiocin of the coumarins has been used, but can no longer be used due to a 
combination of low solubility, toxicity and spontaneous resistance forcing it to be removed 
from clinical use (David and Burgner, 1956, Kirby et al., 1956, Colville et al., 1957, Food and 
Drug Administration, 2011). Regardless of the flaws of novobiocin, the coumarin group of 
antibiotics are interesting for continued studies.  
 
36 
 
 
Figure 1.8.3: Chemical structure of the aminocoumarin novobiocin. Clorobiocin has an identical 
chemical structure, except the methyl group at position 8 of the coumarin ring is substituted for chlorine. 
Coumermycin A1 is a dimeric aminocoumarin with additional substitutions at the termini and in the 
linker region. 
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Table 1.8.1: Novobiocin-resistant mutants in DNA gyrase GyrB and the amino acid positions in the E. 
coli, S. aureus, and M. tuberculosis enzymes. The resulting mutations are indicated for the source 
organism or where not displayed in the S. aureus column. Bacterial mutants were raised as described 
and the enzymatic studies were carried out after analysis of the crystallographic structures. 
 E. coli S. aureus M. tuberculosis Reference 
Bacterial Isolation 
E. coli 
R136C/L/H R144 R141 (del Castillo et al., 
1991, Contreras 
and Maxwell, 
1992) 
G164V G172 G168 
Bacterial Isolation 
S. aureus 
I48 I56S V54 (Stieger et al., 
1996, Fujimoto-
Nakamura et al., 
2005) 
G77 G85S G83 
G81 D89G A87 
I94 I102S/V/T V99 
V120 S128L V125 
R136 R144I/S R141 
T165 T173A/N S169 
M166 I175T T170 
Bacterial Isolation 
S. pneumoniae 
V119 S128L V125 (Munoz et al., 
1995) 
Bacterial Studies 
Resistant 
Halophilic 
archaebacterium 
G81 D89G A87 (Holmes and 
Dyallsmith, 1991) S120 S129T S126 
R136 R144H R141 
Enzymatic studies 
(SPR) 
N46D/L N54 N52 (Kampranis et al., 
1999b) D73N D81 D79 
R136C R144 R141 
Enzymatic studies 
(Sc and ATPase) 
V43A I50 V49 (Gross et al., 
2003) E50A E58 E56 
D73E D81 D79 
R76A R84 R82 
G77A/S G85 G83 
I78A/L/V I86 I84 
P79A P87 P85 
I94A I102 V99 
A100S A108 A105 
K103A K111 K108 
R136A/H/L/S R144 R141 
T165A/V T173 S169 
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1.8.3 Inhibition of DNA gyrase by naphthoquinones 
The naphthoquinones are a class of natural compounds which have been shown to have 
activity against DNA gyrase from M. tuberculosis. One of the major sources that they have 
been reported to have been isolated from Euclea natalensis, or the toothbrush tree, which has 
been associated with traditional medicine (Tannock, 1973, Khan and Rwekika, 1992). These 
compounds have a currently unknown mechanism of action, which is thought to occur through 
interaction with the GyrB N-terminal domain, but away from the site of ATP binding (Karkare 
et al., 2013b). Hence, as they act through a novel mechanism of action it makes them 
interesting to study from a mechanistic point of view. This is important because cross toxicity 
to mammalian cell including intercellular oxidative stress from menadione likely prevents 
their use in the clinic (Brown et al., 1991). The IC50 values of the naphthoquinones vary largely 
with the most active compounds against DNA gyrase reported to be diospyrin and 7-
methyljuglone (Karkare et al., 2013b) (Table 1.8.2). 
 
Two computational models predicting the binding site of diospyrin in the NTD of GyrB have 
been made independently. Between to the two models there is a large degree of agreement 
between the published model produced by Chetty and Soliman (2015) and the unpublished 
model created by Dr S. Ekins (2015) (Figure 1.8.4). The major difference is in the structural 
models that the computational models are based on; the Ekins model is based on the 3ZK7 
crystal structure (Agrawal et al., 2013), whereas the Chetty and Soliman (2015) model utilised 
three homology models at higher resolution to obtain their binding pocket. At present neither 
of the computational models has been tested against the enzyme targets. 
 
Alongside the biological analysis that these compounds have been subjected to, there has also 
been a substantial amount of work on the chemical properties of these compounds. In this area, 
several of the naphthoquinones have been described as unstable with concentration-dependent 
breakdown of these compounds often occurring (van der Kooy, 2007). In the case of 7-
methyljuglone, only 75% was found to remain in the sample at 30 mins when dissolved in 
DMSO; less than 5% remained after one week. Only the poor inhibitors of DNA gyrase such 
as menadione and plumbagin were found to pure after one week when dissolved in DMSO. 
These stability issues raise significant concerns when working with this class of compound; it 
has been reported that 7-methyljuglone is relatively stable in the mycobacterial growth media 
(Middlebrook 7H9 supplemented with 5% glycerol and 20% DMSO), albeit with decreased 
solubility. Under these conditions 92% purity was retained at 8 hours enabling inhibition 
assays to be undertaken (van der Kooy, 2007). 
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Table 1.8.2: Reported IC50 values of selected naphthoquinones against the M. tuberculosis DNA gyrase 
supercoiling reaction and their chemical structures. IC50 values as reported in Karkare et al. (2013b) 
 
Reported IC50 vs M. tuberculosis DNA 
gyrase (supercoiling)/ μM 
Chemical Structure 
Diospyrin 15 
 
 
7-Methyljuglone 30 
 
Neodiospyrin 50 
 
Isodiospyrin 100 
 
Menadione >200 
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Figure 1.8.4: Two views of the model of diospyrin docked into the 3ZM7 crystal structure of the Mtb 
ATPase domain (Agrawal et al., 2013) by Dr S. Ekins. Six amino acids of interest are shown with in 
specific interaction distances labelled. A) and B) show different orientations of the same structure. 
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1.8.4 Inhibition of DNA gyrase by simocyclinones 
Simocyclinone D8 is a Streptomyces natural product that was originally isolated from 
Streptomyces antibioticus Tü 6040 (Schimana et al., 2000, Theobald et al., 2000, Galm et al., 
2002, Trefzer et al., 2002). It is known to target DNA gyrase but unusually for a DNA gyrase 
inhibitor it does not have activity against bacterial topo IV in either E. coli or S. aureus 
(Oppegard et al., 2009). SD8 has an unusual structure combining an aminocoumarin domain 
linked with a tetraene dicarboxylic acid and D-olivose linker to the Angucyclic polyketide 
head (Figure 1.8.5). Despite the presence of the aminocoumarin domain the target of SD8 is 
not GyrB, instead it inhibits DNA binding by GyrA (Flatman et al., 2005). This has been 
proved using mutagenesis and X-ray crystallographic studies, which demonstrate that the 
binding site of SD8 is adjacent but not overlapping with that of the quinolones (Edwards et 
al., 2009, Hearnshaw et al., 2014). One major issue preventing the use of SD8 in the clinic is 
that there is considerable cross resistance to QRDR (quinolone resistance determining region) 
mutants, and as there is an increasing trend of recording cases of these in the clinic it makes it 
an impractical lead to follow further (Edwards et al., 2009). 
 
 
Figure 1.8.5: Structure of Simocyclinone D8 indicating the four different sections including the 
aminocoumarin and Angucyclic polyketide active heads. Image redrawn from (Edwards et al., 2009) 
using Marvin sketch. 
 
1.8.5 Pyrrolopyrimidine and tricyclic GyrB/ParE (TriBE) inhibitors 
Pyrrolopyrimidine derivatives are a well investigated class of compounds, which have been 
developed in a variety of different contexts including as antibacterial agents (Dave and Shah, 
2002, Hilmy et al., 2010, Tari et al., 2013b, Trzoss et al., 2013), although other reported 
activities include being antidiabetic, herbicidal, diuretic and antineoplastic (Asif, 2016). 
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Several chemical optimisation studies have been carried out on these compounds showing 
them to have low level antibacterial activity mostly via the disk diffusion method, but without 
mode of action, toxicity or resistance studies being carried out. Hilmy et al. (2010) managed 
to produce compounds with MIC values better than those for ampicillin for S. aureus; these 
compounds also exhibited antifungal activity against Candida albicans. Subsequently, this 
class of compounds was further investigated by the company Trius therapeutics who described 
them to inhibit by a dual-targeting GyrB and ParE mechanism and crystallised the compounds 
in the likely binding pocket (Tari et al., 2013b). These compounds appear to be stronger 
inhibitors of Gram-positive bacteria, with efflux pumps inhibiting their effectiveness against 
E. coli and other Gram-negative bacteria (Trzoss et al., 2013). In addition to the published 
work on these compounds, the pyrrolopyrimidine compound class has been patented to be 
potentially useful for further clinical developments (Bensen et al., 2012, Cooper et al., 2016). 
 
Further optimisations of the pyrrolopyrimidine compounds lead to the development of the 
novel TriBE class of inhibitors. These compounds have been significantly optimised to have 
significant efficacy against S. aureus, S. pneumoniae and E. faecalis, although in a mouse 
model they did not show activity as good as the clinical antibiotic levofloxacin. Equally 
against clinically-relevant bacteria they showed a range of activities, but importantly in 
antibiotic-resistant strains good activity was seen (Tari et al., 2013a). Like the 
pyrrolopyrimidine compounds the active site of the compounds has been determined by 
crystallography in both DNA gyrase and topo IV (Figure 1.8.6). The gyrase binding pocket 
appears as determined by crystallography appears to have some possible overlap to both the 
ATPase binding site as well as the novobiocin binding site, however from the literature this 
binding pocket has not been confirmed with mutagenesis. The mechanism of action for these 
compounds has been determined to be through a dual targeting mechanism to both GyrB and 
ParE, which leads to very low frequency of resistance values, leading them to be an interesting 
series of compounds to explore further. 
 
From the TriBE group of compounds Redx03863 has been further developed as an 
antimycobacterial agent by Redx AntiInfectives, from which they produced their lead 
compound of Redx04739 (Figure 1.8.7) (McGarry et al., 2018).  
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Figure 1.8.6: Image of the binding pocket of compound 4 in the Enterococcus faecalis V583 ATPase 
sub-domain (PDB entry: 4KSG). Key binding interactions and their residues shown. The residues 
correspond to the following residues in M. tuberculosis GyrB: N48 – N52; S49 – A53; E52 – E56; D75 
– D79; R78 – R82; S122 – V125; T167 – S169 (Tari et al., 2013a). 
 
 
Figure 1.8.7: Chemical structure of Redx03863 which was optimised to give the lead compound of 
Redx04739 
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1.9 Project aims 
The initial aim of the project was to crystallise and characterise the M. tuberculosis fusion 
protein (Mtb GyrBA) as, since the initial cloning of this fusion protein by Dr Fred Collin, 
there had been no comprehensive studies of its total activities, including the ATPase activity. 
Unsuccessful crystallisation trials led us to clone and perform initial characterisations on the 
DNA gyrase enzymes from M. thermoresistibile (Mth GyrA, GyrB, and GyrBA). 
 
Our aim was always to further develop Mtb DNA gyrase as a drug target for novel antibiotics, 
and along our journey we were fortunate to work on two groups of compounds. The first was 
the problematic naphthoquinones, which were eventually dropped in favour of the modified 
TriBE compounds from Redx AntiInfectives. We investigated these compounds in 
collaboration with the company where we characterised them in terms of enzymatic and 
antibacterial properties. This also gave us the novel opportunity to gain additional 
crystallographic studies on the N-terminal domain of GyrB in the absence of crystals of the 
full-length enzyme. An overall summary of the project is shown in (Figure 1.9.1) 
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Figure 1.9.1: Overview of the three pronged approach of the PhD thesis presented to obtain mechanistic 
characterisation of the M. tuberculosis fusion protein; to characterise the various constructs presented 
against known inhibitors; as well as to characterise and perform structural studies on both the full length 
protein as well as the ATPase domain in complex with novel inhibitors. 
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2. Materials and Methods 
2.1 Bacteriology 
2.1.1 Bacterial strains 
The E. coli cloning and expression strains used in this study are listed in Table 2.1.1 
Table 2.1.1: Genotypes of E. coli cloning and expression strains used 
Strain Genotype 
DH5α (NEB) F- φ80lacZ∆M15 ∆(lacZYA-argF) U169 deoR recA1 endA1 
hsdR17 (rk - , mk +) phoA supE44 λ- thi-1 gyrA96 relA1 
StellarTM (Cloantech) F–, endA1, supE44, thi-1, recA1, relA1, gyrA96, phoA, Φ80d 
lacZΔ M15, Δ (lacZYA - argF) U169, Δ (mrr - hsdRMS - 
mcrBC), ΔmcrA, λ– 
BL21 (DE3) (NEB) fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS 
λ DE3 = λ sBamHIo ∆EcoRI-B int::(lacI::PlacUV5::T7 gene1) 
i21 ∆nin5 
RosettaTM 2 (pLysS) 
(Novagen) 
F- ompT hsdSB(rB- mB-) gal dcm (DE3) pLysSRARE2 (CamR) 
 
Bacterial strains for genomic DNA isolation, compound and susceptibility testing are listed in 
Table 2.1.2. All bacteria are classified within group 2 of the ACDP hazard group to human 
health, which means that they have the potential to be a hazard to those working with them, 
but are unlikely to spread to the community, and effective treatment exists (HSE, 2013). 
 
2.1.2 Media and antibiotics 
For molecular biology applications the strains detailed in Table 2.1.1 were grown in LB-broth 
(Formedium: tryptone 10 g/l; yeast extract 5 g/l, sodium chloride 10 g/l) or on LB-agar 
(Formedium: tryptone 10 g/l; yeast extract 5 g/l, sodium chloride 10 g/l, agar 11 g/l) 
supplemented as appropriate with ampicillin (100 mg/l), kanamycin (30 mg/l), and 
chloramphenicol (34 mg/l). In transformation reactions, SOC medium (tryptone 20 g/l; yeast 
extract 5 g/l; sodium chloride 0.58 g/l; potassium chloride 0.186 g/l; magnesium chloride 2.03 
g/l; magnesium sulphate 2.46 g/l; glucose 3.6 g/l) was utilised.   
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Table 2.1.2: Summary of bacterial strains used for genomic DNA isolation, and compound 
susceptibility testing.  
Species name Collection number Obtained from Source 
Acinetobacter 
baumannii 
NCTC13420 RedxPharma Clinical Isolate 
Escherichia coli ATCC25922 RedxPharma/ 
HPA 
Clinical Isolate 
Mycobacterium 
smegmatis 
ATCC19420 RedxPharma Unknown source 
Mycobacterium 
thermoresistibile 
ATCC19527 DSMZ Soil isolate 
Pseudomonas 
aeruginosa 
ATCC27853 RedxPharma Clinical Isolate 
Staphylococcus 
aureus 
ATCC29213 RedxPharma Clinical Isolate 
 
All non-Mycobacterial strains in Table 2.1.2 were grown in Mueller-Hinton broth (Sigma: 
beef infusion solids 2 g/l; casein hydrolysate 17.5 g/l; starch 1.5 g/l) or on Mueller-Hinton 
agar (Sigma: beef infusion solids 2 g/l; casein hydrolysate 17.5 g/l; starch 1.5 g/l; agar 17 g/l). 
No antibiotics or supplements were added to Mueller-Hinton broth or agar. 
 
All mycobacterial strains in Table 2.1.2 were grown in Middlebrook 7H9 broth (Sigma: 
ammonium sulphate 0.5 g/l; disodium phosphate 2.5 g/l; monopotassium phosphate 1 g/l; 
sodium citrate 0.1 g/l, magnesium sulphate 50 mg/l; calcium chloride 0.5 mg/l; zinc sulphate 
1 mg/l; copper sulphate 1 mg/l; ferric ammonium citrate 40 mg/l; L-glutamic acid 0.5 g/l; 
biotin 0.5 mg/l) supplemented with Middlebrook OADC growth supplement (bovine albumin 
fraction V 5 g/l; dextrose 2 g/l; catalase 4 mg/l; oleic acid 50 mg/l; sodium chloride 0.85 g/l), 
0.2% (v/v) glycerol and 0.05% (v/v) Tween-80 or on Middlebrook 7H11 agar (Sigma: casein 
enzymatic hydrolysate 1g/l; ammonium sulphate 0.5 g/l; monopotassium phosphate 1.5 g/l; 
disodium phosphate 1.5 g/l; sodium citrate 0.4 g/l; magnesium sulphate 50 mg/l; L-glutamic 
acid 0.5 g/l; ferric ammonium citrate 40 mg/l; pyridoxine 1 mg/l; biotin 0.5 mg/l; malachite 
green 1 mg/l; agar 15 g/l) supplemented with Middlebrook OADC growth supplement and 
0.2% (v/v) glycerol. 
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2.1.3 Preparation of chemically competent E. coli cells 
Fifty microliters of competent cells were grown overnight in 5 ml LB-broth (37°C, 200 rpm) 
with the appropriate antibiotics. One millilitre of the overnight culture was used to inoculate 
100 ml LB-broth with the appropriate antibiotics grown at 37°C, 200 rpm until the optical 
density 600 nm (OD600) reached a value of 0.3. The cultures were cooled on ice and pelleted 
at 4°C, 3000 rpm for 12 min. The supernatant was removed, and the pellets resuspended in 
total 12 ml ice cold 100 mM calcium chloride. The resuspended bacteria were pelleted at 4°C, 
3000 rpm for 12 min. The supernatant was removed, and the pellets resuspended in 2.5 ml ice 
cold calcium chloride before supplementation with final concentration 25% (v/v) ice cold 
glycerol. 100 µl aliquots were flash-frozen in liquid nitrogen and stored at -80°C until use. 
 
2.1.4 Heat shock transformation of chemically competent cells 
Chemically competent cells (Table 2.1.1) were defrosted on ice, before supplementation with 
0.5 µl purified plasmid, 5 µl of ligation reaction or 5 µl InFusion cloning reaction. The cells 
were mixed by flicking before being returned to ice for 10-20 min. The cells were transferred 
to a 42°C heat block for 45 s, briefly returned to ice (maximum 2 min) before addition of 250 
µl SOC medium. Transformation reactions were placed in a 37°C shaking incubator (200 rpm) 
for 45-60 min before plating 50-100 µl of expression cells or the whole cloning reaction on to 
LB-agar with the appropriate antibiotics overnight at 37°C. 
 
2.2 Molecular biology methods 
2.2.1 Oligodeoxynucleotides (primers) 
Multiple sets of primers were used in this thesis for various different purposes. The initial set 
of primers was used to generate new protein constructs (Table 2.2.1), the second were used to 
generate the three sets of single point mutants (Table 2.2.2). A third set of primers were used 
for the amplification of the type IIA topoisomerase from E. coli and M. smegmatis bacterial 
mutants (Table 2.2.3). Further primers were used for sequencing reactions (Table 2.2.4).  
49 
 
 
50 
 
 
Table 2.2.1: NC 
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Table 2.2.2: P2 
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Table 2.2.3: Landscape 
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Table 2.2.4: Sequencing primers used to sequence plasmids and amplified genes. Orientation indicated 
as (F) for forwards and (R) for reverse orientated primers. 
Protein Primers 
E. coli gryA AAACTGCGCGGCTGTGTTAT (F) 
AATTCCGGACGTCATGCCAA (F) 
CTACTCCCAGACCCAGTTGC (F) 
CGCGGAACTGTTGCGTATTC (F) 
TCTTCATGGCGACCGCTAAC (F) 
CAGCCAAACTTTACCGTGCC (R) 
E. coli gyrB ACGAAAATTCGAAGATGTTTACCGT (F) 
ATCCAGCGCGAGGGTAAAAT (F) 
TGGACAAAGAAGGCTACAGCA (F) 
AGGAAGTGGCGACGCTTATC (F) 
TGAACGCCTTATCCGGCCTA (R) 
E. coli parC GGAAAAGCGTATTGTTAATCGCAAC (F) 
TCGGAAGCATCTTCAATCACCA (F) 
CTGCCTGCAGTTCTTTCTTCA (F) 
ATATCCACGCGGTTGGAACG (F) 
GCAAAGAGTTGTATATCAAGGCACA (R) 
E. coli parE AAACGTATTACACCTCTTCCATCGC (F) 
GACCGTGTTTCACCAATGCG (F) 
CCCAGATATCTTCCGCCGAC (F) 
TATTTCAACCCGATCGTCGATTTTC (R) 
M. smegmatis gyrA AAGGGTCTCGGTGAGATGGA (F) 
TGGCGATGGAGATGTTGCGTG (F) 
CAGGTGCGCGACGGCAAG (F) 
CCTCGAGCGGCAGAAGATCG (F) 
AACCTCCTGGCCTTCCAGCC (F) 
ACCTACAGCTCCTTAGCTCG (R) 
M. smegmatis gyrB ATAGGTGGAAACGCGGCTAC (F) 
GCTGGAGGCCACGGTCCTG (F) 
TCGAGATCGCGATGCAGTGGA (F) 
CGACATCGGTGGGTTGCCG (F) 
GGCAGCGTCGTATCAGTCAT (R) 
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Protein Primers 
M. tuberculosis gyrA TTGGCGATGGAGATGCTGAG (F) 
TCTGGGCGCTGGA (F) 
CCGGCATTTCCAACATTGAGGACC (F) 
ACGTCAGCGACGAGGATTTG (F) 
CATGCGGTTCAATATCGACGAC (F) 
M. tuberculosis gyrB GGATGGCGGTGTCGAGGT (F) 
ACCTTTCACTATCCGGGTGGC (F) 
ATCCGCGCAAGTCCGAACTGTATG (F) 
AAGGCCGGGAAGAAGATCAACAAG (F) 
M. thermoresistibile 
gyrA (G) 
AATCGACGAGGAGACAGTCG (F) 
CTGCGCATGGTCATCGAACT (F) 
GTGCGTGACGAGCTCAAG (F) 
M. thermoresistibile 
gyrA (CO) 
ATGCTGCGTGAAATTGATGA (F) 
ATCGTGTTGGTCTGCGTATG (F) 
GCGTGGTATTGTTCGTGATG (F) 
CAGAAGGTGATACACTGGTTGC (F) 
M. thermoresistibile 
gyrB (G) 
TTGTATTTCCAGGGCGTGGCTGCCCAGAAGAA (F) 
TATGACAAATCGGTCCCCG (F) 
CTTCCGGGCCGCGTTGAC (F) 
ATCATCAACGTCGAGAAGGC (F) 
ATGGGCGAGGACGTCGAG (F) 
CAAGCTTCGTCATCACTAAACGTCCAGGAACCGA (R) 
M. thermoresistibile 
gyrB (CO) 
TTGTATTTCCAGGGCATGGCAGCCCAGAAGAAA (F) 
TATGATAAAAGCGTTCCGGG (F) 
AGAAGGTTTTCGCGCAGC (F) 
TTAATGTTGAAAAAGCGCGTA (F) 
GAAGATGTTGAAGCACGTCG (F) 
CAAGCTTCGTCATCATTACACATCCAGAAAACGCAC (R) 
T7 Promoter TAATACGACTCACTATAGGG (F) 
T7 Terminator CTAGTTATTGCTCAGCGGT (R) 
 
2.2.2 Agarose gel electrophoresis 
Agarose gel electrophoresis was prepared typically as 1% agarose (Melford) melted in 1xTAE 
buffer (Formedium) in a microwave oven (900 W) for 3 min at 70% maximum power with 
evaporated water added back in before casting. Gels to separate topological states were 
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typically run at 60 V for 200 mins. Gels to separate linear DNA fragments were typically run 
for 1 hour at 100 V. Gels were stained in ca. 2 µg/ml ethidium bromide before imaging in a 
SynGene Gel imaging system. 
 
2.2.3 PCR and cloning 
Primers were designed for the fragments of DNA to be cloned (Table 2.2.1;Table 2.2.3). Thirty 
cycles of PCR were typically carried out in 20 µl reactions with Phusion polymerase in the 
GC buffer as per manufacturer’s instructions (Table 2.2.5; Table 2.2.6). Following successful 
amplification of the insert (confirmed by gel electrophoresis) the insert was purified by either 
gel purification or PCR clean up (see section 2.2.5). The vector was typically prepared by 
cleavage with restriction enzymes for at least 3 hours at 37°C before gel purification. The 
vector and insert were used in either a ligation reaction with T4 ligase (NEB) as per 
manufacturer’s instructions or an In-Fusion cloning reaction (Takara Bio Inc.) as per 
manufacturer’s instructions, followed by transformation into cloning cells with the appropriate 
antibiotics. Colony PCR with a primer in the vector and one in the insert (e.g. a cloning primer 
and a sequencing primer such as T7), with 2x GoTaq® Green Master Mix (Promega) to a total 
of 2.5-5 µl reactions were used to confirm positive results as par manufacturer’s instructions 
(Table 2.2.7). The thermocycling procedure used was analogous to that of the Phusion® DNA 
polymerase protocol with an alteration to 6 mins in the initial denaturation step (Table 2.2.6). 
Positive results from colony PCR were amplified through overnight culture and performing a 
mini prep. Sequence analysis (section 2.2.7) was performed to confirm the correct sequence 
before purification. 
 
Table 2.2.5: Typical reaction components for PCR reactions carried out with Phusion® DNA 
Polymerase (NEB). 
Component Final Concentration 
MilliQ water To final reaction volume 
5X Phusion HF or GC buffer 1X 
dNTPs 200 µM 
Forwards Primer 0.5 µM 
Reverse Primer 0.5 µM 
Template DNA 5 pg/µl 
DMSO 3% (v/v) 
Phusion DNA Polymerase 1.0 units / 50 µl PCR reaction 
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Table 2.2.6: Typical thermocycling reaction for a PCR reaction carried out with Phusion® DNA 
Polymerase (NEB). 
Step Temp Time 
Initial Denaturation 95-98°C 2 min 
30 Cycles 95-98°C 
Annealing Temperature 
72°C 
10-60 s 
30-40 s 
2-4 min 
Final Extension 72°C 10 min 
 
Table 2.2.7: Typical reaction components for PCR reactions carried out with 2x GoTaq® Green Master 
Mix (Promega). 
Component Final Concentration 
MilliQ water To final reaction volume 
2x GoTaq® Green Master Mix (Promega) 1X 
Forwards Primer 0.5 µM 
Reverse Primer 0.5 µM 
 
2.2.4 Site-directed mutagenesis 
Site-directed mutagenesis was performed through use of a PCR-based method by which 
primers were designed to be complementary to the base sequence around the mutants to 
change with the altered codon (Table 2.2.2). The PCR reaction was carried out using Phusion® 
DNA polymerase using the conditions previously described (Table 2.2.5; Table 2.2.6). Fifty 
picograms of the GyrB or GyrBA plasmids were used as the template DNA. After a successful 
PCR reaction, the template DNA was removed by digestion by DpnI (NEB) for 1 hour at 37°C 
in CutSmart buffer (NEB). The resulting plasmid DNA was heat-shock transformed into 
cloning cells (Table 2.1.1) with the appropriate antibiotics. Successful base change was 
confirmed by sequencing analysis of the coding sequence of the plasmid. 
 
2.2.5 DNA purification 
Linear DNA purification was either carried out by gel extraction and subsequent clean up kit 
(Qiagen Gel purification kit or NucleoSpin Gel and PCR clean up kit) or through use of a PCR 
clean-up kit (Qiagen PCR clean-up kit or NucleoSpin Gel and PCR clean up kit) following 
the manufacturer’s instructions with the following alterations as described. Gels run for gel 
purification were typically made as 0.8% agarose in TAE, and gel slices were typically melted 
in the appropriate amount of buffer over an elongated time of 1-3 hour at temperatures ranging 
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between 37-50°C. The spin columns were eluted after a prolonged period of time (15-30 min) 
with the elution buffer at an elevated temperature of 30-40°C. 
 
Plasmid DNA was purified by the Qiagen mini-prep kit following the manufacturer’s 
instructions with the following alteration that the spin columns were eluted after a prolonged 
period (15-30 min) with the elution buffer at an elevated temperature of 30-40°C. 
 
2.2.6 DNA concentration determination 
DNA concentrations were estimated through use of a Nanodrop (ThermoFisher). Two 
microliter drops of DNA solution were compared to a buffer blank to obtain an absorbance 
reading at 260 nm which was converted by the machine with the Beer-Lambert into an 
estimate of the total DNA concentration. 
 
2.2.7 DNA sequencing 
DNA sequencing was performed by either SourceBioscience (Cambridge) or EuroFins 
Genomics. 
 
2.3 Protein methods 
2.3.1 Buffers and solutions 
Buffer components were purchased from either Sigma Aldrich or Melford Chemicals. 
 
The following buffers were routinely used in protein purification: 
Lysis Buffer: 50 mM Tris-HCl pH 7.9, 400 mM NaCl, 20 mM imidazole 
His-elution buffer: 50 mM Tris-HCl pH 7.9, 400 mM NaCl, 500 mM imidazole 
TEV cleavage buffer: 50 mM Tris-HCl pH 7.9, 50 mM NaCl, 5 mM DTT 
Gel filtration buffer: 50 mM Tris-HCl pH 7.9, 50 mM NaCl, 5 mM DTT 
Mtb storage buffer: 50 mM Tris-HCl pH 7.9, 50 mM NaCl, 5 mM DTT, 20% (v/v) glycerol 
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2.3.2 Protein expression 
Approximately 30-50 ng of plasmid DNA was transformed into the RosettaTM 2 (pLysS) cell 
line via heat shock transformation (section 2.1.4). After overnight incubation on the correct 
antibiotics, single colonies were selected and grown in 100 ml LB in 250 ml conical flasks 
supplemented with the appropriate antibiotics and 0.5% (v/v) glycerol overnight (37°C, 200 
rpm). 25-35 ml of the overnight culture was used to inoculate 1 L LB supplemented with the 
appropriate antibiotics in 2 L shaker flasks and grown at 37°C 200 rpm until OD600 of c.a. 0.6 
(0.4-0.8; 1.5-2.5 hours). Cultures were induced with typically 0.8 mM IPTG (Mtb) or 0.4 mM 
IPTG (Mth) and the temperature reduced to 28-30°C for 4.5 hours for the full-length subunits 
and fusion proteins. The Mtb ATPase domain and subdomain constructs were induced with 1 
mM IPTG at 37°C for 4.5 hours, meanwhile the Msm and Mth loop deletion sub-ATPase 
domain constructs were induced at 30°C with 0.4 mM IPTG for 4.5 hours. The cultures were 
typically harvested at 5000 rpm for 8-10 mins (F8S-6x1000y or F9S 4x1000y rotor). Cells 
were resuspended in the lysis buffer except for the Mtb full ATPase domain construct (50 mM 
Tris-HCl pH 8, 400 mM sodium chloride, 20 mM imidazole) and the Msm and Mth loop 
deletion constructs (50 mM Tris-HCl pH 7.6, 400 mM sodium chloride, 20 mM imidazole). 
One EDTA-protease inhibitor tablet (Roche) was added per maximum 4 L of cells. 
Resuspended cells were stored at -80°C until purification. 
 
2.3.3 Protein purification 
Two to eight litres of resuspended cell pellets were defrosted from -80°C before lysis at 25,000 
psi in a Constant Systems cell disruptor in one-shot mode or in an Avestin EmulsiFlex-B15 
homogeniser at 40,000 psi. The lysate was centrifuged at a minimum of 17,500 rpm for 45 
mins (SS34-rotor). The supernatant was removed and filtered at 0.45 µm before application 
to a 5 ml HisTrap HP or equivalent column. The column was washed in lysis buffer 
supplemented with 2-5% His-elution buffer before elution over a gradient from 5-100% His-
elution buffer. Fractions were analysed on 8-12% SDS-PAGE gels depending on the size of 
the protein. Fractions deemed to contain the protein of interest were dialysed overnight against 
TEV cleavage buffer in the presence or absence of 1 mg TEV protease. If TEV cleavage was 
carried out, a second 5 ml HisTrap HP column was run collecting the flow-through followed 
by application to a MonoQ 10/100 column. The column was subsequently washed to a stable 
base line before eluting on a gradient 50 -1000 mM sodium chloride. If no TEV cleavage was 
carried out, the dialysed protein was directly run onto a MonoQ 10/100 column as described 
above. Fractions were analysed on 8-12% SDS-PAGE gels depending on the size of the 
protein. Fractions deemed to contain the protein of interest were pooled and concentrated to 
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less than 1 ml before application to a gel filtration column in gel filtration buffer (SuperdexTM 
75 10/300 for the GyrB24 constructs and HiPrep 16/60 Sephacryl S-400 HR for the GyrBA 
constructs). Fractions were analysed on 8-12% SDS-PAGE gels depending on the size of the 
protein. Fractions deemed to contain pure protein of interest were pooled and dialysed 
overnight against the Mtb storage buffer. Proteins were concentrated to the desired 
concentration before aliquoting and flash freezing in liquid nitrogen before storage at -80°C. 
 
The Mtb GyrA and GyrB subunits (including mutants) were purified with a single column 
strategy using the initial HisTrap HP column before dialysis into Mtb storage buffer. The Mth 
GyrA and GyrB subunits were purified with a dual column strategy using the initial HisTrap 
HP column before TEV cleavage and a reverse HisTrap HP column and dialysis into the Mtb 
storage buffer. 
 
The final preparations of the Msm and Mth GyrB sub-ATPase domains were performed at pH 
7.6 and additionally supplemented with 1 mM EDTA for the MonoQ and Gel Filtration 
columns as well as in the final storage buffer. 
 
2.3.4 Sodium dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) 
Three different types of SDS-PAGE gels were used in this project. 8% polyacrylamide Tris-
Glycine gels were used for the identification of the GyrBA fusion proteins (8% (v/v 
acrylamide, 375 mM Tris-HCl pH 8.8, 0.1% (v/v) SDS, 0.1% (v/v) APS, 0.1% (v/v) TEMED) 
with a 4% stacking gel made as per the resolving gel with 125 mM Tris-HCl pH 6.8. Gels 
were typically run in a Tris-Glycine running buffer (25 mM Tris-base, 192 mM glycine, 0.1% 
(v/v) SDS) for 1 hour at 180 V. 
 
12% acrylamide Bis-Tris gels were prepared and used for the identification of the GyrB sub-
ATPase domain. The resolving gels were prepared to contain 0.35 M Bis-Tris-HCl pH 6.8, 
12% (v/v) acrylamide, 0.1% (v/v) APS, 0.1% (v/v) TEMED, with a 0.5-1 cm of 5% (v/v) 
acrylamide stacking gel was set on top of the resolving gel to contain the wells. Gels were 
typically run in a 1x MOPS running buffer (50 mM MOPS, 50 mM Tris-HCl, 3.5 mM SDS, 
1 mM EDTA, pH 7.3) for 1 hour at 180 V. 
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TruPage precast gels (10%) (Sigma Aldrich) were used for identification of the full-length 
subunits. Samples were prepared by boiling with 1x loading buffer (50 mM Tris-HCl pH 6.8, 
2% (v/v) SDS, 100 mM DTT, 10 (v/v) glycerol and 0.05% (w/v) bromophenol blue). Gels 
were run in the TruPage running buffer for 1 hour at 180 V. 
 
Samples for SDS-PAGE analysis were prepared by boiling in final 1x sample application 
buffer (50 mM Tris-HCl pH 6.8, 10% (w/v) SDS, 100 mM DTT, 10% (v/v) glycerol, 0.05% 
(w/v) bromophenol blue) prior to loading. All SDS-PAGE gels were stained with 
InstantBlueTM stain (Expedeon) and imaged in a SynGene gel imager. 
 
2.3.5 Dialysis 
Dialysis was conducted in SnakeSkinTM (Thermo Scientific) tubing (10 kDa MWCO) clipped 
with food clips attached to polystyrene flotation devices overnight at 8°C in 2 L buffer with a 
magnetic stirrer bead stirring at a low rate. 
 
2.3.6 Protein concentration 
Protein concentration was performed in Amicon Ultra centrifugal filters (Merck) with a 
maximum molecular weight cut off (MWCO) of half the monomeric molecular weight of the 
protein of interest. Concentration was typically carried out at between 3000-4500 rpm on a 
bench top centrifuge (Sorvell Legend RT) or at 14,000 xg in a bench top microcentrifuge at 
4°C. Concentration analysis was carried out at regular intervals to determine the desired 
endpoint. 
 
Pre-concentration of samples was additionally assisted by addition of 1-2.5% (w/v) PEG 
35,000 to overnight dialysis solutions. 
 
2.3.7 Protein concentration determination 
Protein concentration was determined by taking multiple readings at 280 nm on a NanoDrop 
spectrophotometer system. Where the absorbance reading was above 1 unit, serial dilutions 
were made in the same buffer to calculate the concentration more accurately. Buffer blanks 
were carried out and subtracted from the protein readings. The protein concentration was then 
determined using the theoretical absorption co-efficient and molecular weight as calculated 
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by the ExPASy ProtParam tool (https://web.expasy.org/protparam/), via the Beer-Lambert 
Law: 
𝐴 =  ɛ𝑏𝑐 
Where A is the absorbance value (1 mm pathlength corrected to a 1 cm by the nanodrop 
software); ɛ is the absorbance co-efficient in units of M-1 cm-1 at the absorbance wavelength; 
b the path length (1 cm); and C the concentration of the protein (M). Therefore: 
𝐶 =  
𝐴
ɛ
 
To determine the concentration in units of mg/ml, the concentration in M was multiplied by 
the calculated molecular weight. 
 
2.3.8 Surface plasmon resonance 
Surface plasmon resonance was carried out in a Biacore T200 machine at 25°C with the 
assistance of Dr Rosaria Campilongo. The Mtb and E. coli GyrB sub-ATPase domains were 
bound at concentrations of 50 µg/ml in 10 mM sodium acetate pH 4.5 to CM5 sensor chips 
after activation of the surface carboxyl groups through the injection of a mixture of N-
hydroxysuccinimide (50 mM) and 1-ethyl-3-(3-diaminopropyl) carbodiimide (20 mM) from 
the Biacore amine coupling kit. Once the desired saturation was reached the active amines 
were deactivated through injection of ethanolamine. 
 
The system was primed in the SPR running buffer (10 mM HEPES-NaOH pH 7.4, 150 mM 
sodium chloride, 3 mM EDTA, 0.05 % (v/v) Tween-20, 5% (v/v) DMSO). Two-fold 
compound dilutions of Redx04739 were prepared in the SPR running buffer from a maximum 
concentration 50 µM. These compound dilutions were injected across the chips in single-cycle 
kinetics, with the reference cell (chip no protein) being subtracted for analysis. Data was 
subsequently analysed in Microsoft Excel to generate Kd values.  
  
2.4 Compounds and solvents 
Novel compounds supplied by Redx AntiInfectives were made up as stocks to 12.8 mg/ml in 
100% DMSO. Dilutions were made in broth for bacterial assays and in DMSO for enzymatic 
and crystallographic studies. 
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2.5 DNA topology assays 
2.5.1 Assay of DNA supercoiling by DNA gyrase 
Supercoiling assays were carried out in a 30 µl reaction volume at varying concentrations of 
DNA gyrase always with 0.5 µg relaxed pBR322* in 1x supercoiling assay buffer (Table 
2.5.1). A 6 µl reaction proportion was typically reserved for enzyme, dilution buffer (storage 
buffer of enzyme in the absence of enzyme (Table 2.5.1)), compounds and solvents. Reactions 
were typically incubated at 37°C in a waterbath for 30 mins unless otherwise stated. The 
reaction was stopped through addition of 30 µl 24:1 chloroform: isoamylalcohol solution and 
15 µl 2x STEB buffer (40% sucrose, 100 mM Tris-HCl pH 8.0, 100 mM EDTA, 0.5 µg/ml 
bromophenol blue), and vortexing before centrifugation (13,000 rpm 4 mins). The aqueous 
product was loaded onto native 1% (w/v) agarose in TAE gels. Gels were run as stated in 
section 2.2.2. 
 
Table 2.5.1: Typical assay and dilution buffers used in the respective E. coli and mycobacterial DNA 
gyrase supercoiling assays 
 E. coli Mycobacteria 
1x Assay buffer 35 mM Tris-HCl pH 7.5 
24 mM potassium chloride 
4 mM magnesium chloride 
2 mM dithiothreitol 
1.8 mM spermidine 
1 mM ATP 
6.5 % (w/v) glycerol 
0.1 mg/ml bovine serum albumin 
(acetylated) 
50 mM HEPES-KOH pH 7.9 
6 mM magnesium acetate 
4 mM dithiothreitol 
1 mM ATP 
100 mM potassium glutamate 
2 mM spermidine 
0.05 mg/ml bovine serum albumin 
(acetylated) 
Dilution buffer 50 mM Tris-HCl pH 7.5 
100 mM potassium chloride 
2 mM dithiothreitol 
1 mM EDTA 
50% (w/v) glycerol 
50 mM Tris-HCl pH 7.9 
50 mM sodium chloride 
5 mM dithiothreitol 
20% (v/v) glycerol 
 
2.5.2 Assay of DNA relaxation by DNA gyrase 
Relaxation assays were carried out in a 30 µl reaction volume at varying concentrations of 
DNA gyrase always with 0.4 µg supercoiled pBR322* in relaxation assay buffer (50 mM 
HEPES-KOH pH 7.9, 6 mM magnesium acetate, 4 mM dithiothreitol, 100 mM potassium 
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glutamate, 2 mM spermidine, 0.05 mg/ml bovine serum albumin (acetylated)). A 6-8 µl 
reaction proportion was typically reserved for enzyme, dilution buffer (storage buffer of 
enzyme in the absence of enzyme), compounds and solvents. Reactions were typically 
incubated at 37°C in a waterbath for 1-2 hours as stated. 0.1 mg/ml proteinase K was added to 
the reaction and incubated at 37°C for 30 mins before addition of 30 µl 24:1 chloroform: 
isoamylalcohol solution and 15 µl 2x STEB buffer (40% sucrose, 100 mM Tris-HCl pH 8.0, 
100 mM EDTA, 0.5 µg/ml bromophenol blue), vortexing and centrifugation (13,000 rpm 4 
mins). The aqueous product was loaded onto native 1% (w/v) agarose in TAE gels. Gels were 
run as stated in section 2.2.2. 
 
2.5.3 Assay of DNA decatenation by DNA gyrase 
Decatenation assays were carried out in a 30 µl reaction volume at varying concentrations of 
DNA gyrase always with 200 ng kDNA in either decatenation buffer (40 mM Tris-HCl pH 
7.5, 10 mM sodium chloride, 10 mM dithiothreitol, 1 mM ATP, 250 mM potassium glutamate, 
6 mM magnesium acetate and 0.5 mg/ml bovine serum albumin (acetylated)) or supercoiling 
assay buffer (Table 2.5.1). A 6 µl reaction proportion was typically reserved for the enzyme 
and dilution buffer (storage buffer of enzyme in the absence of enzyme (Table 2.5.1)). 
Reactions were typically incubated at 37°C in a waterbath for 30 mins. The reaction was 
stopped through addition of 30 µl 24:1 chloroform: isoamylalcohol solution and 15 µl 2x 
STEB buffer (40% sucrose, 100 mM Tris-HCl pH 8.0, 100 mM EDTA, 0.5 µg/ml 
bromophenol blue), and vortexing before centrifugation (13,000 rpm 4 mins). The aqueous 
product was loaded onto native 0.8% (w/v) agarose in TAE gels. Gels were run as stated in 
section 2.2.2. 
 
2.5.4 Assay of DNA cleavage by DNA gyrase 
Cleavage assays were carried out in a 30 µl reaction volume at 0.074 µM M. tuberculosis or 
0.25 µM M. thermoresistibile DNA gyrase with 0.3 µg supercoiled pBR322* in relaxation 
assay buffer. A 6 µl reaction proportion was typically reserved for enzyme, dilution buffer 
(storage buffer of enzyme in the absence of enzyme (Table 2.5.1)), compounds and solvents. 
Reactions were typically incubated at 37°C in a waterbath for 30 mins. To trap the linear DNA, 
0.1 mg/ml proteinase K and 0.2 (v/v) SDS were added to the reaction and further incubated at 
37°C in a waterbath for 30 mins. The reaction was stopped through addition of 30 µl 24:1 
chloroform: isoamylalcohol solution and 15 µl 2x STEB buffer (40% sucrose, 100 mM Tris-
HCl pH 8.0, 100 mM EDTA, 0.5 µg/ml bromophenol blue), and vortexing before 
centrifugation (13,000 rpm 4 mins). The aqueous product was loaded onto native 1% (w/v) 
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agarose in TAE gels. Gels were typically left for 15 mins before being run at 60 V for 200 
mins. Gels were stained in 2 µg/ml ethidium bromide solution before imaging. 
 
2.5.5 Assay of ATP turnover by DNA gyrase 
The PK/LDH (pyruvate kinase/lactate dehydrogenase) assay (Figure 2.5.1) was carried out in 
96-well flat bottomed micro-titre plates in 50 µl reaction volumes. A typical reaction contained 
10 µl 5x ATPase assay buffer (Table 2.5.2), 1-2 ng pBR322*, 0.8 mM phosphoenolpyruvate, 
0.75 µl PK/LDH solution (Sigma), 0.4 mM NADH, a 5 µl reaction volume was reserved for 
compounds, drugs and solvents, with reactions being carried out in 1% (v/v) DMSO. 
 
 
Figure 2.5.1: Cartoon representation of the PL/LDH linked ATPase assay system used. Three enzymes 
work co-operatively to convert PEP into Lactate while Relaxed DNA is negatively supercoiled, and 
ATP is continually regenerated, and NADH oxidised into NAD+ resulting in a decrease in absorbance 
at 340 nm which can be measured and using the Beer-Lambert law the number of ATP molecules 
hydrolysed by DNA gyrase can be calculated. 
 
Table 2.5.2: 1x Assay buffer used in the PK/LDH-linked ATPase assay of E. coli and mycobacterial 
gyrases. 
 E. coli Mycobacteria 
Assay buffer 50 mM Tris-HCl pH 7.5 
1 mM EDTA 
5 mM magnesium chloride 
10% (w/v) glycerol 
50 mM HEPES-KOH 7.9 
4 mM DTT 
6 mM magnesium acetate 
100 mM potassium glutamate 
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The rate of ATP turnover was calculated using the Beer-Lambert law (∆𝐴 = 𝜀𝑐𝑙). The 
extinction co-efficient (𝜀) of NADH at 340 nm of 6220 M-1cm-1, and a path length (l) of 1.37 
mm were applied with the change of absorbance (ΔA) over a minimum time period of 30 mins 
directly after the addition of ATP being measured through use of the equation for linear 
regression (𝑦 = 𝑚𝑥 + 𝑐), using an 𝑥 value of 1/60 corresponding to 1 s. The resulting 
concentration decrease in NADH directly corresponds to the total number of ATP molecules 
turned over per second. To determine the number of ATP molecules turned over per individual 
GyrB or GyrBA subunit the final value was divided by the concentration of the protein in M. 
To account for the fraction of the ATP molecules turned over per second by contaminating 
enzymes, the novobiocin-independent rate when 100-200 µM novobiocin was included in the 
reaction was subtracted from the measured rate to give the novobiocin-dependent rate. All 
trial reactions were carried out in duplicate, and the errors calculated using the linear 
regression feature in GraphPad Prism. The final error value was calculated through the 
following equation: ∆𝐾𝑑 =  √(𝐾2 + 𝐾𝑛𝑜𝑣2) . 
 
IC50 values were obtained by performing non-linear regression [log(inhibitor) vs response – 
variable slope (four parameters)] on the novobiocin independent rates (Redx03863 and 
Redx04739) or absolute rates (novobiocin).  
 
2.5.6 Assay of DNA relaxation by topo IV 
Relaxation assays were carried out in a 30 µl reaction volume at varying concentrations of 
DNA gyrase always with 0.4 µg supercoiled pBR322* in relaxation assay buffer (50 mM 
HEPES-KOH pH 7.6, 100 mM potassium glutamate, 10 mM magnesium acetate, 10 mM 
dithiothreitol, 1 mM ATP, 0.05 mg/ml bovine serum albumin (acetylated)). A 6 µl reaction 
proportion was typically reserved for enzyme, dilution buffer (40 mM HEPES-KOH pH 7.6, 
100 mM potassium glutamate, 1 mM dithiothreitol, 1 mM EDTA, 40% (v/v) glycerol), 
compounds and solvents. Reactions were typically incubated at 37°C in a waterbath for 1-2 
hours as stated. 0.1 mg/ml proteinase K was added to the reaction and incubated at 37°C for 
30 mins before addition of 30 µl 24:1 chloroform: isoamylalcohol solution and 15 µl 2x STEB 
buffer (40% sucrose, 100 mM Tris-HCl pH 8.0, 100 mM EDTA, 0.5 µg/ml bromophenol 
blue), vortexing and centrifugation (13,000 rpm 4 mins). The aqueous product was loaded 
onto native 1% (w/v) agarose in TAE gels. Gels were run as stated in section 2.2.2. 
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2.5.7 Assay to determine cleavage profile by DNA gyrase 
Three cleavage assays were carried out using either the mycobacterial supercoiling assay 
buffer containing ATP and 2 ng of relaxed pBR322* (120 µl final volume), or mycobacterial 
relaxation assay buffer (no ATP) with either 1.2 ng of negatively supercoiled pBR322* (120 
µl final volume) or 1.2 ng of EcoRI-linearised pBR322* (50 µl final volume) in the presence 
of 3.3% (v/v) DMSO, with or without DNA gyrase subunits, and 50 µM moxifloxacin. The 
assay was incubated in a waterbath at 37°C for 30 min before addition of 0.1 mg/ml proteinase 
K and 0.2% (v/v) SDS, and further incubation in a waterbath at 37°C for 30 min. The assay 
was immediately subjected to the NucleoSpin Gel and PCR clean up kit following the 
manufacturer’s instructions and being eluted in 40-50 µl of Buffer EB. A 20 µl digestion was 
performed on 10-16.5 µl of purified product with 10 units of BsaI-HF, EcoRI-HF and BsaI-
HF in a waterbath at 37°C overnight. The products were analysed on native 1.2% (w/v) agarose 
in TAE gels run as stated in section 2.2.2. 
 
2.6 Whole cell compound testing 
2.6.1 MIC determination 
A top concentration was selected to a maximum of 128 µg/ml and a two-fold dilution series 
was applied to the compound diluted in growth medium to a final concentration decrease of 
210. A maximum final concentration of 1% (v/v) DMSO was used. Bacteria grown on agar 
were suspended in assay growth media to a dilution factor of 1/100 of the 0.5 McFarland 
constant (CLSI, 2012). An equal volume of the bacterial growth suspension and the compound 
dilution series were mixed, the positive growth control contained media without drug, the 
negative control contained 100 µl media in the absence of bacteria. The OD600 was read and 
the bacteria were incubated for 20 hours for E. coli ATCC25922, A. baumannii 
NTCC13420, Pseudomonas aeruginosa ATCC 27853, and Staphylococcus aureus 
ATCC29213 at 37°C, or for 48 hours for M. smegmatis ATCC19420 at 35°C before taking 
visual and OD600 readings. All data were confirmed as a minimum of n = 2 where both repeats 
were within a 2-fold difference. 
 
2.6.2 Agar MIC determination 
A top concentration was selected (maximum 64 µg/ml), and a 10X solution was made and a 
two-fold dilution series was applied to the compound diluted in broth to a final concentration 
decrease of 210. The maximum final concentration of 1% (v/v) DMSO was used. 100 µl of 
compound dilution or plain broth (positive and negative control wells) was mixed with 900 µl 
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of Muller-Hinton agar for E. coli or Middlebrook 7H11 agar for M. smegmatis both at 50°C 
and allowed to set in the wells of a 24-well plate. Two replicates were made at each drug 
dilution. The bacteria grown on agar were suspended in broth to a dilution factor of 1/100 of 
the 0.5 McFarland constant. 20 µl of bacterial suspension was used to inoculate each well. 
The plates were incubated for 20 hours for E. coli ATCC25922 or for 72 hours M. smegmatis 
ATCC19420. All data were confirmed as a minimum of n = 2 where both repeats were within 
a 2-fold difference. All experiments were performed at a minimum of two repeats. 
 
2.6.3 Time of kill 
A single 10 ml starter culture was inoculated with a single bacterial colony grown on agar 
incubated overnight for E. coli ATCC25922 or for 2.5 days M. smegmatis ATCC19420 at 
37°C 200 rpm. 50 µl of the starter culture was subbed into 5 ml pre-heated medium and grown 
at 37°C 200 rpm until OD600 0.3. The inoculum was diluted to the 0.5 McFarland standard in 
broth and 250 µl was used to inoculate 50 ml prewarmed broth in 250 ml flasks. 100 µl was 
removed to form the T-5 plate dilutions made in sterile PBS. 200 µl of compound diluted in 
broth to form a 1000x or 4000x MIC stock was added to duplicate flasks. Duplicate flasks 
were kept aside as no drug controls. 100 µl was removed from each flask to form the T0 plate 
dilution series made in sterile PBS. All flasks were incubated at 37°C 200 rpm. Plate dilutions 
were taken at 30, 60, 120, 240, 360, 1440 min for E. coli ATCC25922 or 6, 12, 24, 48, 96, 
144 hours for M. smegmatis ATCC19420 made in sterile PBS. Colonies were counted after 
24-hour incubation at 37°C for E. coli ATCC25922 or after 3-day incubation for M. smegmatis 
ATCC19420 at 37°C. The percentage of colony forming units remaining was calculated as a 
percentage of the average number of colonies from the no drug control plates divided by those 
counted on each of the plates from the cultures treated with compound. The point at which no 
colony was counted on a plate emerging from a drug treated culture was defined as the time 
of kill. 
 
2.6.4 Disruption of biofilm assay 
Initially two 10 ml starter cultures were set up from solid medium of E. coli ATCC25922 and 
grown at 37°C. After 24 hours the culture was diluted to 1/10th of the 0.5 McFarland constant 
in broth. 200 µl was used to inoculate each well of a 96-well plate. A Calgary Biofilm device 
was attached, sealed and the plate was incubated at 37°C shaking at 400 rpm. After 24 hours 
the Calgary Biofilm device was washed twice in sterile 1x PBS for 5 min shaking at 400 rpm, 
before being incubated in a series of two-fold antibiotic and compound dilutions of 200 µl 
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starting at 1028 µg/ml for antibiotics and 64 µg/ml for compounds. The plate was incubated 
at 37°C 400 rpm. After 24 hours the bMIC was read and the Calgary Biofilm device was 
washed twice in sterile PBS for 5 min shaking at 400 rpm, before being incubated in 200 µl 
plain broth at 37°C shaking at 400 rpm. After 24 hours the MBEC was read to determine the 
lowest concentration that can effectively eradicate biofilms and inhibit shedding and growth 
in the wells. 
  
The timings were altered to 48 hours for M. smegmatis with the exception that the drug 
incubation step was 72 hours. 
 
2.7 Bacterial mutant generation 
2.7.1 Frequency of mutation experiment 
A 10 ml starter culture was inoculated with a single colony of E. coli ATCC25922 was grown 
for 24 hours or a single colony of M. smegmatis ATCC19420 was grown for 48 hours in broth. 
To generate inoculum 2 ml starter culture was concentrated to 1 ml by the pelleting of 1 ml of 
culture followed by resuspension of the pellet in a further 1 ml of culture. Fifty microlitres of 
each concentrated inoculum was used to inoculate each of four 10 ml half 90 mm Petri dishes, 
containing concentrations of the compound of interest at either 2x or 4x the agar MIC value. 
A further 50 µl of each concentrated inoculum at 100 – 10-7 were plated on 2 no-drug 
containing half 90 mm Petri dishes. Compound-free plates were incubated for 20 hours (E. 
coli) and 48 hours (M. smegmatis) at 37°C. Compound containing plates were incubated for 
48 hours (E. coli) or 5 days (M. smegmatis). 
 
Following successful isolation of mutants, a representative selection (maximum 8) was 
restreaked onto the base agar without antibiotics. After their growth period (24 hours E. coli 
or 48 hours M. smegmatis) the MIC of the parent strain was compared to the mutant strain to 
confirm mutagenesis. Two independent replicates were performed. After successful validation 
of resistance mutation, glycerol stocks of the strain were made by mixing colonies from the 
plate in a mix of 150 µl broth with 50 µl 80% (v/v) glycerol and frozen at -80°C. Mutants were 
characterised by cross-MIC testing against a panel of known antibiotics and other novel 
compounds of known mode of action. Additionally, 5 ml liquid culture was grown from each 
mutant and the genomic DNA extracted using the EdgeBio (85171) PurEluteTM Bacterial 
Genomic kit as per manufacturer’s instructions for E. coli strains. The manufacturer’s protocol 
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was altered for M. smegmatis to break open the mycolic acid cell wall through the extension 
of incubation periods and by introducing the use of BeadBugTM prefilled tubed 0.1 mm/ 2 ml 
capacity (silica) for the vortexing steps to allow for mechanical breakage of the mycolic acid 
cell wall. PCR amplification of the DNA gyrase genes (gyrA and gyrB) and the topo IV genes 
(parC and parE) was performed using primers (Table 2.2.4), and purification of fragments 
was performed with the Qiagen PCR clean-up kit as per the manufacturer’s instructions. The 
products were sent for sequencing (Eurofins) within the sequencing primers (Table 2.2.4). 
 
2.7.2 Serial passage 
Serial passage experiments were conducted by the same method as the broth MIC protocol 
(Section 2.6.1) with the following alterations. Technical duplicates were always performed. 
The plates were initially inoculated with a final dilution of 1/200 of a 10 ml starter culture of 
E. coli ATCC25922 incubated for 24 hours or M. smegmatis ATCC19420 incubated for 48-
72 hours. All subsequent passages were performed with a final dilution of 1/100 from the ¼ 
MIC well every 24 hours (E. coli) or 48-72 hours (M. smegmatis). Glycerol stocks were made 
at least every 4 passages through addition of 33 µl 80% (v/v) glycerol to the ¼ MIC well and 
frozen at -80°C. The passage could be restarted from a 1/100 final dilution from the glycerol 
stock. Glycerol stocks were additionally prepared from the ¼ and ½ MIC wells when the MIC 
approached 64 µg/ml, with a top achievable MIC concentration of 128 µg/ml. 
 
Upon an end being reached by either an MIC of greater than 64 µg/ml or a significant fold 
change in the MIC, a glycerol stock was made as described above, and an agar plate was 
streaked. Cross-resistance analysis and genomic extraction, PCR amplification of the type IIA 
topoisomerase genes with subsequent sequencing analysis was carried out as described in 
section 2.7.1. 
 
2.8 Protein crystallography: crystal methods 
2.8.1 Screening of crystallisation condition 
Forty microlitre volumes of multiple 96-well commercial sparse matrix screens were aliquoted 
into the wells of Swissci 96-well 2-drop MRC sitting drop vapour diffusion crystallisation 
plates. An Oryx8 robot (Douglas instruments) was used to dispense 600 nl drops containing 
300 nl of each protein and screen. Plates were sealed with Fortitude PCR seals and imaged at 
20°C in a MinstrelTM HT UV robot (Rigaku). 
70 
 
 
The commercial sparse matrix screens (JCSG-plusTM, Morpheus®, The BCS screen, SG1TM 
screen, Structure screen 1 + 2, MIDASplusTM, PACT premierTM, The PGA screenTM) were 
purchased in HT-96 format from Molecular Dimensions. The AmSO4 suite and PEGs suite 
crystallisation screens were purchased from Quiagen. In addition, the inhouse KISS (keep it 
simple screen) screen was made and aliquoted by Molecular Dimensions. The KISS screen 
combines a buffer system (sodium acetate pH 4; sodium citrate pH 5; MES pH 6, HEPES pH 
7, Tris-HCl pH 8, CHES pH 9) with PEG3350 (5-40% (w/v)) and ammonium sulphate 0.2-
3.2 M. 
 
2.8.2 Optimisation of crystallisation conditions 
Crystal hits were optimised if they showed likelihood of containing protein (including those 
which did not show UVA-fluorescence). Conditions of interest were optimised in terms of pH, 
precipitant concentration and ionic strength, and pipetted in 40 µl well volumes by an Orxy8 
robot (Douglas instruments). The wells were pipetted, sealed and the plates were imaged as 
per the method used for screening. 
 
2.8.3 Seeding of crystallisation conditions 
After semi-successful optimisation, seed stocks were made by harvesting wells of crystals in 
40-100 µl mother liquor and vortexing for 4 mins with between one and three 1 mm glass 
beads (Sigma Aldrich). Seed stocks were stored at 4°C for short term storage or -20°C for 
long-term storage. When applying seed stocks to crystallisation optimisations the drop ratio 
was altered to contain 300 nl protein solution, 200 nl well solution and 100 nl seed stock 
without dilution.  
 
2.8.4 SDS-PAGE of crystals 
A well of sub-optimal crystals was chosen, and 2 µl of the well solution was added to the drop, 
and the full well of crystals was removed to a 1.5 ml Eppendorf. The crystals were pelleted at 
2000 xg for 1 min and the supernatant was removed. The crystals were washed in 10 µl well 
solution. A total of 4 wash steps were completed. The crystals were pelleted, and the 
supernatant removed, before addition of 10 µl 5x loading buffer (250 mM Tris-HCl pH 6.8, 
10% (w/v) SDS, 0.5 M EDTA, 50% (v/v) glycerol, 0.25 (w/v) bromophenol blue). The 
samples were boiled and run on 12% SDS-PAGE with a positive control of pure protein. 
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2.8.5 Crystal soaking 
Novobiocin crystal-containing wells were selected and mother liquor supplemented with 
between 1-4% (v/v) DMSO 0.25-1 mM Redx03863 or Redx04739 and 25% (v/v) ethylene 
glycol was applied to these wells (1-2 µl per 600 nl drop). Crystal soaks of between 20 min 
and several days were tested. These wells were harvested without the need of additional 
cryoprotectants as per section 2.8.6. 
 
2.8.6 Harvesting of crystals 
Crystals were harvested in Litholoops (Molecular Dimensions) by Dr Clare Stevenson. 
Crystals were either harvested from the well before being washed in a cryoprotectant and flash 
frozen in liquid nitrogen or cryoprotectant was added to the well solution before harvesting 
the crystals which were directly flash frozen in liquid nitrogen. Cryoprotectants were typically 
made to contain the well solution supplemented with 25% ethylene glycol. 
 
2.9 Protein crystallography: data collection and structure determination 
2.9.1 X-ray data collection 
X-ray data collection was carried out on beamlines i03 and i04 under cryogenic conditions at 
the Diamond Synchrotron, Oxford, UK. X-ray data were collected for 3600 x 0.05-0.1° images 
at a wavelength of 0.97 Å (1.2782 Å for data collected at the zinc edge) to maximum resolution 
1.2-1.3 Å with a beam size of 80x20 or 54 x40 µm. All data sets were collected with a Pilatus3 
6M hybrid photon counting detector (Dectris). Auto processing was carried out on the 
Diamond computers to determine the best data sets to work with. 
 
2.9.2 DIMPLE analysis 
A partially refined structure of the Msm GyrB sub-ATPase domain without ligands was 
uploaded to the ISPyB database prior to data collection. This was used by the Difference Map 
Pipeline (DIMPLE (Winn et al., 2011)) to identify unmodeled density that could contain 
ligands of interest.  
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2.9.3 Processing of diffraction data 
The Xia2 DIALS (Winter, 2010) datasets from auto processing after integration and scaling 
were merged (without further scaling) by AIMLESS (Evans and Murshudov, 2013). Expert 
molecular replacement (PHASER (McCoy et al., 2007)) was carried out with a monomer of 
the 4B6C published structure of the M. smegmatis sub-ATPase domain (Shirude et al., 2013) 
for the M. smegmatis structure. The resultant M. smegmatis structure was used for the 
molecular replacement of the M. thermoresistibile structures by PHASER. The model was 
largely completed through use of BUCCANEER (Cowtan, 2006) before iterative rounds of 
refinement (REFMAC (Murshudov et al., 1997)) and manual model building (COOT (Emsley 
et al., 2010)) until the structure appeared complete and no further improvement in the R-
factors and geometries were observed. Structures were validated through MOLPROBITY 
(Chen et al., 2010), PDB-REDO (Joosten et al., 2009) and the PDB-validation server (Berman 
et al., 2003). 
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3. Mechanistic Studies of DNA Gyrase from M. tuberculosis 
and M. thermoresistibile 
Presently there have been several mechanistic and structural studies carried out on DNA 
gyrase from both M. tuberculosis and M. smegmatis. However, in the past these studies have 
focused on just the A2B2 heterotetramer, here we investigate if there are any mechanistic 
differences through using a (BA)2 construct where the subunits have been fused to form a 
protein that resembles eukaryotic topo II. We have also carried out preliminary analysis of 
both of these constructs from the thermophilic mycobacterium M. thermoresistibile with the 
idea that it may be a stronger candidate for structural studies. 
 
3.1 DNA gyrase from M. tuberculosis 
3.1.1 Construct development of the GyrBA fusion protein 
Three Mtb DNA gyrase constructs (GyrA, GyrB and GyrBA) were passed on from previous 
lab members Dr Steven J. Hearnshaw (SJH) and Dr Frederic Collin (FC; Figure 3.1.1). The 
GyrBA fusion construct was an idea designed and cloned by FC, expression and purification 
were optimised by SJH. The construct was initially designed to be GyrB fused N-terminally 
to GyrA, with a single lysine linker inserted as a restriction enzyme site to create the construct; 
at the C-terminus a TEV site was followed by a His-tag before the stop codon in the pET-
20b(+) vector (Figure 3.1.1). On the original construct the extra 40 amino acids that have been 
determined not to be biologically relevant were included (Karkare et al., 2013a). Both the 
GyrB and GyrBA constructs were altered initially by deleting the N-terminal 40 amino acids. 
Following this the C-terminal TEV sequence and His-tag was removed from the GyrBA 
construct and the GyrBA coding sequencing was inserted using In-Fusion cloning (Takarabio) 
into the pET28-MHL vector at the BseRI site. This inserted an N-terminal His-tag followed 
by the TEV cleavage sequence before the GyrBA coding sequence (Figure 3.1.1). The natural 
valine start codon was altered to a methionine for expression in E. coli. 
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Figure 3.1.1: Cartoon representation of the three Mtb DNA gyrase constructs obtained from other lab 
members. The GyrB and GyrBA constructs contained the 40 amino acids at the N-terminus that have 
been defined as not being biologically relevant. The GyrBA construct was created with a single lysine 
linker between the GyrB and GyrA subunits. The original GyrB and GyrBA constructs were altered to 
remove the biologically irrelevant 40 amino acids. The C-terminal TEV-His-tag on the GyrBA 
construct was also moved to create a construct with a N-terminal His-TEV tag. 
 
3.1.2 Protein expression and purification of the GyrBA fusion protein 
Expression of the fusion protein had been partially optimised by SJH before the construct was 
altered. To determine if these conditions were still optimal, the expression conditions 
including cell lines, induction temperatures, media, and IPTG concentrations were trialled on 
a small scale to determine the preferred conditions.  It was found that the cells expressed the 
170 kDa protein in a variety of different conditions, but optimally in the RosettaTM 2 (pLysS) 
cell line, by induction with 0.8 mM IPTG at 28-30°C, for a time greater than 4 hours (Figure 
3.1.2a). 
 
To determine if the expression conditions of the fusion protein produced active proteins the 
cell lysate assay was developed. This involved using cell lysate in a traditional supercoiling 
assay obtained on a small scale to see if activity was observed eliminating the need to purify 
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a protein before determining its activity. The method trialled included lysing 1 ml of cell pellet 
at OD600 of 0.1 in 100 µl of lysis buffer via three rounds of freeze-thaw treatment followed by 
a 30 min spin to remove cell debris at 13,200 rpm bench top centrifuge (4°C). 3 µl of the 
clarified lysate showed significantly increased supercoiling activity compared to the 
uninduced sample under standard supercoiling assay conditions (Figure 3.1.2b). 
 
 
Figure 3.1.2: Induction of the 168 kDa Mtb GyrBA fusion protein under optimal expression conditions: 
E. coli RosettaTM 2 (pLysS) cell line, before (uninduced) or after (induced) induction with 0.8 mM IPTG 
at 28°C for 4.5 hours. One millilitre of both samples was pelleted and resuspended in lysis buffer, so 
that a sample with an OD600=0.6 was resuspended in 100 µl lysis buffer. The samples were lysed by 3 
rounds of freeze-thaw treatment before centrifugation for 30 min at 13,200 rpm. A) 8% SDS-PAGE 
showing induction of a protein between 150-200 kDa likely to be the GyrBA fusion protein of 168 kDa. 
B) 1% agarose in TAE gel showing a lysate supercoiling assay carried out with 3 µl of clarified lysate 
suggesting that the GyrBA protein has increased activity in supercoiling compared to the uninduced 
sample. 
 
After optimisation of expression on a small scale, the protein was expressed on a large scale 
(4-8 L). The lysing protocol was altered to use an Avestin EmulsiFlex-B15 homogeniser at 
40,000 psi as a method of lysing the cells as use of repeated freeze-thaw cycles on a large 
scale was not found to be as efficient. After lysis and a centrifugation step (45 min, 17,500 
rpm, SS-34 rotor), purification of the clarified lysate was trialled by a variety of methods 
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(Figure 3.1.3a), before the final purification protocol was reached (Figure 3.1.3b). The 
protocol was optimised to give the optimal balance of purity and yield and hence did not give 
consistently the highest purity protein which was obtained on a very small yield. Cleavage of 
the His-tag was not found to affect activity of the protein, therefore, the TEV protease cleavage 
step followed by a reverse HisTrap was not always performed. 
 
 
Figure 3.1.3: Purification method of the Mtb GyrBA fusion protein. A) Alternative purification methods 
trialled before B) obtaining optimal purification method. Cleavage of the His-tag and subsequent 
reverse His column was found to be optional in regards to activity, and the purity yield balance was not 
found to be significantly different with or without this step. 
 
The protein obtained of the highest purity after size exclusion chromatography was judged to 
be suitable for crystallography trials and ATPase assays (Figure 3.1.4a) whereas for 
topoisomerase assays less pure fractions and including samples collected from a MonoQ 
column could be used (Figure 3.1.4b). 
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Figure 3.1.4: SDS-PAGE gels showing “Pure” GyrBA (168 kDa) for crystallography and ATPase 
assays, and “Dirty” GyrBA suitable for topoisomerase assays after S400 size exclusion 
chromatography. 
 
3.1.3 The GyrBA fusion protein is active in supercoiling 
As implied from the cell lysate assay, it was determined using purified proteins that the fusion 
construct is as active in supercoiling at the same concentration as the gyrase subunits (Figure 
3.1.5a). After initial tests of activity under the previously published conditions (Aubry et al., 
2006a), it was determined that a concentration of 74 nM was appropriate to carry out further 
optimisations of the supercoiling reaction. To determine if there was any difference in the 
speed of supercoiling activity between the two different constructs, a time course was carried 
out. This determined that both constructs behaved very similarly with a satisfactory level of 
supercoiling being observed at 30 min (Figure 3.1.5b). Hence, for future experimentation it 
was determined that a 30 min incubation at 37°C with 74 nM of each gyrase or fusion subunit 
was sufficient. In terms of specific activity, this was found to be highly variable and 
preparation dependent, varying between 0.04 x 104 and 1.7 x 104 U/mg for the fusion 
construct, with values of around 0.2-0.4 x 104 U/mg for the individual subunits, where 1 U is 
the amount of enzyme required to fully supercoil 0.5 mg relaxed pBR322* in 30 minutes at 
37°C. 
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Figure 3.1.5: Supercoiling activity comparison between the Mtb DNA gyrase subunits and fusion 
constructs. A) Supercoiling as a function of decreasing concentration (370-0.73 nM) under fixed assay 
conditions (37°C, 30 min). B) Supercoiling as a function of increasing time (0-120 min) using 74 nM 
of each enzyme at a temperature of 37°C. -ve refers to reaction conditions lacking DNA gyrase at the 
final reaction time. 
 
Potassium glutamate has been previously identified as a key factor in supercoiling activity of 
DNA gyrase, with the activity of Mtb gyrase being described as optimal in 100 mM potassium 
glutamate (Aubry et al., 2006a). To ascertain if this was the same for the fusion protein, a 
titration of potassium glutamate (0-500 mM) was carried out with both constructs. It was 
determined that both an absence of potassium glutamate as well as high concentrations 
inhibited the activity of the enzyme. Our results were slightly different to the published result 
of 100 mM, under suboptimal assay conditions (40 nM enzyme, 18 min incubation) an optimal 
concentration was determined to be 200 mM for the individual subunits, whereas the fusion 
construct appeared to show good activity in concentrations ranging from 50-500 mM 
potassium glutamate (Figure 3.1.6).  
79 
 
 
Figure 3.1.6: Induction of supercoiling as a function of potassium glutamate concentration in both the 
Mtb GyrA2B2 individual subunits and the GyrBA fusion construct. Forty nanomolar of each individual 
protein assayed for 18 min at 37°C with potassium glutamate concentrations ranging 0-500 mM. The 
expected positions of relaxed (Rel), linear (Lin) and negatively supercoiled (Sc) pBR322* is indicated. 
-ve control contains all assay components in the absence of DNA gyrase at the maximal potassium 
glutamate concentration. 
 
3.1.4 The GyrBA fusion protein is active in relaxation 
DNA gyrase can weakly relax negatively supercoiled DNA in the absence of ATP (Gellert et 
al., 1977). It has been reported that this relaxation ability in the Mtb enzyme is better than 
gyrase from other species (e.g. those from S. aureus or E. coli) (Aubry et al., 2006a). Hence, 
it was investigated if fusing the B and A subunits had any influence on this ability. It was 
determined that both constructs could perform relaxation, although the relaxation assay was 
tricky to work with owing to a high degree of cleavage observed making the visualisation of 
relaxation difficult to observe. However, at relatively high concentrations (>0.1 µM) and long 
incubations (2 hours), relaxation is observed (Figure 3.1.7). The reaction appears to be slow, 
as even at 0.5 µM, relaxation is not apparently observed until 30-60 min whereas at much 
lower concentrations of enzyme some supercoiling is already observed within the first 5 min 
(Figure 3.1.5). No significant differences between the behaviours of the two constructs under 
these conditions were observed.  
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Figure 3.1.7: ATP-independent relaxation activity comparison between the Mtb gyrase subunits and 
fusion constructs. A) Relaxation as a function of decreasing concentration (0.75-0.1 µM) under fixed 
conditions (37°C, 2 hours). B) Relaxation as a function of increasing time (0-120 min) at 37°C and 0.5 
µM enzyme concentration. -ve control contains all reaction components in the absence of DNA gyrase 
at the final incubation timepoint in the case of assay B. Linear bands observed are a consequence of the 
large amounts of enzyme and longer time required for this assay. 
 
It has been reported in the literature that the relaxation activity is inhibited by the presence of 
potassium glutamate (Aubry et al., 2006a). This was investigated to determine if the fusion 
protein behaves differently to the wild type. At a concentration of 0.5 mM enzyme with a 1 
hour incubation period it was determined that like the ATP-dependent supercoiling reaction, 
high concentrations of potassium glutamate inhibited the relaxation reaction. The supercoiling 
reaction did not seem to occur in the absence of potassium glutamate (Figure 3.1.6), whereas 
there does appear to be weak relaxation activity under these conditions. Optimal concentration 
of potassium glutamate was determined to be between 100-200 mM for both constructs 
(Figure 3.1.8). 
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Figure 3.1.8: Optimisation of ATP-independent relaxation as a function of potassium glutamate 
concentration in both the Mtb GyrA2B2 individual subunits and the GyrBA fusion construct. 0.5 µM of 
each monomeric protein was assayed for 1 hour at 37°C with potassium glutamate at concentrations 0-
500 mM. -ve control contained all assay component in the absence of DNA gyrase at the highest 
potassium glutamate concentration. Linear bands observed are a consequence of the large amounts of 
enzyme and longer time required for this assay. 
 
3.1.5 The GyrBA fusion protein is active in decatenation 
Decatenation, the process of unlinking plasmids is typically carried out by topo IV in bacterial 
species (Zechiedrich et al., 1997). In the absence of topo IV in mycobacteria there have been 
several reports that the decatenation activity of DNA gyrase is enhanced compared to DNA 
gyrase from other species that contain topo IV (Manjunatha et al., 2002, Aubry et al., 2006a). 
To determine if this was also true for the fusion protein, this was investigated using the 
commonly-used assay to visualise decatenation which utilises Kinetoplast DNA purified from 
Crithidia fasciculata. kDNA is a large network of entangled mini-circles which cannot enter 
an agarose gel so may be visible in the wells (Shapiro et al., 1999) (Figure 3.1.9). In a positive 
assay result the mini-circles are released into their monomers and visualised within the gel 
either as a combination of nicked and supercoiled DNA in the case of DNA gyrase or as a 
combination of nicked and relaxed DNA in the case of topo IV. A linearising or nicking 
enzyme may also be able to release the mini-circles but will not form topoisomers (Figure 
3.1.9). 
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Figure 3.1.9: Expected banding pattern of a decatenation assay carried out and imaged on a native 0.8-
1% agarose in TAE gel stained with ethidium bromide. No migration is observed in the absence of 
enzymes with the kDNA being stuck in the wells. M. tuberculosis DNA gyrase should result in a mix 
of open circular (nicked) and negatively supercoiled mini-circles entering the gel if the reaction is 
carried out. Topo IV decatenates the kDNA resulting in a mix of relaxed topoisomers and open circular 
DNA. A restriction enzyme would simply linearise the mini-circles and no other topoisomers would be 
visible. A nicking enzyme would result in open circular or nicked mini-circles. 
 
It has been published that decatenation for this enzyme is preferential in assay conditions that 
are different to those of supercoiling and are characterised by a higher potassium glutamate 
concentration, the absence of spermidine, alongside a different buffer composition and pH 
(Aubry et al., 2006a). To confirm this result for the fusion protein, the kDNA decatenation 
assay was carried out with both the supercoiling and decatenation assay buffers. Unambiguous 
evidence for some decatenation activity was demonstrated in both the constructs. This activity 
for the fusion protein was not seen to be different between the two buffer compositions. 
However, it does appear that the subunits show enhanced decatenation activity in the 
supercoiling assay buffer. The fusion protein showed enhanced decatenation activity in both 
buffers compared to the subunits (Figure 3.1.10). 
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Figure 3.1.10: Decatenation assay using the kinetoplast DNA substrate. The kDNA is unable to enter 
the gel so may be seen in the wells of the gel, the product of a positive reaction shows a combination 
of open circular and negatively supercoiled mini-circles as seen by the two bands. A) was performed 
using the decatenation assay buffer, whereas B) was performed using the supercoiling assay buffer, 
with both reactions being performed at 37°C for 30 min. 0.8% (w/v) agarose in TAE gels were run at 
60 V for 3 hours. -ve control contained all assay components in the absence of DNA gyrase in the 
appropriate assay buffer to confirm no decatenation is seen in the absence of DNA gyrase. 
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3.1.6 The ATP turnover rate of M. tuberculosis DNA gyrase is appreciable 
In the literature it is reported that the ATP turnover rate of Mtb is too low to produce 
reproducible and reliable data for inhibitor studies (Karkare et al., 2013b) (Shirude et al., 
2013). In this study this was investigated (see methods chapter 2.5.5), and it was found that 
an appreciable rate could be determined. Initial studies using relaxed pBR322* showed that 
the individual Mtb gyrase subunit complex (A2B2) at 550 nM showed a much shallower 
decrease in absorbance at 340 nm corresponding to a lower oxidation of NADH and therefore 
a lower ATP turnover rate compared to the same complex from E. coli at 222 nM (Figure 
3.1.11). This corresponded to a rate of around 0.2 s-1 per individual Mtb GyrB subunit 
compared to 1.4 s-1 for E. coli gyrase when directly compared, suggesting that as previous data 
suggested the rate is indeed low compared to that of E. coli as stated in the literature (Agrawal 
et al., 2013, Karkare et al., 2013b, Shirude et al., 2013). Interestingly, when the rate of ATP 
turnover was compared using linear, negatively supercoiled and relaxed pBR322* substrates 
on the M. tuberculosis A2B2 complex the rates were slightly higher but comparable (Table 
3.1.1). 
 
Table 3.1.1: The novobiocin-sensitive ATP turnover rate with 550 nM of the individual GyrA and GyrB 
subunits in the presence of 2 ng of pBR322* in three different topological forms measured over 48 min 
after addition of 2 mM ATP. Data is representative of minimum of two experiments with duplicate data 
for each assay. 
pBR322* Topological Form ATP Turnover per GyrB subunit / s-1 
Relaxed 0.36±0.03 
Negatively supercoiled 0.31±0.04 
Linear 0.53±0.03 
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Figure 3.1.11: Raw absorbance data for the PK/LDH linked assay carried out with (Top) E. coli DNA 
gyrase (222 nM) with 1.5 ng relaxed pBR322* or (Bottom) M. tuberculosis DNA gyrase (550 nM) 
A2B2 constructs and 2 ng relaxed pBR322*. Despite a much larger amount of enzyme being used with 
the M. tuberculosis assay the results clearly demonstrate a greater rate of E. coli DNA gyrase. Negative, 
no NADH, and ADP controls contain DNA but no DNA gyrase, positive control contained DNA gyrase 
in the absence of novobiocin. ATP was substituted for ADP in ADP control, and no NADH was added 
to the no NADH control to obtain an absolute baseline. 
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We find that the rate of ATP turnover in the GyrBA fusion protein was very variable, likely 
depending on the purity of the protein. Initially it was found to be very comparable to that of 
the individual GyrB subunit. After swapping to a purer preparation of the fusion protein stock 
at a higher concentration, the rate was found to be consistently higher and more comparable 
to that of the E. coli protein in the presence of topologically unrestrained linear or nicked 
pBR322* substrates (Table 3.1.2). Surprisingly, it was found that if topologically-constrained 
relaxed or negatively supercoiled pBR322* substrates were used as the DNA substrate the 
ATP turnover rate was low (Table 3.1.2). Additionally, preliminary data indicates that there 
is a low ATP turnover rate in the presence of positively supercoiled DNA. 
 
Table 3.1.2: The novobiocin-sensitive ATP turnover rate with 200 nM of the Mtb GyrBA fusion protein 
in the presence of 1 ng of pBR322* in four different topological forms measured over 45 min after the 
addition of 2 mM ATP. Data is representative of duplicate repeats. 
pBR322* Topological Form ATP Turnover per GyrBA subunit / s-1 
Relaxed 0.03±0.06 
Negatively supercoiled 0.16±0.04 
Nicked 1.27±0.20 
Linear 1.00±0.10 
 
 To determine if the difference in the activity of Mtb DNA gyrase was due to a lack of 
stimulation from negatively supercoiled DNA, gel samples were taken at intervals over a 45 
min time course after ATP addition, as well as following the absorbance at 340 nm to allow 
the topological state to be monitored alongside the ATP turnover rate. Unsurprisingly, at the 
high concentrations used in the topoisomerase reactions (200+ nM, compared to 74 nM in 
supercoiling reactions) it was found that the positively supercoiled and relaxed pBR322* 
substrates were rapidly converted into a plasmid that was negatively supercoiled (Figure 
3.1.12). Although it is not possible to resolve positive and negative supercoils on a native 
agarose gel, it can be assumed that due to the lack of intermediate species at any timepoints 
that the positive supercoils were rapidly removed and negative supercoils inserted into the 
plasmid.  
 
To investigate if the low rate was due to the DNA concentration being sub-optimal (i.e. not 
enough DNA was being used to stimulate the ATP reaction), DNA titrations were carried out. 
The concentration required to reach a maximal ATP turnover rate with the topologically 
restrained pBR322* substrates appears to be greater than for the topologically unrestrained 
87 
 
substrates. Despite this, it was also found that they were still unable to reach rates close to 
those reached by the unrestrained substrates (Figure 3.1.13). 
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Figure 3.1.12: Visualisation of the topological state of 1 ng A) relaxed B) negatively supercoiled C) 
positively supercoiled pBR322* at 0, 1, 5, 10, 15, 20, 30, 45 min time points after addition of 2 mM 
ATP (ADP in ADP control) during an ATPase linked assay, visualised on a native 1% agarose in TAE 
gels. 200 nM enzyme assayed. The novobiocin controls block ATP activity allowing relaxation of 
negative supercoils as observed in B. The no NADH, negative and ADP controls do not contain DNA 
gyrase. 
 
Unlike DNA gyrase from E. coli the rate of ATP hydrolysis in the absence of DNA was found 
to be negligible – the gradients obtained were very close to those of the negative and 
novobiocin controls (Figure 3.1.13a). This indicates that the ATP hydrolysis reaction is highly 
coupled to DNA binding. To confirm this the ATP hydrolysis rate for the ATPase domain 
alone in the absence of the rest of the DNA gyrase heterotetramers was analysed. The reported 
ATP turnovers of 0.02 s-1 for the E. coli GyrB43 fragment (Ali et al., 1993) and 0.002 s-1 for 
the same Mtb fragment (Agrawal et al., 2013) are equivalent to the average novobiocin-
dependent DNA-independent rate of 0.05±0.08 s-1 over a concentration range 2-64 µM. Due 
to this rate being extremely slow with the Mtb GyrB NTD it was determined to be almost 
undetectable even at the highest enzyme concentration used. 
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Figure 3.1.13: A) Plot of absorbance at 340 nm monitoring the loss of NADH in the PK/LDH-linked 
assay. Control samples (no NADH, negative without enzyme, positive with ADP not ATP) contained 
no DNA substrate or DNA gyrase. The novobiocin-independent rate was measured in the presence of 
31.1 nM linear pBR322*. DNA titration with linear pBR322* with constant 250 nM GyrBA. B) 
Novobiocin-dependent ATP turnover rate with nicked pBR322* substrate measured using 150 nM 
GyrBA and nicked pBR322* concentration range of 0-37.6 nM. C) Novobiocin-dependent ATP 
turnover with negatively supercoiled pBR322* substrate measured using 150 nM GyrBA and 
negatively supercoiled pBR322* concentration range of 0-37.5 nM. All data is representative of 
multiple repeats and duplicate data points. Linear/Nicked represent the topologically unconstrained 
DNA class whereas negatively supercoiled DNA is representative of the topologically constrained DNA 
class. Error bars represent the range of data points collected for each data point, and all data were 
collected at a minimum of two duplicates. 
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3.1.7 Preliminary cleavage profile of M. tuberculosis DNA gyrase 
In order to determine an optimal DNA fragment for structural studies of the full-length enzyme 
(X-ray crystallography and CryoEM) we investigated the cleavage specificity of Mtb DNA 
gyrase. Cleavage reactions on relaxed pBR322* in the presence of ATP and on negatively 
supercoiled and EcoRI-linearised pBR322* in the absence of ATP were carried out in the 
absence and presence of moxifloxacin. These were subsequently linearised with three 
restriction enzymes (BsaI, EcoR1 and SalI) to help identify where the cleavage was occurring 
(Figure 3.1.14). 
 
 
Figure 3.1.14: Plasmid map of pBR322 (benchling.com) showing all the single cutting restriction 
enzymes. SalI cuts at 652 bp, BsaI cuts at 3428 bp and EcoR1 at 4360 bp. Cutting with these three 
restriction enzymes from intact pBR322* results in three fragments of 2776, 932 and 653 bp. Extra 
bands may be observed if there is additional cleavage by DNA gyrase. 
 
The reaction with relaxed pBR322* was carried out in the presence of ATP. Confusingly an 
additional band of ca. 1600 bp was seen in the restricted substrate for the reaction with relaxed 
pBR322*. This can be explained as incomplete restriction by EcoRI, although it was not 
observed when DNA gyrase was added to the reaction mixture. The linearized product formed 
in the absence of moxifloxacin did not appear as prevalent as in the presence of moxifloxacin. 
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Under these reaction conditions no distinct banding pattern was observed in the presence or 
absence of moxifloxacin with or without the restriction enzymes. Instead in the presence of 
moxifloxacin a smear was seen suggesting that multiple linear cleavage was occurring but not 
at distinct positions around the plasmid (Figure 3.1.14a). 
 
Like the cleavage with relaxed pBR322* and ATP, that of negatively supercoiled pBR322* 
in the absence of ATP was observed to be much greater in the presence of moxifloxacin than 
in its absence. Similarly, no distinct banding pattern was observed, with the results displaying 
a smear of DNA down the gel indicating a variety of differently sized DNA fragments being 
formed without a significant preference for any particular cleavage sites (Figure 3.1.14b). 
 
In the absence of any enzyme in the linear substrate there is also a very faint contaminating 
band approximately 1500 bp shorter than pBR322* - this band did not appear to alter the 
cleavage profile of the substrate. In contrast to the relaxed and negatively supercoiled 
substrates, when using the linear substrate in the absence of ATP a distinct band pattern was 
observed, however no alteration to the pattern after restriction was observed, probably likely 
due to low proportions of each species being obtained (Figure 3.1.14c). Overall, further 
optimisation is needed for all the substrates in the reaction protocol to determine the cleavage 
profile in the presence of moxifloxacin.  
 
This preliminary study demonstrates that in the presence of moxifloxacin linear DNA appears 
to give a discrete banding pattern suggesting preferential cleavage sites. This preliminary 
study clearly demonstrates that with further work an optimal DNA fragment should be able to 
be determined for use in structural studies. 
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Figure 3.1.15: Preliminary cleavage profile optimisations with Mtb GyrA2B2 A) Relaxed pBR322* in 
the presence of ATP, B) Supercoiled pBR322* in the absence of ATP, C) Linear pBR322* in the 
absence of ATP. Control reactions were carried out in the absence of DNA gyrase and moxifloxacin. 
After cleavage with BsaI. EcoRI, and SalI expected cleavage bands of pBR322* are 2782, 926, 651 bp. 
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3.2 DNA gyrase from M. thermoresistibile 
3.2.1 Construct design, cloning, expression and purification 
The following sub-section of work was for the most part carried out by Mr Brandon Malone 
(BM; JIC Summer School Student, 2016) under the supervision of SRH. Constructs were 
designed based on the M. thermoresistibile ATCC19527 genomic sequence. These were 
additionally codon-optimised using the GeneArt service (Fisher Thermo Scientific). The 
constructs were cloned into the pET28-MHL expression vector with an N-terminal His-tag 
and TEV protease sequence via the InFusion cloning system (Takarabio). To make the GyrBA 
fusion construct a single amino acid linker (lysine) was added between the GyrB and GyrA. 
After the clones were confirmed as correct via sequencing (SourceBioscience) expression 
trials were carried out in a range of E. coli expression hosts and under a range of conditions. 
It was determined that the optimum conditions were the expression of the codon-optimised 
genes in the RosettaTM 2 (pLysS) E. coli strain in LB with induction at OD600 of 0.6, by addition 
of 0.4 mM IPTG at 28°C for 4-5 hours. 
 
Large-scale expression using the optimised conditions followed. Harvested cells were 
resuspended in lysis buffer and stored at -80°C. Purification of the subunits was achieved 
through a two-column strategy: application to a 5 ml His Trap (GE) in lysis buffer with elution 
in lysis buffer + 500 mM imidazole on a gradient. The semi-purified fractions were dialysed 
overnight against TEV cleavage buffer, with 1 mg of TEV protease. The flow-through was 
collected from a second 5 ml His Trap column. In addition, a Sephycryl S400 size exclusion 
column was run on the GyrBA fusion protein in Gel Filtration buffer. Pure fractions analysed 
via 8% tris-glycine SDS-PAGE were collected, concentrated and dialysed against storage 
buffer before concentration, allotting and flash freezing to -80°C for storage.  
 
3.2.2 Crystallography trials of M. thermoresistibile DNA gyrase 
BM carried out multiple crystallisation screens on the GyrBA fusion protein. After running 6 
sparse matrix screens (Table 3.2.1) and one optimisation based on conditions presenting with 
over nucleation being initially crystallised at 30°C, no crystal hits were obtained that were 
suitable for further optimisation or X-ray diffraction. 
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Table 3.2.1: Sparse matrix crystallisation conditions trialled with purified Mth GyrBA protein. No 
crystal hits suitable for optimisation or X-ray diffraction were observed at 4 weeks. 
Enzyme Concentration 
(mg/ml) 
Enzyme Conditions Sparse matrix screens 
2.8 Apo JCSG-plusTM, PACT 
premierTM 
2.4 0.118 mM 20-12p-8 doubly 
nicked oligo 
10.1 mM MnCl2 
10.1 mM MgCl2 
2.9 mM Moxifloxacin 
1.4% (v/v) DMSO 
Structure screen 1+2, KISS 
2.4 0.118 mM d20-447T doubly 
nicked oligo 
10.1 mM MnCl2 
10.1 mM MgCl2 
2.9 mM Moxifloxacin 
1.4% DMSO 
Structure screen 1+2, KISS 
2.3 5.6 mM AMP-PNP 
0.111 mM 20-12p-8 doubly 
nicked oligo 
9.7 mM MgCl2 
9.7 mM MnCl2 
Morpheus® 
2.3 5.6 mM AMP-PNP 
0.111 mM d20-447T doubly 
nicked oligo 
9.7 mM MgCl2 
9.7 mM MnCl2 
Morpheus® 
4.8 3 mM AMP-PNP 
10.6 mM MgCl2 
10.6 mM MnCl2 
JCSG-plusTM 
 
3.2.3 DNA gyrase from M. thermoresistibile supercoils DNA 
To our knowledge, we are the first people to work with DNA gyrase from M. thermoresistibile. 
From this point of view, it was important to determine its activity and possible function within 
the bacterium. Unsurprisingly, we found that the activity of the M. thermoresistibile enzymes 
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was very similar to that of the M. tuberculosis enzyme. The only significant difference 
observed was that the thermophilic enzyme bound significantly tighter to the DNA substrates 
tested and hence it was difficult to remove the protein at the end of assays. In relation to this, 
an additional incubation step with proteinase K was added prior to the addition of 24:1 
chloroform : isoamyl alcohol and 2xSTEB. 
 
Due to the high degree of homology between the Mtb and Mth enzyme sequences it was 
decided to initially assay the enzyme under the same conditions as the Mtb enzymes: 37°C for 
30 min, to confirm activity before performing further optimisations. It was found that 
supercoiling occurred under the same conditions as the Mtb enzyme, although there was a 
requirement for a greater concentration of the Mth enzymes (Figure 3.2.1). At a concentration 
of 250 nM supercoiling was observed within 30 min, whereas the Mtb enzyme required about 
15 min and a lower enzyme concentration to reach this level of supercoiling. Low levels of 
negative supercoiling were observed at lower concentrations or shorter times (Figure 3.2.1). 
It was confirmed that the fusion construct was also active to a similar level to the subunits, 
although there was a difference in the level of supercoiling that was achieved at 15 min, with 
both constructs achieving similar levels of supercoiling at 30 min. There appeared to be a 
visible amount of cleavage activity by the fusion construct when assayed at high concentration 
(750 nM) or for prolonged periods of time (>45 min), although this is likely to be due to 
impurities in the sample and did not appear to affect the interpretation of the results. In terms 
of specific activity this was determined to be similar for the subunits and fusion construct at 
0.04 x 104 U/mg and 0.08 x 104 U/mg respectively. Although this is lower than those 
determined for the Mtb enzymes, we suggest that this was only one preparation and this value 
is likely to depend on a variety of factors that were not optimised within the scope of this 
experiment. 
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Figure 3.2.1: Negative supercoiling activity comparison between the Mth gyrase subunits and fusion 
constructs. A) Negative supercoiling as a function of decreasing concentration (750-25 nM) under fixed 
assay conditions (37°C, 30 min). B) Supercoiling as a function of increasing time (0-60 min) at constant 
250 nM enzyme concentration and a temperature of 37°C. -ve controls contain DNA substrate in the 
absence of DNA gyrase. The linear bands observed are a consequence of the larger amounts of enzyme 
and longer incubation times. 
 
As Mth DNA gyrase is a previously uncharacterised enzyme the optimal reaction conditions 
were investigated. Initially a range of potassium glutamate concentrations between 0-500 mM 
were assayed at a sub-optimal concentration (250 nM) and time (15 min) to determine if more 
optimal conditions could be obtained. It was determined that when assaying the individual 
subunits, they did not present any activity in the absence of potassium glutamate (Figure 
3.2.2), increasing the concentration to 100-200 mM increased the activity of the enzyme to 
give maximal supercoiling activity. Raising the potassium glutamate concentration beyond 
300 mM led to a decrease in the activity of the enzyme. Interestingly, when performing the 
same experiment with the fusion construct, the same pattern was not seen. Instead, from the 
very poor activity obtained in the absence of potassium glutamate an increase of activity 
appeared to be observed on increasing the concentration of potassium glutamate up to 150 
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mM where the activity level plateaued. Beyond this there did not appear to be a decrease in 
activity like the subunits (Figure 3.2.2) 
 
.  
Figure 3.2.2: Induction of supercoiling as a function of potassium glutamate concentration in both the 
Mth GyrA2B2 individual subunits and the GyrBA fusion construct. 250 nM of each individual protein 
assayed for 15 min at 37°C with potassium glutamate concentrations ranging 0-500 mM. -ve control 
contains DNA substrate in the absence of DNA gyrase with 500 mM potassium glutamate. The linear 
bands observed are a consequence of the large amounts of enzyme and longer time required for this 
assay. 
 
3.2.4 DNA gyrase from M. thermoresistibile relaxes DNA 
In the absence of ATP, it was observed that Mth DNA gyrase was able to relax DNA. Like 
the supercoiling reaction it was determined that it was difficult to remove the protein from the 
DNA at the end of the reaction, potentially made more difficult by the increased protein 
concentration and time needed for this reaction to proceed. Hence, an incubation period with 
proteinase K was included to enhance the interpretability of the results. Additionally, there 
was a more prominent cleavage occurring which at points interfered with the interpretation of 
results (Figure 3.2.3). To better resolve the topoisomers from linear fragments in any future 
repeats should be additionally run on chloroquine gels. 
 
ATP-independent relaxation was performed at 37°C with a small amount of relaxation being 
observed. Assaying the time of reaction, it was clear to see that leaving the biological (A2B2) 
enzyme longer assisted with relaxation activity, as it is much poorer at carrying out this 
reaction than the ATP dependent supercoiling reaction. High concentrations of the enzymes 
(1 µM) were also needed to observe relaxation (Figure 3.2.3). 
 
99 
 
It was very difficult to observe any relaxation with the fusion protein as the gels of the 
reactions showed a large amount of contaminating cleavage, and hence it was difficult to 
determine if the enzyme was relaxing the DNA or if the DNA was simply being linearized 
and cut to form a smear on the gel (Figure 3.2.3). It is possible that this cleavage activity was 
because of contaminations in the protein sample, or alternatively the enzyme may simply have 
a high intrinsic cleavage activity in the absence of ATP. It is suggested that this experiment 
needs to be repeated to confirm that this enzyme can relax DNA. Overall, the Mth enzymes 
appear to be weaker at the ATP-independent relaxation reaction than their Mtb counterparts. 
 
 
Figure 3.2.3: Comparison of the two constructs of M. thermoresistibile DNA gyrase in ATP-
independent relaxation. A) Titration of the enzyme at monomeric concentration 125-1000 nM at fixed 
assay conditions (37°C for 1 hour). B) Time course 0-120 min at 37°C at a fixed enzyme concentration 
of 1 µM and 150 mM Potassium glutamate concentration. -ve control was incubated under full assay 
conditions in the absence of DNA gyrase for the longest incubation time of the reaction. The linear 
bands observed are unavoidable and a consequence of the large amounts of enzyme and longer time 
required for this assay. 
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To optimise the relaxation reaction, the concentration of potassium glutamate in the reaction 
was altered under sub-optimal reaction conditions. Again, there was a significant cleavage 
band observed throughout, and some smearing from the fusion protein. Like the supercoiling 
reaction it was obvious that when assaying with the subunits both the absence of potassium 
glutamate and an excess of potassium glutamate inhibited this reaction (Figure 3.2.4). Optimal 
conditions when the subunits were assayed were found to be around 150 mM, with significant 
relaxation being observed between 100-150 mM (Figure 3.2.4). When the reaction was carried 
out with the fusion construct the reaction was uninterpretable due to contaminating cleavage 
(Figure 3.2.4). 
 
 
Figure 3.2.4: ATP-independent relaxation as a function of potassium glutamate concentration with both 
the Mth GyrA2B2 individual subunits and the GyrBA fusion construct. 1 µM of each protein assayed 
for 1 hour at 37°C with potassium glutamate concentrations 0-500 mM. -ve control was incubated under 
full assay conditions in the absence of DNA gyrase with 500 mM potassium glutamate. The linear bands 
observed are unavoidable and a consequence of the large amounts of enzyme and longer time required 
for this assay. 
 
3.2.5 DNA gyrase from M. thermoresistibile can decatenate DNA 
Under ATP-dependent conditions it was found that Mth gyrase displayed weak decatenation 
activity. At this time ATP-independent conditions have not been trialled. The current 
decatenation assay utilising a kinetoplast DNA (kDNA) substrate can be difficult to interpret, 
as previously described, the kDNA substrate cannot enter a 1% agarose gel under native or 
intercalating conditions, with the product being observed further down the gel in supercoiled 
and nicked bands (Figure 3.1.9). The decatenation was studied under two different buffer 
conditions – the supercoiling assay conditions and a buffer recorded as a decatenation buffer 
(Aubry et al., 2006a). The individual subunits appeared to prefer the supercoiling assay buffer 
when assayed for 30 min at 37°C (Figure 3.2.5). Very little decatenation was observed when 
the same conditions were assayed in the decatenation assay buffer (Figure 3.2.5). The activity 
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of the individual subunits in supercoiling assay buffer was comparable to the fusion protein 
which gave good levels of decatenation in both assay buffers (Figure 3.2.5).  
 
 
Figure 3.2.5: Decatenation assay using kinetoplast DNA. The kDNA is unable to enter the gel so may 
be seen in the wells of the gel, the product of a positive reaction shows a combination of open circular 
and negatively supercoiled mini-circles as seen by the two bands. Assay was performed using 
decreasing enzyme concentrations (750-62.5 nM) of each construct using both the decatenation assay 
buffer and the supercoiling assay buffer (see methods section 2.5.3). Reactions were performed at 37°C 
for 30 min. 
 
3.2.6 ATPase stimulation of DNA gyrase from M. thermoresistibile by DNA 
The ATPase-linked assay was initially carried out with both the individual subunits and the 
fusion protein to determine the ATP turnover rate of the enzyme. This was determined in 
duplicate assays by giving values much lower than those found for the Mtb fusion protein, but 
more comparable to those obtained for the Mtb subunits (Table 3.2.2). As the rates were much 
slower it produced larger comparable errors in the results, which made it particularly difficult 
to tell if there was indeed a greater stimulation of the ATPase activity with topologically 
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unconstrained DNA, compared to topologically constrained DNA. There may be a small 
difference between the results when topologically constrained and unconstrained DNA were 
used as substrates, suggesting a slight preference for unconstrained DNA. 
 
Table 3.2.2: ATP turnover rate with 508 nM of Mth individual GyrB or GyrBA subunits and 2 ng of 
pBR322* plasmid of differing topologies measured over a 45 min period after the addition of 2 mM 
ATP. All rates displayed are the novobiocin sensitive rates. Data is the average of two repeats, and 
representative of multiple (more than 2) experiments. 
pBR322* Topological Form ATP Turnover / s-1 
Subunits (GyrA2GyrB2) Fusion (GyrBA2) 
Relaxed 0.16±0.14 0.13±0.06 
Negatively supercoiled 0.12±0.02 0.28±0.02 
Nicked 0.17±0.03 0.32±0.03 
Linear 0.26±0.03 0.44±0.04 
 
Using linear pBR322* and the individual subunits there was unambiguous evidence of a much 
lower ATP turnover in the absence of DNA. However, the rates obtained were inconsistent 
and low, with no obvious plateaux (Figure 3.2.6). This assay does appear to suggest that a 
DNA concentration of 2 ng, as was used with 504 nM of each of the subunits, does appear to 
be sufficient to stimulate ATPase activity, although it is unclear if this amount of DNA in the 
reaction may be sub-maximal (Figure 3.2.6). Due to the difficulties working with these 
enzymes in the ATPase linked assay, a DNA titration on any of the substrates was not 
performed with the fusion construct. 
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Figure 3.2.6: A) Plot of absorbance at 340 nm monitoring the loss of NADH in the PK/LDH linked 
assay, carried out with 508 nM of Mth GyrA and GyrB subunits. Control samples (no NADH, negative 
without enzyme, positive with ADP not ATP, novobiocin independent rate) contained no DNA 
substrate. DNA titration of 0-20 µg linear pBR322*. B) DNA titration on increasing the concentration 
of linear pBR322* from 0-20 µg when assayed with 508 nM of Mth GyrA and GyrB subunits. 
 
3.2.7 Inhibition of M. thermoresistibile DNA gyrase by known inhibitors 
To determine if Mth gyrase can be inhibited in the same way as Mtb gyrase, the inhibition 
profile of both the subunits and fusion constructs were compared to those of the Mtb subunits 
and fusion constructs. Inhibition of supercoiling was investigated by novobiocin – a 
competitive inhibitor of the ATPase reaction (Sugino et al., 1978). Inhibition of the Mtb 
constructs was analysed at 74 nM enzyme at a concentration range of 10-0.1 µM novobiocin, 
giving an approximate IC50 value of ca. 1 µM for both constructs (Figure 3.2.7). This value is 
in approximate agreement with the literature value of 0.5 µM (Aubry et al., 2006a). In 
comparison a concentration of 0.25 µM for the Mth gyrase enzymes was assayed with a 
concentration range of 10-0.1 µM, giving an approximate IC50 value of ca. 0.3 µM (Figure 
3.2.7). Accounting for a 3x higher enzyme concentration in the Mth assay, it is possible that 
there could be an order of magnitude difference in the IC50 values of the two different gyrase 
enzymes from the different species. Interestingly, there does not appear to be any difference 
regardless of whether the GyrB subunit is fused to the GyrA subunit. 
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Figure 3.2.7: Inhibition of A) M. tuberculosis DNA gyrase subunits A2B2 and BA fusion constructs (74 
nM) and B) M. thermoresistibile DNA gyrase subunits A2B2 and BA fusion constructs (250 nM) 
supercoiling activity by novobiocin (10-0.1 µM). All reactions except +ve control contained 1% 
DMSO. -ve control contained all reaction conditions except DNA gyrase, positive control contained 
DNA gyrase without DMSO, DMSO control contained all reaction conditions including 1% DMSO. 
The linear bands observed in the Mth assay are a consequence of the large amounts of enzyme required 
for this assay, and they do not affect the interpretation of this assay. 
 
As novobiocin is a known competitive inhibitor of ATP in other gyrase enzymes (Sugino et 
al., 1978), an ATPase titration was applied to determine the IC50 value in the ATPase reaction. 
Unfortunately, after duplicate experimentation it was determined that the ATP turnover rate 
was too low to generate reliable data and hence this was not obtained. Likewise, as the specific 
ATPase assay was found to be very difficult when working with the fusion construct this 
experiment was not trialled (Table 3.2.2). 
 
Inhibition of gyrase by a fluoroquinolone was also examined. Moxifloxacin was used as it has 
been reported to have a high degree of activity against Mtb gyrase (Blower et al., 2016) and 
is routinely used as a second line antibiotic against TB (WHO, 2010). To determine the 
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activity, inhibition of both supercoiling and induction of cleavage were analysed. Analysing 
the subunits, a CC50 value of ca. 2.5 µM was obtained when assaying using 0.25 µM of the 
Mth gyrase subunits. Difficulty was observed in obtaining an accurate CC50 value when using 
the fusion construct due to a prominent level of background cleavage in the no drug controls, 
however through gel analysis it was determined to be similar to that of the subunits (Figure 
3.2.8). In contrast, a CC50 value for the individual gyrase subunits from the Mtb proteins has 
a CC50 value around 0.5-1 µM when assayed at 74 nM (Figure 3.2.8). The CC50 of the Mtb 
fusion protein appears to be similar to that of the subunits (Figure 3.2.8). Accounting for 
effects of protein concentration it suggests there is unlikely to be a significant difference in 
the cleavage response to moxifloxacin. Additionally, these values appear to be similar to those 
reported within the literature of 10 µM (Aubry et al., 2004). 
 
As the fluoroquinolones inhibit the relegation of DNA and stabilise the cleavage complex they 
also stop the propagation of the supercoiling reaction (Gellert et al., 1977), hence the inhibition 
of supercoiling was compared between the four constructs. It was found that the supercoiling 
reaction was not inhibited as strongly by moxifloxacin as it was by novobiocin. Instead at 100 
µM incomplete inhibition of supercoiling was observed at an enzyme concentration of 0.25 
µM for both the Mth gyrase individual subunits and the fusion protein (Figure 3.2.8). Like the 
Mth enzyme, inhibition of Mtb gyrase was only possible at higher concentration of 
moxifloxacin at 74 nM of either construct. The IC50 values are in the order of approximately 
25 µM for all of these constructs, which is somewhat similar to the value of 11.2 µM reported 
in the literature (Aubry et al., 2004) (Figure 3.2.8). The differences in these values can likely 
be accounted for in the differences of the enzyme concentrations assayed for the two different 
source species of the proteins.  
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Figure 3.2.8: Activity of Moxifloxacin on the two alternate constructs of A/C) Mth DNA gyrase at 0.25 
µM and B/D) Mtb DNA gyrase at 0.74 µM. Induction of cleavage complex assay using A) 25-0.25 µM 
B) 25-0.25 µM moxifloxacin. C) Inhibition of supercoiling assay using C) 100-5 µM D) 100-1 µM 
moxifloxacin. All assays except positive controls contained 3.3% (v/v) DMSO -ve control contained 
all assay components without DNA gyrase, +ve control contained all assay components in the absence 
of DMSO (or moxifloxacin), DMSO control contained all assay components and 3.3% (v/v) DMSO. 
The linear bands observed in the positive control/ DMSO control were controlled for in the calculation 
of the CC50 values. The linear bands observed in supercoiling are unavoidable and a consequence of the 
large amounts of enzyme and longer time required for this assay, and do not affect the result of this 
assay. 
 
3.3 Discussion 
3.3.1 The mycobacterial DNA gyrase fusion proteins are active 
The results in this chapter clearly show that by fusing the C-terminus of GyrB to the N-
terminus of GyrA you do not lose gyrase-specific activity in the fusion protein. This is 
somewhat surprising when you consider that no significant linker was inserted to separate the 
two subunits. However, when you put this result in context of other type IIA topoisomerases 
this is somewhat unsurprising as the eukaryotic topo II contains a similar domain arrangement 
to DNA gyrase and topo IV, but, unlike the bacterial proteins topo II contains one single 
protein subunit equivalent to that of a GyrBA subunit which also dimerises (Miller et al., 
1981). 
 
Several studies, carried out in the Klostermeier laboratory, have used and described fusion 
proteins to be active (reviewed in (Klostermeier, 2018)). Additionally, the ParE-ParC fusion 
has been determined to have activity (Lavasani and Hiasa, 2001); the results here agree that 
the fusion proteins have activity in the absence of a linker between the proteins. These results 
are important in the context of structural studies which have been presented in the form of the 
core fusion protein structures (Srikannathasan et al., 2015, Blower et al., 2016) and the full-
length low resolution cryoEM structure (Papillon et al., 2013) in demonstrating the potential 
biological relevance of these structures as it implies that these structures are likely to be 
biologically active. Additionally, it is hoped that these two new GyrBA proteins will be 
subjected to further structural studies to determine the full-length structure of DNA gyrase 
from a mycobacterial species.   
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In terms of the specific activity differences between the four proteins, no major differences 
were observed (Table 3.3.1), although there were some subtle differences. These included the 
Mth proteins being less active and hence requiring more enzyme for both supercoiling and 
decatenation to occur. It is however obvious that there is some difference between the subunits 
and fusion in terms of activity at high potassium glutamate concentrations. In the subunits a 
decline in the activity is clearly observable at high potassium glutamate concentrations 
whereas this is not visible when assaying the fusion construct (Figure 3.1.5; Figure 3.2.2) 
(Table 3.3.1). This discrepancy was not observed in the ATP-independent relaxation reaction. 
Furthermore, although both fusion proteins could decatenate effectively in both the 
decatenation and supercoiling assay buffer, the Mtb protein preferred the supercoiling buffer 
and the Mth proteins the decatenation buffer (Table 3.3.1). 
 
Table 3.3.1: Table of the optimal assay conditions for the Mtb and Mth DNA gyrase proteins in both 
the subunits and the fusion proteins. Sc = supercoiling buffer; DC = decatenation buffer. 
 M. tuberculosis M. thermoresistibile 
 Subunits Fusion Subunits Fusion 
Supercoiling     
Concentration 73 nM 74 nM 250 nM 250 nM 
Time 30 min 30 min 30 min 30 min 
Potassium 
glutamate 
concentration 
150-200 mM 50-500 mM 100-200 mM 150-500 mM 
Relaxation     
Concentration 500 nM 500 nM 1000 nM 1000 nM 
Time 2 hr 2 hr 1 hr 1 hr 
Potassium 
glutamate 
concentration 
100-200 mM 100-200 mM 100-150 mM Undetermined 
Decatenation     
Concentration 217 nM 73 nM 250 nM 250 nM 
Preferred 
Buffer 
Sc Dc or Sc Dc Dc or Sc 
 
3.3.2 DNA Gyrase from M. tuberculosis can give an appreciable ATP turnover rate 
From the scope of this work it can be clearly observed that there is indeed an appreciable and 
detectable rate of ATP turnover. This rate is comparable to that of the published rate from the 
M. smegmatis enzyme of 0.39 s-1 (Manjunatha et al., 2002), which appears to support the 
published literature that the protein was unsuitable to use for a high throughput assay system 
(Agrawal et al., 2013, Karkare et al., 2013b, Shirude et al., 2013). It was however discovered 
that the GyrBA fusion protein appeared to give ATP turnover rates more comparable to those 
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from the E. coli enzyme (Table 3.1.2) (Maxwell and Gellert, 1984). It is unclear why this 
enzyme can give a much greater rate of ATP turnover; however, it is suggested that the purity 
of the enzyme stock used to obtain these rates was superior to the purity of the individual 
subunits. This could mean that the portion of the enzyme stock able to give a novobiocin-
independent rate was significantly smaller than in the fusion protein hence preventing 
artificially lowered rates. The second explanation for this enhanced rate is that by fusing the 
proteins it has enhanced the ATPase activity of the proteins perhaps by reducing the time 
needed for a GyrB to bind to a GyrA subunit before the enzyme can process the reaction. A 
final consideration to make is that it has previously been observed that the ATPase rate of the 
human topo IIα N-terminal domain is almost inactive when purified on a nickel column, but 
has much higher activity when purified on cobalt (Gardiner et al., 1998). Typically, the fusion 
protein was subjected to further purification than the subunits which were generally purified 
only on nickel, hence, it would be interesting to purify these proteins without using a nickel 
column in the future to determine if this makes a difference. 
 
It was found that like the E. coli enzyme it was difficult to obtain a rate of ATP turnover when 
the ATPase domain was used in isolation in the absence of DNA (Ali et al., 1993). The rate 
presented here of 0.05±0.08 s-1 was described to be in the same order as the published rate of 
0.02 s-1 for the E. coli B43 subunit, and similar to the value for the equivalent Mtb fragment 
of 0.002 s-1 (Agrawal et al., 2013). However, the quality of the results appeared to be 
questionable, and given that no rate could be detected for the M. smegmatis GyrB in the 
absence of GyrA and DNA it is questioned if this is simply an artefact of the experiment 
(Manjunatha et al., 2002). 
 
The full-length Mtb DNA gyrase fusion protein did not give an appreciable rate in the absence 
of DNA. This indicates a high degree of coupling between DNA binding and ATP hydrolysis. 
This phenomenon was also described for E. coli and M. smegmatis DNA gyrase, whereby a 
background rate of ATP hydrolysis by GyrB is unaffected by either addition of GyrA or 
double-stranded DNA, however the addition of both GyrA and double-stranded DNA led to 
an appreciable increase in the ATP hydrolysis (Maxwell and Gellert, 1984, Manjunatha et al., 
2002). A 1.5-2.5 fold increase in the ATPase activity of Mtb DNA gyrase in the presence of 
DNA has also been previously suggested by Agrawal et al. (2013). Previously the length of 
DNA fragment needed to stimulate ATP hydrolysis in E. coli DNA gyrase has been 
investigated (Maxwell and Gellert, 1984). This is only the second study where the effect of 
DNA topology has been compared, but the initial study was conducted with DNA plasmid 
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samples with relatively high estimated nicked contamination within the negatively supercoiled 
samples using E. coli DNA gyrase (Sugino and Cozzarelli, 1980). It was suggested in this 
paper that relaxed, linearised or nicked plasmids gave equivalent levels of ATP specificity and 
maximum velocity, although the authors do question the result of the relaxed plasmid pointing 
out that the substrates are rapidly converted into a negatively supercoiled plasmid. In the 
results presented here, we have demonstrated that there is unambiguous evidence for 
stimulation of ATPase activity in the presence of a linear or nicked plasmid as compared to 
one that is negatively supercoiled or relaxed when the fusion construct of Mtb DNA gyrase 
was used. This can be explained as we visualised samples from multiple timepoints in the 
ATPase reaction time course to determine the topological state of the DNA and found that 
there was rapid conversion of these substrates to a form which is negatively supercoiled. It is 
likely that the requirements for ATP hydrolysis of Mtb DNA gyrase require that DNA is bound 
in a right-handed orientation that negatively supercoiled DNA cannot readily adopt (Liu and 
Wang, 1978). This is not to say that there could be a significant difference between the 
enzymes from Mtb and E. coli allowing relaxed DNA to stimulate DNA gyrase and to allow 
it to remain stimulated for longer. 
 
3.3.3 Is DNA gyrase able to convert positive supercoils in to negative supercoils? 
In the scope of this work we briefly examined the rate of ATP hydrolysis in the presence of 
positively supercoiled pBR322*. To determine the topological state we ran a native agarose 
gel which showed all wells to be maximally supercoiled (Figure 3.1.12) with no apparent 
intermediate topoisomers. However, it is not possible to resolve the directionality of supercoils 
on a native agarose gel (Shure et al., 1977), hence due to the lack of intermediate topoisomers 
it was assumed that the DNA substrate was rapidly converted into a negatively supercoiled 
plasmid. This would make sense in the context of the literature where it is known that Mtb 
DNA gyrase rapidly removed positive supercoils from DNA at a rate faster than it is able to 
negatively supercoil DNA (Ashley et al., 2017). Three additional methods should be 
considered in the future to gain greater insight into point at which the plasmid is maximally 
negatively supercoiled. The first of these is to use a gel with added chloroquine, which 
increases the resolution of the topoisomers, and in combination with a native gel would 
indicate if a sample was positively or negatively supercoiled due to difference in the migration 
of the sample. The migration of DNA topoisomers is influenced by chloroquine as it 
intercalates to make DNA appear more positively supercoiled, which causes positive 
supercoiled and relaxed DNA to run faster, and negative supercoils to run slower than on gels 
performed in the absence of chloroquine (Shure et al., 1977, Clark and Leblanc, 2009). 
Although it is possible to resolve positive and negatively supercoiled DNA on a 2D gel, this 
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method is impractical with large numbers of samples as run in this experiment (Wang et al., 
1982). The final method is a new non-gel based technique known as the Qiaxcel which is able 
to both resolve topoisomers better than in a native agarose gel and resolve positive and 
negative supercoils (Mitchenall et al., 2018) (Unpublished data – Ms L.A. Mitchenall). It is 
proposed that this new method should be trialled in the future for resolving positive and 
negative supercoiling. 
 
3.3.4 What are the optimal assay conditions for a thermophilic bacterium? 
Preliminary assay conditions for the Mth proteins are described in Table 3.3.1 inferring that 
there are no significant differences between the proteins from Mth and the well-characterised 
Mtb homologues. This does not rule out alternative differences between the enzymes that have 
not yet been assayed, for example it has been reported that the M. avium DNA gyrase has been 
reported to have a low specific activity when compared with that from M. smegmatis and E. 
coli (Guillemin et al., 1999). From these studies it implies that Mth DNA gyrase may have a 
lower specific activity like M. avium. 
 
As a thermophilic bacterium one of the major considerations is the optimal operational 
temperature for proteins from this species may differ. It has been reported that growth is viable 
at temperatures up to 55°C which is significantly greater than that of M. tuberculosis (Edwards 
et al., 2012). This suggests that the Mth DNA gyrase should have activity at temperatures 
greater than that of the Mtb DNA gyrase, therefore it would be interesting to see if the optimal 
growth temperature corresponds to the optimal assay temperature for Mth DNA gyrase in the 
future. 
 
It was difficult to interpret the results of the relaxation and decatenation assays due to 
contaminating cleavage occurring. This was particularly observable when assaying the fusion 
protein in the ATP-independent relaxation assay (Figure 3.2.3; Figure 3.2.4). This is likely to 
be at least in part due to contamination in the protein purification which was not perfect. It is 
suggested that in the future the protein should be further purified to yield purer protein to 
determine if this is an intrinsic property of the protein or if it is because of a contamination. 
Additionally, it can be difficult to determine if decatenation is occurring through a cleavage 
mechanism whereby proteins are cleaved to release the mini-circles or if they are truly 
decatenated when using the current method. However, a newer alternative is currently being 
developed by Inspiralis Limited which uses a pair of intertwined plasmids of varied sizes 
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which can be unlinked in a decatenation reaction (Figure 3.3.1). If optimisation of this reaction 
can occur it is suggested that in the future this new assay should be attempted on this protein 
to determine with more certainty if decatenation is truly occurring (N. Waraich, Pers. Comm.). 
 
Figure 3.3.1: Demonstration of how an alternative decatenation assay in development by Inspiralis 
Limited using two interlinked plasmids of distinct sizes which can be resolved on a gel. Decatenation 
by DNA gyrase would result in two supercoiled bands alongside potentially two open circular nicked 
bands. Topo IV such as that from E. coli would result in two groups of relaxed topoisomers. Meanwhile 
a restriction enzyme would still be able to unlink the plasmids through a double stranded break but 
additional banding at decreased sizes should also be seen. 
 
Overall, the data obtained alongside the evidence presented by Edwards et al. (2012) indicates 
that the Mth homologue of DNA gyrase and the fusion protein is a suitable candidate for 
structural studies of mycobacterial DNA gyrase. Although, the preliminary crystallisation 
studies were not successful, it is suggested that further trials should be carried out in the future 
with a purer protein stock alongside the use of cryoEM to attempt to resolve a high-resolution 
full-length structure of this highly interesting enzyme. 
 
3.3.5 Decatenation happens in 100 mM and 250 mM potassium glutamate 
It is suggested in the literature that Mtb DNA gyrase decatenates optimally in the decatenation 
assay buffer (Aubry et al., 2006a). The results here clearly show that these conditions do not 
always result in the optimal decatenation conditions (Table 3.3.1). For some of the constructs 
this assay buffer does appear to be optimal, whereas others decatenate to a superior level in 
the assay buffer used for supercoiling. As described in section 3.3.4 it is possible that this 
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result is artificial hence it is suggested that when the substrate for the alternative decatenation 
assay substrate is commercially available the decatenation activities of these enzyme should 
be further optimised.  
115 
 
4. Inhibition of Mycobacterial DNA Gyrase 
Presently there is increasing resistance being observed in the clinic against the current DOTS 
first line regime of antibiotics for the treatment of tuberculosis (WHO, 2017). Hence, there 
have been significant advances towards further drug discovery against M. tuberculosis to 
decrease the mortality rate and treatment times in recent year; some of which are reviewed 
within (Campanico et al., 2018). We therefore investigated the inhibition of Mtb DNA gyrase 
with both previously known and unknown inhibitors, the results of which are within this 
chapter. The aim was to find a lead compound with a novel mode of action which could be 
further optimised into a compound that could be advanced to clinical use in the future. This 
was achieved initially by comparing the activity of the lesser known compound classes of the 
naphthoquinones and the tricyclic inhibitors (Redx AntiInfectives) including the novel 
Redx04739 to the known classes of DNA gyrase inhibitors of the fluoroquinolones and the 
aminocoumarins. 
 
4.1 Fluoroquinolone Antibiotics 
The quinolone antibiotics are clinically-used inhibitors targeting the bacterial type IIA 
topoisomerases DNA gyrase and topo IV though a dual-targeting mechanism in most bacteria. 
However, in the absence of topo IV only the single target of DNA gyrase is present in 
mycobacteria. Here we investigated the third-generation fluoroquinolone moxifloxacin, which 
is clinically used as a second-line antibiotic against M. tuberculosis against the two Mtb DNA 
gyrase constructs to determine if any difference in the inhibition was obtained by fusing the 
two subunits. The fluoroquinolones act through a known mechanism of action which includes 
inducing cleavage complexes via prevention of the religation reaction (Heddle et al., 2000). 
Hence, we set out to determine both the IC50 and the CC50 of moxifloxacin against both the 
Mtb individual subunits and the fusion protein (see method sections 2.5.1; 2.5.4). The CC50 of 
moxifloxacin was found to consistently be around 0.5-1 µM for both the fusion and subunit 
constructs (Figure 4.1.1A), on the other hand the IC50 values were found to be much more 
modest of around 25 µM (Figure 4.1.1B). These values appear consistent between the two 
constructs analysed hence indicating that no difference in the inhibition of DNA gyrase occurs 
when using the fusion construct. The literature values for both the CC50 and IC50 values for 
moxifloxacin are around 10 µM (Aubry et al., 2004).  
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Figure 4.1.1: Activity of Moxifloxacin on the two alternate constructs of Mtb DNA gyrase at 0.74 µM. 
A) Induction of cleavage complex assay using 25-0.25 µM moxifloxacin. B) Inhibition of supercoiling 
assay using 100-1 µM moxifloxacin. All assays except positive controls contained 3.3% (v/v) DMSO. 
-ve control contained all assay components in the absence of DNA gyrase, +ve and DMSO controls 
were carried out with all assay components in the absence of moxifloxacin. Enzyme concentration was 
chosen to be less than 100% supercoiling for better determination of the IC50 values. 
 
Overall, the data obtained here is in contrast to those in the literature as it indicates that the 
enzyme can function at higher concentrations of moxifloxacin than is required for transient 
induction of the cleavage complex. It is plausible, for instance, that the rate of supercoiling 
was simply decreased with the intermediate cleavage complex being stabilised as per the 
mechanism of action of microcin B17 (Pierrat and Maxwell, 2003). However, it is unusual 
that fluoroquinolones gives rise to such a significant difference in CC50 and IC50 values. It is 
instead suggested that as the CC50 value was obtained in an ATP-independent reaction where 
a negatively supercoiled substrate was used in the absence of ATP, whereas, the supercoiling 
reaction was carried out in the presence of ATP and a relaxed substrate to generate an IC50 
value. It is possible that the presence of ATP or topology of the DNA substrate may influence 
these values, and hence, this should be investigated more thoroughly in the future. However, 
despite any differences in the values from those presented in the literature, this work clearly 
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demonstrates that there are no significant differences in our hands between the two inhibitions 
of the subunits or fusion constructs of Mtb DNA gyrase by moxifloxacin. 
 
4.2 Aminocoumarin Antibiotics 
The aminocoumarin family of non-clinical antibiotics, including novobiocin, inhibit DNA 
gyrase through competitive inhibition of the ATPase reaction (Mizuuchi et al., 1978). To 
determine if the mechanism of action or the potency of these compounds was altered by fusing 
the DNA gyrase subunits together we investigated the IC50 values for the inhibition of the 
supercoiling reaction against both the A2B2 heterotetramer and the GyrBA dimer (see methods 
section 2.5.1). It was initially determined that the IC50 value of both constructs in the 
supercoiling reaction were determined to be approximately 1 µM when assaying against 74 
nM enzyme monomer (Figure 4.2.1a). These values appear to be of a similar order of 
magnitude to the literature value of 0.5 µM (Aubry et al., 2006a). 
 
As the inhibition of supercoiling appeared to be equivalent between the two constructs of Mtb 
DNA gyrase and the ATP turnover of the GyrBA fusion construct has been determined 
suitable for inhibitor studies in the ATPase-linked assay, with experiments trialled to 
determine an IC50 value for the ATPase reaction. An IC50 value of the ATPase reaction was 
determined to be 0.21±0.04 µM (representative of duplicate repeats; Log(IC50): -0.68±0.08) 
(Figure 4.2.1B). However, as the value obtained for the IC50 is close to the enzyme 
concentration used within this reaction (200 nM), it is possible that a true IC50 value was not 
obtained. This is because the limit of detection is defined by the enzyme concentration used 
in this reaction, therefore it is suggested from this result that the IC50 value would be better 
represented as <0.21 µM. Although the ATPase reaction has been optimised for the Mtb 
GyrBA construct the reaction is still difficult to work with at low enzyme concentrations, and 
hence it was not possible to obtain data at lower enzyme concentrations to confirm the true 
value of this reaction. 
 
Unusually the value of the IC50 for the ATPase reaction appears to be somewhat smaller than 
the IC50 value obtained in the supercoiling reaction. This is unexpected because novobiocin 
indirectly inhibits the ATP-dependent supercoiling reaction through competitively inhibiting 
the ATPase reaction that allows supercoiling to occur (Sugino et al., 1978). Therefore, it is 
suggested that the true IC50 for novobiocin is represented by the ATPase reaction, meaning 
that you would normally expect an equal or larger IC50 value to be obtained for the ATPase 
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reaction. This can potentially be explained as there is a large degree of error in the values 
obtained, and if the inhibition of supercoiling experiment were to be repeated additional data 
pointed in the range used should be taken to increase the accuracy in the interpretation of the 
IC50 value. Likewise, although the value obtained is close to the limit of detection, it may be 
found to be accurate if it were possible to assay with lower enzyme concentrations in the 
future. 
 
Figure 4.2.1: A) Inhibition of supercoiling assay against both the Mtb subunits and fusion proteins 
(protein concentration of 78 nM) by 10-0.1 µM novobiocin in 1% (v/v) DMSO. -ve control contained 
all assay components in the absence of DNA gyrase. +ve control lacked DMSO, and the DMSO control 
contained all assay components in the absence of novobiocin. Enzyme concentration was chosen to be 
less than 100% supercoiling for better determination of the IC50 values. B) Analysis of an ATPase assay 
carried out with 200 nM GyrBA enzyme over a time period of 45 minutes with duplicate repeats. Plot 
shows the number of ATP molecules turnover per GyrBA subunit per second plotted against the base 
10 logarithm of the novobiocin concentration in µM. The IC50 value was determined to be 0.21±0.04 
µM. Error bars represent the range of duplicate replicate points being plotted. 
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4.3 Naphthoquinone Antibiotics 
Preliminary studies of the naphthoquinones were performed by Karkare et al. (2013b) who 
determined diospyrin to be inhibiting DNA gyrase at the N-terminal domain away from the 
ATPase site. Due to difficulties in the synthesis of diospyrin, we therefore sought to determine 
the mechanism of action of these compounds using 7-methyljuglone in collaboration with Dr 
MJ Austin (UEA, Pharmacy). The 7-methyljuglone was supplied in a powder form. When 
dissolving the powder in DMSO the solution formed was orange in colour. On leaving the 
compounds at room temperature or at -20°C, the solution turned progressively to a green 
colour, which appeared to have superior activity against Mtb DNA gyrase. MJA was able to 
determine that a reaction was occurring but was unable to identify the final reaction product 
obtained. 
 
As it appeared that 7-methyljuglone dissolved in DMSO was chemically unstable resulting in 
a colour change in the solution, it was decided to investigate the stability of 7-methyljuglone 
in other solvents. Since some solvents are known to interfere with enzyme reactions a range 
of different solvents were trialled to determine which ones would be acceptable in the DNA 
gyrase supercoiling reaction (Figure 4.3.1). From this data it was determined that methanol 
would be the best alternate substitute for DMSO at concentrations less than 3.3% (v/v), but 
other possibilities included ethanol and isopropanol (at less than 1.7% (v/v)). Significant 
inhibition of the supercoiling reaction was observed when glycerol or PEG400 were added to 
the reaction (Figure 4.3.1). The unexpected result from glycerol (supercoiling was only visible 
at the 3.3% (v/v) but not 2.5 or 1.7% (v/v)) may be due to pipetting errors from the pipetting 
of viscous solutions, and as a consequence it was decided as a precaution to avoid the use of 
glycerol.  
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Figure 4.3.1: Supercoiling assay using 78 nM Mtb GyrBA to test which solvents inhibited the negative 
supercoiling reaction over a standard assay at 37°C for 30 minutes. All solvents were trialled at 3.3%, 
2.5% and 1.7% (v/v) final reaction concentration. MeOH = methanol, EtOH = ethanol, iPrOH = 
isopropanol. Data representative of multiple experiments. -ve control contained DNA substrate in the 
absence of DNA gyrase, +ve control contained no solvent. Enzyme concentration was chosen to be less 
than 100% supercoiling to better determine any enhancement or decrease in supercoiling within these 
reactions. 
 
To confirm if 7-methyljuglone was chemically stable in methanol, a 3-day time course was 
performed. This experiment involved performing a supercoiling reaction with compound 
dilutions of freshly dissolved 7-methyljuglone in methanol which was repeated with the same 
stock of dissolved compound in methanol kept at room temperature after 24 and 48 hours to 
determine if a change in the inhibition of Mtb DNA gyrase was observed. From these results 
it was clear that pure 7-methyljugone dissolved in methanol was a relatively poor inhibitor of 
DNA gyrase not resulting in full inhibition at 50 µM (Figure 4.3.2a), as per the results found 
with the compound dissolved in DMSO. After one day, inhibition of supercoiling was 
observed at concentrations >30 µM, indicating that a chemical alteration was already 
occurring (Figure 4.3.2b). The unknown product that formed after 2 days was determined to 
be a potent inhibitor of the Mtb DNA gyrase supercoiling reaction giving full inhibition of 
supercoiling at >5 µM (Figure 4.3.2c). 
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Figure 4.3.2: Three-day time course of the inhibition of Mtb DNA gyrase fusion protein supercoiling 
activity of 7-methyljuglone when dissolved in 100% methanol. A) freshly dissolved compound, B) 
compound after 1 day at room temperature, C) compound after 2 days at room temperature. 
Supercoiling assays were carried out with equivalent protein samples on three consecutive days at the 
same time of day. Enzyme concentration was chosen to be less than 100% supercoiling for better 
determination of the IC50 values. 
 
Based on the literature it appeared that the naphthoquinones were promising inhibitors of DNA 
gyrase to explore further (Karkare et al., 2013b). In this knowledge Dr S. Ekins (SE) of 
Collaborative Drug Discovery created a model of a proposed binding site of diospyrin to 
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determine the binding site and hence its mode of action. This model described a binding pocket 
in the GyrB NTD domain away from the ATPase site, as this domain was indicated previously 
to be involved in the mode of action of the diospyrin (Figure 4.3.3) (Karkare et al., 2013b). 
From the model, multiple amino acid residues including R40, W47, H121, T189, N309, and 
T373 were hypothesised to be involved in the binding of diospyrin assuming the model created 
was correct. Based on these findings site-directed mutagenesis was performed on the modified 
pET20b(+) GyrBA plasmid to result in 7 new plasmids encoding mutants in the proposed 
binding region (R40A, R40Q, W47F, H121A, T189A, N309A, T373A). Expression and 
purification of 6 of these mutants was successful, yielding active fusion proteins. 
Unfortunately, the H121A mutant did not appear to express under the optimal fusion 
expression conditions, hence purification was not possible. However, it was decided not to 
actively test the model provided by SE as MJA was unable to synthesise diospyrin. Moreover, 
the 7-methyljuglone provided by MJA proved unstable and we were unable to identify an 
appropriate stable and active compound to test against the model. As we were unable to 
determine the true active compound at this time any compound tested could not be taken 
forwards as a clinical target and therefore further developments with these compounds have 
been stopped until a time when we can determine a stable and active compound. Although 
there are more stable naphthoquinones such as menadione these are reported to be only weak 
inhibitors of DNA gyrase and hence not ideal to test the model either (van der Kooy, 2007, 
Karkare et al., 2013b). 
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Figure 4.3.3: Two views of the model of diospyrin docked into the 3ZM7 crystal structure of the Mtb 
ATPase domain (Agrawal et al., 2013) by Dr S. Ekins. Six amino acids of interest are shown with in 
specific interaction distances labelled. A) and B) show different orientations of the same structure. 
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4.4 Tricyclic GyrB ParE (TriBE) antibiotics from Redx AntiInfectives 
The TriBE antibiotics are an optimisation of pyrroloprimidine antibiotics which were 
characterised as GyrB and ParE inhibitors in 2013 (Tari et al., 2013a, Tari et al., 2013b, Trzoss 
et al., 2013). RedxAI followed up the initial work performed by Trius Therapeutic on these 
antibiotics through using a lead compound from the Trius series (Redx03863) (Bensen et al., 
2012), and performing further optimisations resulting in a new lead compound, Redx04739, 
for their mycobacterial compound series (Figure 4.1.1) (McGarry et al., 2018). We determine 
here the bacterial growth inhibition, enzyme IC50 values as well as determining the mechanism 
of action and searching for the binding pockets of both Redx03863 and Redx04739. 
 
 
Figure 4.4.1: Chemical structure of Redx03863 which was optimised to give the lead compound of 
Redx04739 
 
4.4.1 Growth Inhibition by Redx03863 and Redx04739 
Initially we needed to confirm the effectiveness of these compounds against whole cells to 
compare their use as potential TB drugs, therefore broth MIC100 testing was initially performed 
(see section 2.6.1). Additionally, it was important to determine if these compounds were broad 
spectrum or mycobacterial specific, hence these compounds were tested against a limited 
primary screen containing both Gram-positive and Gram-negative bacteria. The broth MIC100 
data demonstrated that the less potent lead antibiotic in the series (Redx04739) showed a high 
degree of selectivity towards the laboratory mycobacterial strain M. smegmatis ATCC19420 
in comparison to the other bacteria tested (Table 4.4.1). In comparison the initial lead of 
Redx03863 showed broad spectrum activity against both the Gram-positive and Gram-
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negative bacteria tested with superior activity compared to Redx04739 (Table 4.4.1). 
However, Redx04739 showed better selectivity against M. smegmatis ATCC19420 compared 
to Redx03863. Additional collaborative testing by the NIAID on behalf of RedxAI found that 
Redx04739 was highly potent against M. tuberculosis H37Ra and M. tuberculosis H37Rv 
under aerobic conditions (data not shown). This indicates that Redx04739 is an interesting 
compound to take forwards for further microbial and biochemical studies and to definitively 
determine the mode of action. 
 
Table 4.4.1: MIC100 data for the two novel RedxAI antibiotics Redx03863 and Redx04739 against a 
primary screen of bacteria containing both clinically-relevant Gram-negative and Gram-positive 
bacteria alongside the laboratory mycobacterium strain M. smegmatis ATCC19420. Data was taken at 
a minimum of 2 replicates with a maximum 2-fold difference between the two replicates. 
Bacterial Strain Redx03863 (µg/ml) Redx04739 (µg/ml) 
Acinetobacter baumannii NCTC13420 0.031 64 
Escherichia coli ATCC25922 0.016 8 
Mycobacterium smegmatis ATCC19420 0.016 0.25 
Pseudomonas aeruginosa ATCC27853 4 32 
Staphylococcus aureus ATCC29213 0.125 8 
 
4.4.2 Inhibition of Mycobacterial Biofilms by Redx03863 and Redx04739 
As it is possible for M. tuberculosis to form biofilms in clinically-relevant settings (Spinner et 
al., 1996, Sendi and Brent, 2016) it was decided to investigate the effects of Redx03863 and 
Redx04739 against biofilms in a laboratory setting. The inhibition of biofilm growth assay 
was used to determine if compounds are effective in preventing growth, or killing bacteria 
within a biofilm grown reproducibly on Calgary biofilm pegs within the laboratory setting 
was initially carried out with the E. coli ATCC25922 strain (Harrison et al., 2010) (see section 
2.6.4). In this assay the compounds of interest were compared to the known biofilm inhibitor 
of moxifloxacin as well as novobiocin, a compound known to be inefficient against biofilms 
(Dr N Ooi, Pers. Comm.). It was found that in this assay both the compounds of interest had 
activity in preventing growth of a biofilm (bMIC – biofilm MIC) with Redx03863 as expected 
presenting with better activity than Redx04739. Unexpectedly Redx03863 performed as well, 
if not better than the positive control of moxifloxacin for this assay (Table 4.4.2). At the 
concentration range tested Redx04739 was unable to prevent the regrowth of a biofilm after 
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exposure to the compound (MBEC – minimum biofilm eradication concentration). On the 
other hand, Redx03863 was not only able to outperform Redx04739 in preventing regrowth 
of a biofilm, it also appeared to be have improved activity compared to the moxifloxacin 
control used (Table 4.4.2). 
 
Table 4.4.2: Inhibition of Biofilm formation against both E. coli ATCC25922 and M. smegmatis 
ATCC19420. Novobiocin is a known not to be an inhibitor of biofilms while moxifloxacin is a known 
positive biofilm inhibitor. Both Redx03863 and Redx04739 were trialled to determine their effectivity 
at both inhibiting biofilm growth (bMIC) and preventing regrowth (MBEC). Data was taken at a 
minimum of 2 replicates with a maximum 2-fold difference, where this was not possible the two 
alternative recorded values are shown and indicated with*. 
 
bMIC (µg/ml) MBEC (µg/ml) 
 
E. coli M. smegmatis E. coli M. smegmatis 
Redx03863 <0.125 >64 4 64/0.5* 
Redx04739 16 >64 >64 16 
Novobiocin 
(negative) 128 >1024 >1024 >1024 
Moxifloxacin 
(positive) <2 >1024 32 256/32* 
 
Based on the growth rate of M. smegmatis it was necessary to increase the incubation times to 
allow a mature biofilm to grow. Consequently, the protocol for inhibition of biofilm growth 
and regrowth for M. smegmatis was optimised based on published data, to increase the biofilm 
growth and regrowth stages to 48 hours (from 24 hours) meanwhile the drug incubation stage 
before obtaining the bMIC was altered from 24 hours to 72 hours. 
 
Unusually, the bMIC values found when using this protocol with M. smegmatis were high 
throughout testing even with moxifloxacin which is known to be an inhibitor of biofilm growth 
in E. coli ATCC25922 (Table 4.4.2). It was unclear if this was an artefact of the protocol being 
used (e.g. clumps of dead cells in the wells being observed) or if this was a true result. On the 
other hand, the MBEC value for regrowth after exposure to antibiotics showed clearly that 
Redx04739 had increased selectivity towards M. smegmatis ATCC19420 with an MBEC 
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value at least 4-fold lower than against E. coli ATCC25922 (Table 4.4.2). The value obtained 
for both moxifloxacin and Redx03863 is somewhat unclear as due to time constraints a third 
repeat was needed but could not be performed leaving an extensive range for the MBEC value 
(Table 4.4.2). Regardless, Redx03863 is likely to be similar if not better than moxifloxacin at 
effectively killing a biofilm from the preliminary data. 
 
4.4.3 Time of kill for Redx03863  
To determine if Redx03863 was causing cell death and the timeframe on which this was 
happening in the presence of Redx03863, a time of kill assay was employed to determine the 
difference in the growth kinetics of a culture in the presence and absence of Redx03863. This 
assay involved plating serial dilutions of duplicate cultures exposed to multiples of the MIC100 
of a compound and duplicate cultures not exposed to any treatment to compare the colony 
forming units and percentage of the surviving colonies at multiple timepoints to identify the 
time to kill the bacteria being tested. Unfortunately, due to the MIC100 of Redx04739 against 
E. coli ATCC25922 being 8 µg/ml it was not possible to carry this experiment out with 
Redx04739 due to the concentration of DMSO within the growth media. Furthermore, because 
Redx04739 was not tested against E. coli ATCC25922 it was decided not to test it against M. 
smegmatis ATCC19420 as no direct comparison to E. coli was possible.  
 
In the presence of Redx03863 it was determined that at 4x MIC100 the percentage of colony 
forming units of E. coli was below 0.1% within 120 minutes of plating and 0.0001% (less than 
30 colonies per culture compared to an excess of 109 in the no drug control flasks) within 240 
minutes. No colonies were found to be surviving after 24 hours (Figure 4.4.2). Overall, this 
suggests effective killing of E. coli ATCC25922 is occurring in the presence of Redx03863. 
 
In contrast when the experiment was scaled for M. smegmatis no colonies were found to be 
surviving after 2 days in the presence of 16x MIC100 Redx03863, with just two surviving 
colonies at 4x MIC100. By 4 days no colonies were surviving in either culture. In general, the 
CFU count for both 4x and 16x MIC100 had a similar percentage of the cultures containing no 
drugs, with there being less than 0.01% colonies surviving at 24 hours for both the 4x and 16x 
MIC100 samples (Figure 4.4.3). Overall, this indicates that the drug is highly active against M. 
smegmatis grown in a laboratory setting, implying it would be suitable to take on to further 
studies, including animal models, depending on toxicity data not examined here. 
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Figure 4.4.2: Percentage of colony forming units of E. coli ATCC25922 remaining when treated with 
4x broth MIC100 Redx03863 compared to untreated bacterium over 6 hours. Data recorded as two 
technical replicates, and representative of 2 experimental replicates. Error bar represent range of 
individual replicates. 
 
 
Figure 4.4.3: Percentage of colony forming units of M. smegmatis ATCC19420 remaining when treated 
with 4x or 16x broth MIC100 Redx03863 compared to untreated bacterium over 2 days. No colonies 
were obtained at 2 days in the presence of 16x MIC100 and from one of the 4x MIC100 cultures and hence 
data could not be plotted. Data recorded as two technical replicates, and representative of duplicate 
experiments. Error bar represent range of individual replicates. 
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4.4.4 Inhibition of DNA Gyrase by Redx03863 and Redx04739 
As the TriBE compound series was previously optimised from known DNA gyrase and topo 
IV inhibitors with some crystallographic data on other compounds in the same series, it was 
assumed that the molecular target would also be the type II topoisomerases for these two 
compounds (Bensen et al., 2012, Tari et al., 2013a). To confirm this, initially the compounds 
were tested against DNA gyrase from M. tuberculosis as they showed superior specificity for 
whole cell activity against mycobacterial species M. smegmatis (see section 2.5.1). It was 
observed that Redx03863 and Redx04739 inhibited the supercoiling reaction of Mtb DNA 
gyrase with nanomolar affinity (Figure 4.4.4) implying that, as suggested, the target of these 
novel drugs was DNA gyrase in M. tuberculosis. The compounds were additionally tested 
against the E. coli type II topoisomerase enzymes which they were found to inhibit, confirming 
a dual targeting mechanism within E. coli. Surprisingly the inhibition of E. coli DNA gyrase 
was found to be at least equal to that of Mtb DNA gyrase (Figure 4.4.5). The inhibition of topo 
IV was found to not be as potent but was still an inhibitor at a sub-micromolar level (Figure 
4.4.5). 
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Figure 4.4.4: Inhibition of supercoiling assay carried out with 74 nM of each gyrase subunit against A) 
Redx03863 and B) Redx04739 (1000 nM – 1 nM in 1% DMSO). Controls included -ve (no enzyme), 
+ve (enzyme no compound), DMSO (enzyme in 1% DMSO), 10 µM novobiocin in 1% DMSO. 
Apparent IC50 values of 10 nM for Redx03863 and 30 nM for Redx04739. Enzyme concentration was 
chosen to be less than 100% supercoiling for better determination of the IC50 values. C) A plot of the 
intensity of the supercoiled peak as determined with ImageJ plotted by GraphPadPrism to determine 
IC50 values - 9.025 nM Redx03863 and 30.01 nM Redx04739. 
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Figure 4.4.5: Inhibition of the E. coli Type II topoisomerases by Redx03863 and Redx04739. A) 
Inhibition of DNA gyrase supercoiling assay. Compound concentrations 100-0.01 µM. Assay run with 
10 nM GyrA and 9 nM GyrB. IC50 of <10 nM Redx03863 and 10-30 nM Redx04739. A alone and B 
alone controls only contained one subunits in the absence of the other subunit. B) Inhibition of 
topoisomerase IV relaxation assay. Compound concentrations 10-0.01 µM. Assay run with 16 nM of 
ParC in an excess of ParE. IC50 100-300 nM Redx03863 and 300-1000 nM Redx04739. -ve controls 
contained the DNA substrate in the absence of protein, positive controls contained both DNA substrate 
and protein in the absence of DMSO. DMSO controls contained the same solvent content as the 
reactions in the presence of DNA substrate and proteins. Enzyme concentration was chosen to be less 
than 100% supercoiling for better determination of the IC50 values. 
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4.4.5 Redx03863 and Redx04739 competitively inhibit the ATPase reaction of DNA 
gyrase 
The binding pocket of the original TriBE compounds is within the ATPase domain (Tari et 
al., 2013a), therefore experiments were carried out to determine if the mechanism of action 
involved inhibiting the ATPase reaction. Initially, the ATP-independent relaxation assay was 
conducted to determine if either of the compounds showed efficacy against this reaction. It 
was shown that there was little or no inhibition of the relaxation reaction at 300 nM (Figure 
4.4.6), whereas full inhibition of supercoiling was observed at <100 nM for both compounds. 
It is found that at the high concentrations of DNA gyrase required to observe ATP-independent 
relaxation a cleavage band is also observed likely due to contamination in the enzyme 
purification as previously discussed in Chapter 3. Overall, because the compounds do not 
inhibit the ATP-independent relaxation assay it is suggested that their mode of action involves 
inhibition of the ATPase reaction. 
 
 
Figure 4.4.6: Inhibition of ATP-independent relaxation assay carried out with 0.5 µM of each gyrase 
subunit. Controls included negative (no enzyme), positive (enzyme no compound), DMSO (enzyme in 
1% DMSO), 10 µM novobiocin in 1% DMSO and 50 µM moxifloxacin in 1% DMSO. Concentration 
range of Redx03863 300 nM to 3 nM, Redx04739 1000 nM to 10 nM all in 1% DMSO. IC50 could not 
be determined in the concentration range tested. The linear cleavage band is because of the large 
amounts of enzyme and increased times required for this assay, and do not affect the results of the assay. 
 
To further determine if the compounds were inhibiting the ATPase reaction competitively, 
two independent experiments were carried out. The first of these was an ATP-competition 
supercoiling reaction where ATP was titrated into the reaction under constant enzyme and 
compound concentrations. In this assay a control with the enzyme in 1% DMSO was used to 
demonstrate that no significant variation in the level of supercoiling occurred as the 
concentration of ATP was increased. Likewise, the negative drug control Simocyclinone D8 
133 
 
was used to demonstrate that inhibitors of DNA gyrase that are known to have a mode of 
action other than competitively inhibiting the ATPase reaction cannot be out competed by 
ATP (Flatman et al., 2005). Novobiocin, a known competitive ATP inhibitor, showed a 
significant increase in supercoiling activity as the concentration of ATP was increased. 
Likewise, the level of supercoiling appears to increase with increased levels of ATP in the 
presence of either Redx03863 or Redx04739 (Figure 4.4.7). Overall, this suggests that the 
mechanism of action of these compounds is to competitively inhibit the ATPase reaction. 
 
 
Figure 4.4.7: ATP competition assay. Assay run with 150 nM of M. tuberculosis DNA gyrase. All 
reactions were carried out in final DMSO concentration of 1% (v/v). The ATP concentration range of 
0.2 mM to 2 mM was used. 1% DMSO, Novobiocin (Novo) at 1 µM, Simocyclinone D8 (SD8) at 4 
µM, Redx03863 at 20 nM and Redx04739 at 100 nM were all assayed. -ve control contained all assay 
components in the absence of protein at 2 mM ATP. 
 
The second experiment to confirm that the Redx compounds are competitive ATPase 
inhibitors was a titration of the compounds into the ATPase-linked assay with the Mtb fusion 
construct, which was determined to be optimal for use in this reaction (Chapter 3.1). As the 
limit of detection for the linked ATPase assay is determined by the concentration of the 
enzyme used in the assay, true values of the IC50 could not be determined as 200 nM enzyme 
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was assayed. It was possible however, to observe that these compounds are very tight binders 
resulting in apparent IC50 values comparable to that of novobiocin (Table 4.4.3, Figure 4.4.8). 
The raw data shown for Redx03863 supports the calculated rates indicating that greater 
oxidation of NADH in the coupled reaction occurs in the assays with less than 0.2 µM 
Redx03863, whereas there is little to no difference in the assays carried out with between 0.4 
– 62.5 µM Redx03863 or 100 µM novobiocin (Figure 4.4.8A). Similar raw data was observed 
when the assay was run with Redx04739 (data not shown). Overall, it can be clearly 
determined from these biochemical experiments that both Redx03863 and Redx04739 are 
competitive ATPase inhibitors like novobiocin. 
 
Table 4.4.3: IC50 values for novobiocin, Redx03863 and Redx04739 against the novobiocin sensitive 
rate in the ATPase-linked assay run with 200 nM GyrBA stimulated with 1 ng linear pBR322. IC50 
values generated by GraphPad Prism with non-linear regression (log(inhibitor) vs response – variable 
slope (four parameters)). Error given is the standard error in the IC50 value as obtained from GraphPad 
Prism. 
Compound Apparent ATPase IC50 (nM) 
Novobiocin 208±41 
Redx03863 166±67 
Redx04739 211±60 
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Figure 4.4.8: A) Plot of the absorbance at 340 nm over time in the presence of varying amounts of 
Redx03863 within an ATPase PK/LDH linked assay. B, C) Plots of the rate of the novobiocin-sensitive 
ATP turnover per GyrB subunit per second were plotted against the base 10 logarithm of the 
concentration in µM to determine the IC50 value. B) Redx03863, C) Redx04739. Graphs are 
representative of multiple replicates, with all data points being carried out in duplicate. GyrBA protein 
at concentration of 200 nM with a substrate of 1 ng of linear pBR322 was used to obtain all data sets. 
Non-linear regression (log(inhibitor) vs response – variable slope (four parameters)) was performed to 
obtain IC50 values of 166±41 nM Redx03863 and 211±60 nM Redx04739. 
 
4.4.6 Surface plasmon resonance analysis of the binding kinetics of Redx03863 and 
Redx04739 
As we had determined that both Redx03863 and Redx04739 to be competitive inhibitors of 
the ATPase domain, hence it implied that both of these compounds bound at the ATP-binding 
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domain of GyrB. We hence sought to investigate the binding interactions between these 
compounds and the sub-ATPase domain of GyrB. For these studies we choose the technique 
of surface plasmon resonance (SPR), which can measure the interactions of immobilised 
proteins with a binding partner such as an inhibitor, cofactor or binding partner without the 
need for labels; as reviewed by Nguyen et al. (2015). Typically, SPR experiments work better 
with larger binding partners, however advancements in the technique have led to smaller 
molecules <300 Da being detected (Rich et al., 2002). Therefore, with this knowledge and as 
previous groups had had good experiences with compounds of similar sizes on our Biocore 
T200 machine, we chose to trial our compounds which have molecular masses of 420 and 
424. As we knew that both compounds were effective against Mtb and E. coli DNA gyrase 
we investigated the binding interactions of the ATPase sub-domains from both species. The 
proteins were successfully bound to CM5 sensor chips and subsequently singe cycle kinetics 
were performed.  
 
The protocol used for single cycle kinetics involved measuring the binding response in 
response to increasing concentrations of both compounds with intermediate intervals where 
the compounds were washed off the chips. It was however found that Redx03863 bound with 
very high affinity that saturated the chip and did not allow for washing and reusing of the chips 
and hence it was not possible to measure any kinetic data for Redx03863. This however, did 
strongly suggest that we were looking at the correct binding domain for Redx03863. 
 
On the other hand, it was found that Redx04739 bound with lesser affinity to the chips and 
could be partially removed and hence some kinetic data could be obtained. However, there 
was significant background binding to the control chip meaning that the readings obtained 
were very low. Regardless, a Kd value of 12.11±0.92 µM was obtained for the E. coli sub-
ATPase domain (Figure 4.4.9). Unfortunately, although it was clear that there was binding to 
the Mtb chip, it was not possible to generate a Kd value due to unusually high binding to the 
reference cell resulting in very high error values (Figure 4.4.10). Overall, although the data 
obtained for the SPR experiments were not ideal it did demonstrate that the GyrB sub-ATPase 
domain was likely to be the binding domain of both Redx03863 and Redx04739, suggesting 
this domain to be the correct domain to carry out any mutagenesis studies and crystallographic 
studies on. 
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Figure 4.4.9: Single cycle kinetics SPR results from the CM5 chip bound to the ATPase sub-domain 
from E. coli. A) Sensorgram obtained from the Biocore shows that binding appears in a similar pattern 
to the reference (no protein bound chip) as to the active chip. B) Binding of Redx04739 is increased on 
increasing concentration of compound, but the baseline is not reached between concentrations. C) Plot 
of concentration of Redex04739 against the response. The blue line is a best fit curve to fit the data, 
indicating an estimated Kd = 12.11±0.92 µM. 
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Figure 4.4.10: Single cycle kinetics SPR results from the CM5 chip bound to the Mtb ATPase sub-
domain. A) Sensorgram obtained from the Biocore shows that binding appears in a similar pattern to 
the reference (no protein bound chip) as to the active chip. B) Binding of Redx04739 is increased on 
increasing concentration of compound, but the baseline is not reached between concentrations. C) Plot 
of concentration of Redex04739 against the response. The blue line is a best fit line of the data. No Kd 
value could be obtained. 
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4.4.7 Bacterial mutant generation by Redx03863 and Redx04739 by serial passage 
To further identify the binding location of both Redx03863 and Redx04739, bacterial mutants 
were raised against Redx03863 and Redx04739 in E. coli ATCC25922 and M. smegmatis 
ATCC1940 by two independent methods. The first of these methods was the serial passage 
method whereby bacteria were passaged from cultures continually exposed to a quarter of the 
MIC100 value until a resistant strain was isolated. This method is based on continual exposure 
to low levels of the compounds leading to accumulating mutations which confer partial 
resistance to the compound of interest and hence leading to increases in the MIC100 values. 
 
The established method used by RedxAI for serial passages with E. coli ATCC25922 was 
adapted for M. smegmatis ATCC19420 to increase the time between passages from 24 hours 
to between 2-3 days. In the assays carried out we attempted to obtain a strain with a MIC100 
value of ≥64 µg/ml. If this was not achieved in 50 passages but a significantly increased 
MIC100 was obtained it was also considered to be successful and the resulting strain would be 
analysed for mutants. 
 
It was found that the MIC100 value of E. coli ATCC25922 increased steadily over the first 20 
passages from an initial value of 0.016 µg/ml to 1 µg/ml (a 64-fold increase in MIC100). The 
maximal MIC100 value was found to be 4 µg/ml at passage 49. The final strain E. coli 03863 
SP(50) has a MIC100 value of 2 µg/ml resulting in an increase of 128-fold in the MIC100 value 
from the initial starting value of 0.016 µg/ml. An additional intermediate strain E. coli 03863 
SP(25) was taken after the 25th passage with an MIC100 of 0.5 µg/ml, which was 32 times more 
resistant to Redx03863 than the wild type strain (Figure 4.4.11). 
 
On the other hand, it was found that after 33 passages no meaningful change in the starting 
MIC100 value was obtained in the M. smegmatis ATCC19420 starting strain, with many of the 
passages recording MIC100 values below that of the starting culture (Figure 4.4.11). As no 
obvious increase was observed the technique was terminated with no further characterisation 
being performed. 
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Figure 4.4.11: Plot showing the change in MIC100 values (µg/ml) for E. coli ATCC25922 (closed circle) 
and M. smegmatis ATCC1940 (closed square) when raised against Redx03863. E. coli ATCC25922 
was passaged every 24 hours, M. smegmatis ATCC19420 was passaged every 2-3 days. Passages were 
performed with a 1/100 dilution the ¼ MIC100 well. 
 
A strain of E. coli ATCC25922 with an MIC100 value greater than 128 µg/ml could be raised 
in as little as 7 days against Redx04739. It was not possible to raise a strain that had resistance 
greater than 128 µg/ml due to the concentration of DMSO in the media being limiting. 
Regardless of this, the E. coli 04739 SP(7) strain had a 32-fold increase from the starting 
MIC100 value (Figure 4.4.12).  
 
Like E. coli ATCC25922 it was found that a resistant strain of M. smegmatis ATCC19420 
raised against Redx04739 was generated at a much faster rate than Redx03863. After 29 
passages an MIC100 value of 128 µg/ml was achieved resulting in a 256-fold increase in the 
starting MIC100 value. Like the other strains generated, the final strain M. smegmatis 04739 
SP(29) was further analysed to determine differences to the wild-type strain (Figure 4.4.12). 
Interestingly, in terms of fold-change in the MIC100 value for Redx04739 against M. 
smegmatis ATCC14920 and Redx03863 against E. coli ATCC25922 increased at very similar 
rates, with Redx04739 against E. coli ATCC25922 generated resistance marginally faster. 
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Figure 4.4.12: Plot showing the change in MIC100 values (µg/ml) for E. coli ATCC25922 (closed circle) 
and M. smegmatis ATCC1940 (closed square) when raised against Redx04739. E. coli ATCC25922 
was passaged every 24 hours, M. smegmatis ATCC19420 was passaged every 2-3 days. Passages were 
performed with a 1/100 dilution of the ¼ MIC100 well. It was not possible to measure MIC100 above 
128 µg/ml. 
 
Cross-resistance testing to other known DNA gyrase inhibitors was performed to determine if 
resistance mutants to the novel compounds induced resistance to known antibiotics. This 
information is important in determining if these compounds have common mechanisms of 
resistance which is important when considering their potential in the clinic. The M. smegmatis 
04739 SP(29) strain was found to be a very sickly strain and after 4 days on a Middlebrook 
7H11 plate supplemented with glycerol and OADC supplement only a single colony was 
found to have grown. Unfortunately, this precluded cross-resistance MIC100 analysis from 
being carried out. It was however possible to gain this information about the three E. coli 
strains generated. Both of the strains raised against Redx03863 showed significant cross 
resistance to Redx04739, likewise the E. coli 04739 SP(7) showed 8-fold cross resistance to 
Redx03863 (Table 4.4.4). As the MIC100 for novobiocin was found to be 64 µg/ml for 
novobiocin it was not possible to determine to what degree there was cross resistance to it for 
the E. coli 03863 SP(25) and E. coli 03863 SP(50) strains, but both of these strains gave rise 
to partially increased resistance to novobiocin (Table 4.4.4).  
 
145 
 
Table 4.4.4: Cross-resistance MIC100 values for the E. coli mutant strains raised against Redx03863 and 
Redx04739 through use of the serial passage method. Compound dilutions above 64 µg/ml were not 
tested. 
 
Redx03863 
(µg/ml) 
Redx04739
(µg/ml) 
Moxifloxacin
(µg/ml) 
Novobiocin
(µg/ml) 
Escherichia coli ATCC25922 
(WT) 0.016 8 0.016 64 
Escherichia coli 03863 SP(25) 0.5 64 0.125 >64 
Escherichia coli 03863 SP(50) 2 >64 0.5 >64 
Escherichia coli 04739 SP(7) 0.125 >64 0.016 64 
 
In addition to cross resistance MIC100 testing, the mutants and wild type strains were further 
characterised through extraction of genomic DNA, PCR amplification and sequencing of the 
known type II topoisomerase genes to locate resistance mutants in the known targets. There 
were initial problems with obtaining the genomic DNA from the M. smegmatis strains due to 
problems with breaking open the mycolic acid cell wall. After including a mechanical step to 
break open the cell wall by vigorously vortexing the bacterial suspension with glass beads, 
high yields of genomic DNA suitable for PCR were obtained. 
 
In the E. coli strains two mutations were seen within the GyrB gene (Table 4.4.5; Figure 
4.4.13). The first of these was the F182Y mutation which corresponds to the Y185 position in 
the Mtb protein, meanwhile the second was that of T175N, which aligns with V179 in the Mtb 
protein, hence no further action was taken as the hydrophobic properties of valine are quite 
different to that of a threonine. As E. coli also contains topo IV and it has been confirmed that 
the compounds act via a dual targeting mechanism in E. coli, the topo IV genes were 
additionally sequenced. Two-point mutations were observed in the ATPase containing ParE 
subunit, however as both were found in a region that did not show good homology to the Mtb 
GyrB subunit no further action was taken. One single point mutation was found in each of the 
GyrA and ParC subunits although as the compounds are known to be competitive ATPase 
inhibitors no further action was taken at this time (Table 4.4.5). 
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Table 4.4.5: Single point mutants identified from sequencing of the DNA gyrase genes (gyrA and gyrB) 
and topo IV (parC and parE) genes from the E. coli serial passage mutants. Sequence alignment using 
Clustal Omega was performed to locate the comparable mutations in the wildtype Mtb gyrase proteins. 
Strain Protein Mutation Mutation in Mtb 
E. coli 03863 SP(25) GyrA V501M I478 
 ParE S338F Non-conserved 
E. coli 03863 SP(50) GyrB T175N V179 
  F182Y Y185 
 ParE V84G Non-conserved 
E. coli 04739 SP(7) ParC W143L F152 
 ParE S338F Non-conserved 
 
 
Figure 4.4.13: Visualisation of the mutant locations of the locations of the mutants generated by serial 
passage on a model made from 3 structures of M. tuberculosis DNA gyrase. The GyrB N-terminal 
domain is coloured pink and cyan; the GyrB CTD is coloured gold and grey; the GyrA NTD is coloured 
blue and coral; the GyrA CTD is coloured purple and brown. Mutants from the E. coli 03863 SP(25) 
strain are cyan (I478); from the E. coli 03863 SP(50) stain are blue (V179, Y185); from the E. coli 
04739 SP(7) strain are pink (F152); from the M. smegmatis 04739 SP(29) strain are green (E258; D340). 
The mutants that did not demonstrate good conservation in the region on the Mtb DNA gyrase proteins 
are not shown. Model reproduced from with adaptation (Nagaraja et al., 2017). 
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Two mutations were found in GyrA and one in GyrB of the M. smegmatis 04739 SP(29) strain. 
Like the E. coli strains none of these were found to be in the ATPase domain hence no further 
action was taken (Table 4.4.6; Figure 4.4.13). 
 
Table 4.4.6: Single point mutants identified from sequencing the DNA gyrase genes gyrA and gyrB 
isolated from the M. smegmatis serial passage mutant M. smegmatis 04739 SP(29). Sequence alignment 
using Clustal Omega was performed to locate the comparable mutations in the wildtype Mtb proteins. 
Protein Mutation Mutation in Mtb 
GyrB D340E D340E 
GyrA E259K E258K 
 S839L Non-conserved 
 
4.4.8 Bacterial mutant generation by Redx03863 and Redx04739 by frequency of 
resistance 
The second method by which bacterial mutants were obtained by was that of the frequency of 
resistance experiment - a plate-based method of mutant generation whereby wild type bacteria 
were exposed to concentrations of the compound of interest at multiples of their agar-MIC100 
values. As this method is agar-plate based we first conducted experimentation to generate the 
agar-MIC100 values as these are often found to differ from their broth counterparts. An agar 
MIC100 value of ≤16 µg/ml is required to enable the frequency of resistance experiment to be 
viable at 4xMIC100 due to the amount of compound the experiment required and the DMSO 
concentrations in the reaction. Unfortunately, this precluded Redx04739 being used in this 
experiment against E. coli ATCC25922 (Table 4.4.7). 
 
Table 4.4.7: Agar MIC100 values recorded against E. coli ATCC25922 and M. smegmatis ATCC19420 
for Redx03863, Redx04739 and novobiocin. Values taken as a minimum of two data repeats with two 
technical replicates. The agar MIC100 of novobiocin against E. coli ATCC25922 was not tested. It was 
not possible to test values above 64 µg/ml in this method. Values marked with * indicates values 
previously made by an employee of Redx AntiInfectives. 
Bacterial Strain Redx03863 Redx04739 Novobiocin 
E. coli ATCC25922 0.125* >64 - 
M. smegmatis ATCC19420 0.002 0.5 32* 
 
It was found that no mutants were obtained when E. coli ATCC25922 was plated onto 4x 
MIC100 Redx03863 leading to a very low frequency of resistance value despite increasing the 
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concentration of the inoculum used. The consequence of this was a decrease in the FoR value 
from <2.25x10-8 to <2.94x10-11 (Table 4.4.8). To try and obtain mutants the experiment was 
therefore repeated at 2x MIC100, where a single mutant colony was obtained over two 
experimental repeats (Table 4.4.8). This mutant strain (E. coli 2x03863 FoR) was confirmed 
to be a true mutant through testing of the broth MIC100 which was found to be 32 µg/ml, a 
2096-fold increase in the MIC100 value (Table 4.4.9). It was determined that E. coli 2x03863 
FoR exhibited cross resistance with Redx04739 but interestingly increased sensitivity to 
novobiocin, indicating differences in the resistance mechanisms between these compounds 
(Table 4.4.9). When the type II topoisomerase genes were sequenced for this mutant strain 
only one mutation (S338F) was observed in the ParE gene which is not within the ATPase 
domain, hence at this time no further experimentation on this mutant was performed. 
 
In contrast with the E. coli experiments, a high number of colony forming units were observed 
on 4x agar-MIC100 plates when using this method with M. smegmatis ATCC19420 resulting 
in unusually high frequency of resistance values (Table 4.4.8). To confirm if this was an 
artefact of the assay when working with M. smegmatis ATCC19420, we carried out the assay 
with novobiocin which resulted in comparable results. 
Table 4.4.8: Frequency of Resistance values. Measurements made at 2x and 4x agar MIC100 of 
Redx03863 against E. coli ATCC25922 and at 4x agar MIC100 of Redx03863, Redx04739 and 
Novobiocin against M. smegmatis ATCC19420. Control plates without compounds were measured at 
1/3 days (E. coli/M. smegmatis), compound containing plates were counted at 2/5 days (E. coli/M. 
smegmatis).  < indicates no resistant colonies were obtained. 
 E. coli ATCC25922 M. smegmatis ATCC19420 
 Redx03863 Redx03863 Redx04739 Novobiocin 
2x MIC100 <1.65x10-9    
8.20x10-10    
4x MIC100 <3.94x10-11 4.52x10-5 6.82x10-4 2.89x10-5 
<2.25x10-8 5.31x10-5 5.81x10-4 2.95x10-5 
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Table 4.4.9: Cross-resistance MIC100 values for mutants raised via frequency of resistance experiments. 
M. smegmatis mutants raised against Redx03863 at 4x agar MIC100 and E. coli mutants raised against 
Redx03863 at 2x agar MIC100. A concentration range of drugs of 0.125-64 µg/ml was tested. 
 
Redx03863 
(µg/ml) 
Redx04739 
(µg/ml) 
Moxifloxacin 
(µg/ml) 
Novobiocin 
(µg/ml) 
Isoniazid 
(µg/ml) 
Mycobacterium smegmatis 
ATCC19420 (WT) 0.016 0.5 0.125 2 32 
Mycobacterium smegmatis 
4x03863 FoR 1a 0.25 4 <0.125 4 32 
Mycobacterium smegmatis 
4x03863 FoR 1b 0.25 4 <0.125 64 32 
Mycobacterium smegmatis 
4x03863 FoR 2a 0.125 4 <0.125 8 16 
Mycobacterium smegmatis 
4x03863 FoR 2b 0.25 2 <0.125 4 32 
Escherichia coli 
ATCC25922 (WT) 0.016 8 0.016 64 - 
Escherichia coli    
2x03863 FoR 32 >64 0.016 0.5 - 
 
When looking into a sub-selection of the mutants raised against Redx04739 it was not possible 
to confirm resistance using broth MIC100 testing. On the other hand, the mutant strains raised 
against Redx03863 (M. smegmatis 4x03863 1a, 1b, 2a, 2b) all demonstrated at least 8-fold 
resistance in broth MIC100 testing (Table 4.4.9). These four strains like the other mutants raised 
also exhibited cross resistance to Redx04739 with some indication for cross resistance to 
novobiocin, especially in M. smegmatis 4x03863 1b where a 32-fold increase was observed. 
The results observed indicate that there may be increased sensitivity to moxifloxacin as the 
MIC100 value is decreased. However, the extent of this is unclear as testing was not carried out 
at a standard concentration range (64 – 0.125 µg/ml) preventing a true MIC100 value of 
moxifloxacin from being obtained in this assay, and hence it is not possible to determine if a 
true decrease in the MIC100 was observed in the M. smegmatis 4x03863 FoR strains (Table 
4.4.9). 
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Interestingly, sequencing of the DNA gyrase genes from the M. smegmatis 4x03863 FoR 
1a,1b,2a,2b strains revealed an unexpectedly high number of mutations – 5 in GyrA and 13 in 
GyrB (Table 4.4.10). The only one of these that was found in all four of the strains but not the 
wild type was the D340 mutant in GyrB and was also found in the M. smegmatis 04739 SP(29) 
strain. Most interestingly in three of these strains a point mutation of T167 to alanine was 
obtained which is located within the GyrB NTD. Furthermore, in the M. smegmatis 4x03863 
FoR 2a strain there were K159R and K202R mutations and the M. smegmatis 4x03863 1b 
strain had a mutation at G83S, all of which are the GyrB NTD (Table 4.4.10; Figure 4.4.14). 
As there is a high degree of homology between the GyrB N terminal domains of the Mtb and 
Msm proteins it was decided to test these four positions to determine if they generated 
resistance to either of the compounds in the ATP-dependent supercoiling reaction of DNA 
gyrase. 
 
 
Figure 4.4.14: Locations of the mutations located in the GyrB NTD raised and identified by frequency 
of resistance mutagenesis. Residues shown on the known M. tuberculosis ATPase domain structure 
3ZKB, indicating the AMP-PNP binding site as shown. 
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Table 4.4.10: Single point mutants identified from sequencing the DNA gyrase genes gyrA and gyrB 
isolated from the M. smegmatis frequency of resistance mutants raised against Redx03863. Sequence 
alignment using Clustal Omega was performed to locate the comparable mutations in the wildtype Mtb 
proteins 
Strain Protein Mutation Residue in Mtb 
M. smegmatis 4x03863 FoR 1a GyrB T167A T167 
  D340E D340 
  E489K E489 
  D655N D655 
  D657K D657 
M. smegmatis 4x03863 FoR 1b GyrA F603D F602 
  L624P L623 
 GyrB G83S G83 
  D340E D340 
M. smegmatis 4x03863 FoR 2a GyrA E259K E258 
 GyrB K159R K159 
  T167A T167 
  K202R K202 
  D340E D340 
M. smegmatis 4x03863 FoR 2b GyrA A385D A384 
  L624P L623 
 GyrB T167A T167 
  D340E D340 
 
These four mutants (G83S, K159R, T167A, K202R) were successfully obtained via SDM in 
Mtb GyrB and subsequent protein expression and purification was successful. Confusingly 
the G83S mutant did not appear to show any significant activity in supercoiling (Figure 
4.4.15). This may be explained as although there is a very high homology between the Msm 
and Mtb proteins, it is possible that this position may be essential in the Mtb enzyme and not 
in the Msm protein. It is also plausible that the very low levels of supercoiling seen here is 
significant enough for survival of the bacteria. 
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Figure 4.4.15: Time course of supercoiling of GyrBG83S at an enzyme concentration of 0.158 µM, at 
timepoints of 0,15,30,45,60,90,120 minutes. 0.147 µM GyrA used throughout. WT +ve control at 0.147 
µM was made at 30 minutes and -ve no enzyme control at 120 minutes. The emergence of a linear 
cleavage band is as a result of longer incubation times and does not affect the results of this assay. 
 
The other three mutants were active and did not appear to alter the supercoiling activity of the 
enzyme. The supercoiling activity of the K159R, T167A and K202R mutants was tested 
against novobiocin, Redx03863 and Redx04769 to determine if any of them were involved in 
the mechanism of action of the compounds. None of these mutants resulted in resistance to 
novobiocin which is unsurprising as the binding site is already known and none of these 
mutants have previously been implicated in the mechanism of resistance (Figure 4.4.16). 
Additionally, only the M. smegmatis 4x03863 FoR 1b strain had significantly increased 
resistance to novobiocin and none of these mutants were isolated from that strain (Table 
4.4.10). Unfortunately, none of the mutants showed resistance to either Redx03863 (Figure 
4.4.17) or Redx04739 (Figure 4.4.18) either. This may again be an artefact of the different 
species used, or because multiple mutants were required to work in synergy to get an effect. 
It is also possible that these compounds are mutagenic resulting in multiple single point 
mutations throughout the genome and the mutations are not involved in the mechanism of 
mutagenesis which is more likely to come from mutations in efflux pumps. This explanation 
seems somewhat likely as in particular K202 and K159 are unlikely to both be involved in the 
binding site due to the distance between the residues. 
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Figure 4.4.16: Supercoiling assay using GyrB wild type, K159R, T167A and K202R at a final enzyme 
concentration of 150 nM with 150 nM GyrA. -ve control contained DNA substrate in the absence of 
enzymes, DMSO control contained 1% DMSO in the absence of compounds; Novobiocin titration 10-
0.1 µM assayed in 1% DMSO. 
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Figure 4.4.17: Supercoiling assay using GyrB wild type, K159R, T167A and K202R at a final enzyme 
concentration of 150 nM with 150 nM GyrA. -ve control contained DNA substrate in the absence of 
enzymes, DMSO control contained 1% DMSO in the absence of compounds; Novobiocin at 1 µM; and 
compound dilutions 300-3 nM Redx03863. 
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Figure 4.4.18: Supercoiling assay using GyrB wild type, K159R, T167A and K202R at a final enzyme 
concentration of 150 nM with 150 nM GyrA. -ve control contained DNA substrate in the absence of 
enzymes, DMSO control contained 1% DMSO in the absence of compounds; Novobiocin at 1 µM; and 
compound dilutions 1000-10 nM Redx04739. 
156 
 
4.4.9 Testing of the naphthoquinone model against Redx03863 and Redx04739 
A model of the 7-methyljuglone binding site was predicted computationally by SE within the 
GyrB NTD (as described in section 4.3) (Figure 4.3.3). Although this model was not tested 
against the naphthoquinones due to the instability of 7-methyljuglone, the site-directed 
mutagenesis and protein purification had already been carried out, and, as the binding site had 
not been determined by bacterial mutagenesis methods, it was decided to test this model 
against Redx03863 and Redx04739 to determine if these compounds interacted with this 
binding pocket. 
 
All six mutants of the mutants made showed significant levels of supercoiling activity as 
compared to wild type DNA gyrase under standard supercoiling assay conditions. However, 
none of these mutants demonstrated any resistance to either Redx03863 (Figure 4.4.19) or 
Redx04739 (Figure 4.4.20) as compared to the wild type. Interestingly, several of the mutants 
(W47F, T189A, N309A, T373A) appear to show slightly increased sensitivity to Redx03863 
and both W47F and N309A have increased sensitivity to Redx04739, however this is most 
likely to be due to the enzyme having decreased activity that was not optimised for this 
reaction. Of these the most marked difference was observed in the W47F where no 
supercoiling was observed within the concentration range tested, although it is unclear why 
this residue would increase the sensitivity to Redx03863 at this time. Overall, this was not an 
unexpected result, as from the biochemical data we know that these compounds are 
competitive ATPase inhibitors, and the predicted mode of action of diospyrin was to inhibit 
DNA gyrase within the GyrB N-terminal domain, but not at the ATP-binding site (Karkare et 
al., 2013b). 
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Figure 4.4.19: Redx03863 tested against the GyrBA fusion protein wild type and naphthoquinone single 
point mutants (R40A, R40Q, W47F, T189A, N309A, T373A) at a concentration of 74 nM. Controls 
used negative (no enzyme), positive, 1% (v/v) DMSO, and 10 µM novobiocin in 1% (v/v) DMSO. 
Compound dilutions in 1000-10 nM Redx03863 in 1% (v/v) DMSO. The presence of a linear cleavage 
band in some of the reactions is as a result of impurities in the enzyme and does not affect the results 
of the assay. 
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Figure 4.4.20: Redx04739 tested against the GyrBA fusion protein wild type and naphthoquinone single 
point mutants (R40A, R40Q, W47F, T189A, N309A, T373A). Controls used negative (no enzyme), 
positive, 1% (v/v) DMSO, and 10 µM novobiocin in 1% (v/v) DMSO. Compound dilutions in 1000-10 
nM Redx04739 in 1% (v/v) DMSO. The presence of a linear cleavage band in some of the reactions is 
as a result of impurities in the enzyme and does not affect the results of the assay. 
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4.5 Discussion 
This chapter described work on four classes of Mtb DNA gyrase inhibitors. Potentially of the 
greatest interest in the context of developing new antibiotics for use in the clinic against active 
Tuberculosis is that of the TriBE class including Redx03863 and Redx04739, which have been 
investigated in detail here to confirm the mode of action. Despite this these compounds will 
probably never make it to the clinic as further optimisation is needed before they can be taken 
forwards. However, knowing the full mode of action should increase the chance of successful 
optimisation even if the full binding site was not confirmed from this work. The 
naphthoquinone 7-methyljuglone which was already known to have toxicity issues has been 
shown here to be unsuitable to be taken forwards as the pure compound is apparently not the 
active substance. Furthermore, as the active compound is unidentifiable the mode of action 
and binding site cannot be confirmed from this work. 
 
4.5.1 Impacts from further studies on known antibiotics 
The work studied here complements the current literature on the known DNA gyrase inhibitors 
moxifloxacin and novobiocin, demonstrating their inhibition of Mtb DNA gyrase fusion and 
subunit constructs to a similar extent to that previously described in the literature. The IC50 
value presented here for novobiocin is very similar to the value presented by Aubry et al. 
(2006a), meanwhile the value we suggest for the IC50 of moxifloxacin is marginally larger 
while the CC50 value is marginally smaller than the literature values (Aubry et al., 2004). 
However, we did find a larger than expected difference between the CC50 and IC50 values of 
moxifloxacin. Several proposed explanations have been presented including the idea that this 
is an effect that arises from the supercoiling assay being carried out in the presence of ATP 
and the cleavage reaction being carried out in the absence of ATP which may alter the efficacy 
of moxifloxacin. 
 
We also suggest an apparent IC50 value for novobiocin of 0.21±0.04 µM for the ATPase assay 
here which to our knowledge is the first reported value of an IC50 value when using the Mtb 
enzymes in this assay, but also demonstrates the difficulties of this assay which requires large 
enzyme concentrations to get reproducible results. As the IC50 value obtained from this 
reaction is close to the enzyme concentration it prevented a true IC50 value from being 
determined due to reaching the limit of detection of the assay. Overall, the value presented is 
not dissimilar to the value presented for E. coli DNA gyrase of 90 nM (Contreras and Maxwell, 
1992) supporting the idea that the limit of detection may have been reached within this assay. 
It is however quite surprising that the IC50 value for the supercoiling reaction was found to be 
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considerably larger than the IC50 of the ATPase reaction, as previously these values have been 
found to be similar in E. coli (Contreras and Maxwell, 1992). It is why unclear why this is not 
the case with M. tuberculosis DNA gyrase. 
 
4.5.2 Instability of 7-methyljuglone and impacts on further studies 
It is clear looking at the results obtained here alongside the prior results in the work of van der 
Kooy (2007) and Dr M.J. Austin (Pers. Comm.) that 7-methyljuglone is not itself active in 
inhibiting DNA gyrase. It is however plausible that a degradation or reaction product formed 
is instead likely to be the active agent causing the inhibition of supercoiling. At present the 
only information we have about the mode of action of the naphthoquinones is that diospyrin 
inhibits DNA gyrase likely within the N-terminal domain of GyrB but is not out competed by 
increasing concentrations of ATP in the Mtb DNA gyrase supercoiling reaction nor does it 
inhibit the ATPase reaction of S. aureus DNA gyrase (Karkare et al., 2013b). Here we 
focussed our work on the less potent naphthoquinone 7-methyljuglone assuming the 
compound class to act through a common mechanism of action as 7-methyljuglone is half of 
a diospyrin molecule. As the reaction of the 7-methyljuglone does not appear to be 
straightforward (as no individual product could be identified) (Dr M.J. Austin Pers. Comm.), 
we could not test the compound reliably and comparatively against the computational model 
as the activity of the compound was evolving. This information may have also affected the 
parameters used to create the computational model (Figure 4.3.3) and hence a different binding 
pocket may have been identified if the work was repeated. 
 
One of the initial questions arising from this work is should we continue to search for a more 
stable naphthoquinone which we would be able to reliably test the binding model on. The 
major issue arising is that the naphthoquinone menadione has been reported to have superior 
stability with >99% remaining after one week dissolved in DMSO (van der Kooy, 2007), but 
has also been reported to be very weak at inhibiting the supercoiling reaction of Mtb DNA 
gyrase with an IC50 value >200 µM (Karkare et al., 2013b). It is apparent that the less stable 
naphthoquinones appear to have greater activity against the enzymes, implying that there may 
be a link between the reactivity of the compounds and inhibition of DNA gyrase. Overall, it 
would be more productive to try and identify the reaction mixture generated from the less 
stable antibiotics to identify the active component and initiate a new series of studies and 
models based on these data. 
 
161 
 
4.5.3 Whole cell activity of the TriBE antibiotics 
From the whole cell activity, Redx04739 shows greater activity against M. smegmatis than 
against the preliminary panel of Gram-negative bacterial species tested including E. coli as 
previously described by McGarry et al. (2018). The cell wall properties vary between the 
Gram staining of different bacterium, with Gram-negative bacterium having a 
lipopolysaccharide outer membrane beyond the peptidoglycan cell wall (Costerton et al., 
1974, Beveridge, 1999) whereas the Gram-positive bacteria are characterised as not having an 
outer membrane with their plasma membranes being simply covered with a layer of 
peptidoglycan (Shockman and Barrett, 1983). On the other hand, mycobacteria are somewhat 
unique in that they have a mycolic acid outer membrane in addition to their peptidoglycan 
layer (Brennan, 2003). This means there are permeability differences in the cell wall structures 
between Gram-negative bacteria and the mycobacteria that may be able to account for the 
differences in the activity on the whole cells which appear to have greater effects on 
mycobacteria despite the activity on the molecular targets being similar or better in the case 
of E. coli DNA gyrase. 
 
It would have been predicted that the compounds should have been able to permeate the Gram-
positive cell wall of S. aureus more easily, but the whole cell activity is comparable to that of 
the Gram-negative bacteria. Two of the potential explanations for this include differences in 
efflux pumps and differences in target enzyme resulting in less inhibition. 
 
In addition to enhanced MIC100 data of Redx03863 and Redx04739 against M. smegmatis, 
these compounds were also determined to have enhanced activity in killing M. smegmatis in 
a biofilm situation when compared to E. coli in a comparable experiment. The assay to 
compare the inhibition of biofilm growth was uninterpretable for M. smegmatis for an 
unknown reason, meaning no direct comparison can be made. The MBEC is however the 
superior measure as it determines the concentration of the compound or drug that is required 
to effectively kill the biofilm as opposed to the concentration required to stall the growth of a 
biofilm. The method developed and used for the M. smegmatis biofilm assay was not ideal as 
the drug incubation step used was 3 days meanwhile all the other steps were only two days. It 
is unclear if by lengthening the incubation with drugs the bMIC values were somewhat altered 
compared to the MBEC values. 
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The results obtained with regards to the biofilm inhibition demonstrate that these novel 
antibiotics have enhanced properties in accessing bacteria in enclosed environments such as 
the biofilm. Although typically M. tuberculosis is not thought of as a biofilm-forming 
infection in its active state, however, there are known cases of non-pulmonary M. tuberculosis 
infections, and in these cases there have been reports of biofilm-like structures forming over 
implants causing infections (Spinner et al., 1996, Sendi and Brent, 2016). Additionally, 
although M. tuberculosis has not been reported to form an environmental biofilm, several 
environmental mycobacteria (e.g. M. kansasii and M. xenopi) are known to form biofilms in 
water systems, described as being found in hospital water reservoirs in the past (Carson et al., 
1988, Schulze-Robbecke et al., 1992). All together this shows that although M. tuberculosis 
biofilms have rarely been detected in clinical settings they are important to consider as they 
have the potential to form biofilm-like infections.  
 
Redx03863 appears to effectively and quickly kill both E. coli and M. smegmatis in liquid 
culture supplemented with at least four times the MIC100 of the compound. The E. coli culture 
showed no surviving cultures at one day post-antibiotic addition whereas this stage was 
reached at just 2 days for the slower growing M. smegmatis cultures. Based on M. smegmatis 
having a doubling time in the region of several hours, it suggests that Redx03863 kills M. 
smegmatis more efficiently over fewer generations. The initial timepoints derived for the M. 
smegmatis assay were successfully derived from the timepoints used by Maurer et al. (2014), 
with later time points being evenly spread to obtain a protocol where no colonies should 
remain after 6 days. It is suggested that if the work was to be repeated in the future with M. 
smegmatis, that this would be a good method to follow again. 
 
4.5.4 Consequences of the bacterial mutagenesis results 
The TriBE group of antibacterial agents were originally developed to act in a dual-targeting 
mechanism (Bensen et al., 2012, Tari et al., 2013a). In the absence of topo IV it is likely that 
a single targeting mechanism occurs in M. smegmatis and hence is also inferred in M. 
tuberculosis (Cole et al., 1998, Mohan et al., 2015). The result of these compounds dual 
targeting both DNA gyrase and topo IV in E. coli, is to make the frequency of resistance rate 
very low as two spontaneous mutations in both targets are required to induce resistance as 
opposed to the single mutation in M. smegmatis. The difference in these values is possibly 
more surprising as the FoR value for M. smegmatis against Redx03863 is in the order of just 
10-5 as opposed to the 10-11 found in E. coli. The values were found to be of the same order 
when the FoR experiment was performed in the presence of 4x Redx04739 or novobiocin, 
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suggesting they are true results (Table 4.4.8). The high FoR results presented here are 
suggested to be an artefact of working with M. smegmatis, this is proposed because when 
working with the mutant set isolated on 4x Redx04739 plates it was not possible to 
conclusively confirm resistance to Redx04739, hence questioning the values obtained within 
this assay – for instance a “grow-through” effect may have occurred where the drug did not 
efficiently kill the bacteria before the efficacy of the compound was degraded, unfortunately 
it was decided not to carry out the time of kill experiment with Redx04739 and hence this 
theory was not tested. We do however know this is not likely to be the case for Redx03863 
due to the results of the time of kill experimentation (Figure 4.4.3). 
 
In contrast to the FoR results it was found that a resistant strain of M. smegmatis ATCC19420 
could not be effectively raised against Redx03863 using the serial passage method whereas an 
E. coli ATCC25922 strain that had 128-fold increased resistance to Redx03863 was raised 
over a period of 50 days (Figure 4.4.11). This implies that continual exposure of a culture to 
a low compound concentration is less effective at producing resistant strains than the selection 
pressure of the high concentrations of compound on agar plates. Likewise, when considering 
this result in the context of the time of kill data, it suggests that the bacterium is effectively 
killed within 4 days and hence there should be no significant concerns over resistance 
generated in the time taken to treat an infection. 
 
This same pattern was also obtained when the bacteria were passaged against Redx04739, 
although resistant strains were obtained over fewer passages (Figure 4.4.12). These results 
somewhat correlate to the FoR results were marginally higher FoR values against Redx04739 
compared with those from Redx03863 were obtained (Table 4.4.8). It does however suggest 
that Redx04739 would not be less clinically effective against E. coli as it is able to generate 
resistance in a brief period of time (i.e. less than a typical course of antibiotics, i.e. 7 days). 
Conversely, it may be possible to use it clinically verses mycobacteria such as M. smegmatis 
as no significant increase in the MIC100 value was obtained in the first 10 passages (>20 days), 
and although no time of kill data were obtained against Redx04739 it is suggested that whole 
cells should be killed effectively within this time. Furthermore, it is important to consider that 
a multiple drug regime is currently preferred for the treatment of tuberculosis, so future studies 
should be investigated in the presence of alternate antibiotics including synergy studies 
(WHO, 2010). 
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The cross-resistance profile of the resistance strains isolated was analysed and gave some 
interesting results. Firstly, it confirmed that the mechanism of action for both Redx03863 and 
Redx04739 is likely to be the same as cross-resistance was present in all strains raised against 
either compound (Table 4.4.4; Table 4.4.9). Secondly, despite moxifloxacin having a known 
mode of action that is different to the proposed mechanism of the novel compounds there 
appeared to be some cross-resistance of the E. coli 03863 SP(25/50) strains which increased 
over the passage number to final resistance of 32-fold to moxifloxacin (Table 4.4.4), although 
no mutations were observed in the QRDR (quinolone resistance determining region) within 
GyrA (Table 4.4.4). No cross resistance of this mechanism was observed for any of the FoR 
mutants analysed but presents an issue with the compounds if they are able to induce resistance 
to compounds with alternate modes of action.  
 
Several of the mutants appear to have a degree of cross resistance or sensitivity to novobiocin. 
These for the most part are relatively small degrees of resistance (2-4 fold) although one strain 
(M. smegmatis 4x03863 1b) exhibited 32-fold resistance over the wild-type, meanwhile E. 
coli 2x03863 FoR appeared to generate 128-fold sensitivity to novobiocin (Table 4.4.4; Table 
4.4.9). It has been previously presented within the literature that the G83S mutation (G85S S. 
aureus) is involved in the mechanism of resistance of novobiocin, and this point mutation is 
found in the M. smegmatis 4x03863 1b novobiocin resistant strain (Stieger et al., 1996). We 
were unable to confirm if through the inhibition of supercoiling reaction if this point mutation 
was involved in binding of either of the Redx compounds due to the very low activity of this 
mutant. However, as the mechanisms of action are comparable, it is therefore plausible that 
the binding sites of these compounds overlap, and indeed the crystal structures of the TriBE 
compounds presented in (Tari et al., 2013a) suggests overlap with the binding pocket of 
novobiocin (Holdgate et al., 1997) and hence one single point mutation in this region (such as 
the G83S mutation) may affect the binding of both groups of compounds. 
 
An interesting thing to consider in the future would be to examine the cross-resistance profiles 
of M. smegmatis ATCC19420 and E. coli ATCC25922 with the R141A and R136A GyrB 
mutants introduced. This is a primary residue involved in novobiocin resistance (del Castillo 
et al., 1991, Holmes and Dyallsmith, 1991, Contreras and Maxwell, 1992, Stieger et al., 1996, 
Kampranis et al., 1999b, Gross et al., 2003, Fujimoto-Nakamura et al., 2005), and hence 
determining if in whole cell there is cross-resistance between novobiocin, Redx03863 and 
Redx04739 this residue would be important in confirming whether these compounds same 
binding site. 
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Sequencing of the type II topoisomerase genes from resistant strains was carried out, 
indicating a surprisingly large number of mutations within these genes, many of which did not 
appear to make sense in the context of the previously discussed mechanism of action. As the 
wild-type type II topoisomerase genes were additionally sequenced and only differences in 
the resistant strains reported here it was decided to continue with testing of only the mutants 
in the GyrB NTD. However, it is also considered possible that the mutants are an artefact of 
poor sequencing (the chromatograms (not shown) appeared normal), or that the compounds 
themselves induce increased mutagenesis. It appears unlikely that it results from an artefact 
of sequencing as there were several mutations that were observed in multiple resistant strains 
but not the wild type strain (e.g. GyrB T167A, GyrB D340E), as opposed to random mutations 
occurring suggesting that there may be a common resistance mechanism obtained from these 
mutations (Table 4.4.10). 
 
One of the mutants that was sequenced contained a mutant of Gly83 to Ser which when 
purified appeared to lack supercoiling activity (Figure 4.4.15). This is surprising as it was 
expected that any mutants that were isolated from bacterial methods should support 
supercoiling in the cell and therefore it would be expected to support supercoiling in vitro. 
Furthermore, this mutant has been previously described to be involved in bacterial resistance 
mechanisms including against novobiocin in S. aureus (Stieger et al., 1996) suggesting that 
that is not an essential amino acid in vivo. However, this mutation in E. coli has been 
previously reported to have only low level ATPase and supercoiling activity in vitro 
previously (Gross et al., 2003). This theory is further enhanced through the evidence presented 
in this chapter that the mechanisms of actions of the aminocoumarins is remarkably like that 
of Redx03863 and Redx04739, although there does not appear to be consistent cross-
resistance between these compounds and novobiocin. 
 
The other three mutations that were introduced into Mtb DNA gyrase (K159R, T167A and 
K202R) did not show resistance to either compound or novobiocin suggesting that they are 
not involved in the resistance mechanism in M. tuberculosis. As discussed earlier, it does not 
preclude them from being involved in the resistance mechanism in M. smegmatis DNA gyrase 
(Figure 4.4.16; Figure 4.4.17; Figure 4.4.18). The most surprising of these negative results is 
that of the T167A mutations, which was independently identified in three of the four M. 
smegmatis 4x03863 FoR strains, implying it to be important in the resistance mechanism. 
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Additionally, there have been studies on two aminobenzimidazole compounds (VRT-125853 
and VRT-752586) (Figure 4.5.1) demonstrating that resistance is generated against these 
compounds when T167 is mutated (Grossman et al., 2007). Finally, T167V has been reported 
to be weakly involved in resistance to novobiocin (Stieger et al., 1996). Overall, this suggests 
that the binding site of both Redx03863 and Redx04739 is likely to be close to the novobiocin-
binding site as is the binding site of the VRT compounds (Holdgate et al., 1997). 
 
 
Figure 4.5.1: Structures of the VRT aminobenzimidazole dual-targeting compounds from Vertex 
Pharmaceuticals Incorporated (Grossman et al., 2007). 
 
Although there is a high degree of homology between the two different enzymes it is plausible 
that there may be some difference in how these compounds interact with the two different 
enzymes. Additionally, it may require multiple mutations to be made in parallel to enable 
resistance to be observed which was not carried out in this study and hence this theory cannot 
be discounted. 
 
167 
 
4.5.5 Consequences of the mode of action studies and the search for the binding site 
From the enzymatic results shown in this section both Redx03863 and Redx04739 have a 
mode of action that involves competitively inhibiting the ATPase activity of GyrB. 
Importantly, it was demonstrated on the Mtb DNA gyrase through use of the ATPase linked 
assay, which, to our knowledge, is the first time this has been achieved for inhibition studies.  
 
The binding domain of Redx04739 (and hence Redx03863) is suggested through the use of 
SPR to be within the ATPase sub-domain (Figure 4.4.9; Figure 4.4.10). The data obtained 
showed that very strong binding was occurring with the chip and that the compounds were 
difficult to remove after binding. A Kd value could however be obtained for Redx04739 for 
both the E. coli and M. tuberculosis ATP-subdomains, although the M. tuberculosis gave very 
large errors and hence is not quoted (Figure 4.4.9; Figure 4.4.10). Although, specific statistical 
values were not obtained it gave promise that the GyrB NTD was the correct place to be 
searching for the binding sites of Redx03863 and Redx04739, as predicted from the previous 
structural studies of compounds within this series (Tari et al., 2013a). These results also 
confirmed that this was the correct domain to be using for subsequent crystallographic trials 
detailed in chapter 5. 
 
Overall, Redx03863 and Redx04739 appear to be part of a useful class of inhibitors that could 
be further optimised to obtain a mycobacterial-specific inhibitor to be explored as a clinical 
option in the future. At present both compounds present with one major issue in their high 
frequency of mutation results in M. smegmatis with no direct DNA gyrase mutants involved 
in the mechanism of action being obtained. It is suggested that to overcome this in the future, 
a permeable M. smegmatis (or E. coli) strain could be exploited to generate resistance mutants. 
Finally, it was not possible within the work of this chapter to locate the specific binding site 
of these compounds, although we have determined that they bind within the sub-ATPase 
domain within the GyrB NTD and the mode of action has been confirmed as being a 
competitive inhibitor of the ATPase reaction. In the next chapter we will further discus the 
binding site in the context of subsequent structural studies performed. 
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5. Crystallographic Studies of Mycobacterial DNA Gyrase 
At present our structural understanding of DNA gyrase from M. tuberculosis is robust with 
the structure of each subunit of the enzyme having previously been solved (Tretter and Berger, 
2012, Agrawal et al., 2013, Blower et al., 2016). From this structural information we can make 
an educated guess of the final arrangement of the subunits based on homology modelling and 
the low resolution cryoEM structure of T. thermophilus DNA gyrase (Figure 5.1.1) (Nagaraja 
et al., 2017). Although we have some structural information, it is however important to keep 
expanding the structural information we have available to better rationalise both the activity 
and inhibition of mycobacterial DNA gyrase to assist with future drug discovery efforts. 
Hence, in this chapter we investigated the possibility of solving the full-length structure of 
DNA gyrase from M. tuberculosis in addition to further investigating the structures of 
mycobacterial ATPase domains bound to inhibitors to understand their mechanisms of action. 
 
5.1 Crystallisation trials of full-length M. tuberculosis DNA gyrase 
In the past there has been no high-resolution structure of full-length DNA gyrase from any 
species. To determine the full-length structure of DNA gyrase the fusion GyrBA protein was 
subjected to crystallisation trials to obtain protein crystals. The fusion protein was chosen as 
by fusing the two subunits it created a protein already complexed with lesser mobility and 
hence it was theorised that this may increase the chance of successful crystallisation. Indeed, 
there is an almost complete structure of the first 1177 residues of S. cerevisiae topo II available 
in the PDB (Figure 1.7.1) supporting the idea that the fusion protein may be a better target for 
crystallisation trials (Schmidt et al., 2012). 
 
It was discovered that at a concentration of 2.2 mg/ml with a CTD-His-tag removed there was 
little precipitation, but no crystals were observed in the KISS, Morpheus® and JCSG-plusTM 
screens. This implied that the protein concentration was too low and hence the protein was not 
able to enter the nucleation zone. When increasing this to a concentration of 7.5 mg/ml (with 
the CTD-His-tag present) in the same three screens no crystals were obtained although a better 
balance of precipitation and clear drops was observed. 
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Figure 5.1.1: Structural model of M. tuberculosis DNA gyrase. The model was made by taking the 
existing crystal structures (5BS8, 3UC1, and 3ZKB) and using the program COOT to assemble a model 
of the A2B2 complex. Domains are coloured as follows: GyrB-NTDs, ice blue with B24 sub-domain 
highlighted in dark blue; GyrB-CTDs, gold; GyrA-NTDs, grey; GyrA-CTDs, pink. DNA is in a coral 
ribbon representation. Abbreviations: CTD, C-terminal domain; NTD, N-terminal domain. Figure 
edited from (Nagaraja et al., 2017). 
 
As the enzyme is relatively mobile in the absence of DNA, as demonstrated by the CryoEM 
structure where the CTDs were not visible in the absence of DNA, it was decided to introduce 
DNA fragments into the crystallisation conditions starting with two published 20 bp fragments 
that had been previously optimised to determine the structure of the S. aureus DNA gyrase 
core-fusion (GyrB CTD – GyrA NTD). However, when introducing the annealed 20-12-p-8 
or 20-447T published DNA fragments (Srikannathasan et al., 2015) in the presence of 
moxifloxacin with or without magnesium and manganese ions, no crystals were obtained. 
There was however, one confirmed salt crystal – well A5 of the Morpheus® screen in the 
presence of both ions, DNA and moxifloxacin. This is somewhat unsurprising as around 70 
bp are required to wrap each of CTD’s, requiring approximately 128 bp to wrap both CTD in 
the absence of a nucleotide and likely increases to around 142 bp on binding of ADPNP 
(Orphanides and Maxwell, 1994). 
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To additionally try to stabilise the enzyme further we looked to use a nucleotide as there is 
considerable evidence that the GyrB ATPase containing NTDs dimerise in the presence of a 
nucleotide (Ali et al., 1993) increasing the stability of the complex. Therefore, we attempted 
crystallisation in the presence of both hydrolysable (ADP) and non-hydrolysable nucleotides 
(AMPPNP) to determine the optimal crystallisation conditions. However, at 7.5 mg/ml with 
or without a C-terminal His-tag there was no evidence of protein crystallisation in the JCSG-
plusTM, Structure screen 1+2 or KISS screens in the presence of 1 mM ADP-Li salt and 5 mM 
magnesium chloride. Equally, after dialysing an untagged protein into the supercoiling assay 
buffer composition in the presence or absence of AMP-PNP (non-hydrolysable ATP) no 
crystals were obtained. Overall, sixteen 96 well screens of the full length fusion M. 
tuberculosis DNA gyrase construct were set up with only salt crystals being obtained. 
 
5.2 Crystallisation of the M. tuberculosis ATPase domain 
From the biochemistry presented in Chapter 4 it was determined that the TriBE compounds 
Redx03863 and Redx04739 bound to the N-terminal of GyrB as competitive inhibitors of the 
ATPase reaction. To locate the binding site of Redx03863 and Redx04739 within this domain 
and enhance our knowledge of the Mtb ATPase domain it was attempted to co-crystallise the 
full ATPase domain in the presence of both compounds. Previously, the ATPase domain of 
M. tuberculosis had been crystallised (Roue et al., 2013), resulting in the crystal structures 
3ZKB, 3ZKD and 3ZM7 (Agrawal et al., 2013). The construct of this domain was a kind gift 
of Drs C. Mayer and S. Petrella (Institut Pasteur, Paris) and purification and crystallisation 
were performed as before (Agrawal et al., 2013). The protein was crystallised at 10.6 mg/ml 
with 5.2 mM magnesium chloride and 5.2 mM AMP-PCP, in a hanging drop arrangement 
with 1 µl drops with 1 µl of well solution (15-30% (w/v) PEG1500, 0.8-1.3% (v/v) 
myoinositol, 100 mM MES pH 6.5, and 5 mM magnesium chloride, total well volume 400 
µl). Under these conditions the protein formed multiple thin plate-like crystals often clumped 
together. The protein did not crystallise in the absence of the AMP-PCP, and only produced 
small crystals in the presence of either Redx03863 or Redx04739 when crystallised with 
AMP-PCP. 
 
With some minor optimisations it was found that we were able to get some crystals suitable 
for X-ray diffraction, however the crystals obtained did not diffract beyond 3.3 Å. It was not 
possible to resolve the structure of either of the data sets collected in the predicted space group 
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of C2221, or the lower symmetry space groups of C2, P2, or P1. As this construct did not 
crystallise in the absence of AMP-PCP the decision was made not to continue with this 
structure as it is believed that the binding sites of AMP-PCP and the two Redx compounds 
should overlap (Tari et al., 2013a), and hence efforts of co-crystallography with both AMP-
PCP and either Redx03863 or Redx04739 would not be sucessful. Instead the decision was 
made to move to the GyrB24 ATPase sub-domain construct which in other species has been 
crystallised in the absence of an ATP analogue. 
 
5.3 Crystallisation trials of M. tuberculosis GyrB24 ATPase subdomain 
To overcome the problems with crystallisation that were faced with the full-length ATPase 
domain, it was decided to try and crystallise the smaller ATPase sub-domain containing the 
ATP and novobiocin binding sites. Furthermore, SPR experimentation in Chapter 4 gave a 
strong indication that Redx03863 and Redx04739 both bound with high affinity to this 
domain. Overall this suggested that the GyrB24 ATPase subdomain was a good target for 
crystallisation. 
 
The ATPase subdomain was initially cloned without the last β-strand of the domain (see 
sections 2.2.3, 2.8.1). This was purified, and no crystals were obtained with this construct 
when bound to either Redx03863 or Redx04739 overnight at low protein concentration (<1 
mg/ml) and subsequently concentrated to around 4 mg/ml for use in the JCSG-plusTM screen. 
After realising that the final β-sheet in the construct was missing the construct was not trialled 
further. 
 
Subsequently, the construct was remade to include the correct C-terminus, however from five 
96-well screens with both compounds only one crystal hit was obtained although, this was not 
followed up due to a lack of UV-fluorescence in the crystal. Following, this lack of success, 
it was decided to remove a pair of potentially long flexible loops which are not visible in the 
crystal structure of the full-length ATPase domain, to form two constructs from here on known 
as B24 SLD (single loop deletion) and B24 DLD (double loop deletion) (Figure 5.3.1).  
 
The two loop deletion constructs were successfully expressed in Rosetta2TM pLysS cells, 
grown in LB media with induction with 0.4 mM IPTG at OD600 1.0, 37°C for 4.5 hours. The 
constructs were lysed using a homogeniser at 40,000 psi then the soluble cell lysate was 
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subsequently purified using a three-column strategy (5 ml HisTrap FF, MonoQ 10/10, S75 
10/300) yielding 2.6 mg of pure B24 SLD protein. The DLD construct was easier to work with 
and purified to give approximately 26 mg of pure protein, at a concentration of 17.3 mg/ml. 
 
 
Figure 5.3.1: Sequence alignment of the sub-ATPase domain constructs with and without the two long 
loops, created based on the published M. smegmatis structures. The second loop is replaced by the two 
amino acids found in the E. coli GyrB subunit (DG) in the absence of the flexible loop. 
 
Due to the low aqueous solubility of Redx03863 and Redx04739, 19.2 µg of each compound 
was bound to 210 µl of B24 SLD at 5.4 mg/ml with 0.7% (v/v) DMSO for 1 hour, before 
concentrating up to ca. 10 mg/ml. Three sparse matrix screens were trialled (JCSG-plusTM, 
PEG suite, AmSO4 suite screens). No crystal hits were obtained. The remaining protein was 
used in the Structure screen 1+2 at 7.9 mg/ml co-crystallised with 0.7 mM novobiocin. One 
potential hit was obtained with well conditions 2 M sodium chloride, 10% (w/v) PEG6000 
(Figure 5.3.2). As no more protein of this batch was available, and because no UV 
fluorescence was observed it was chosen not to follow this lead at this time.  
 
Due to the lack of successful crystallisation the His-tag was removed from the B24 DLD 
protein which was purified and concentrated to 26 mg/ml. Three sparse matrix screens (KISS, 
Morpheus®, and JCSG-plusTM) were all set up for crystallisation trials under apo conditions. 
In addition, the His-tagged B24 DLD protein was concentrated to 38 mg/ml and the PEG and 
JCSG-plusTM screens were trialled both in the presence and absence of 1.6 mM novobiocin. 
Regardless of all these efforts no further crystal hits were obtained for optimisation or 
harvesting. 
173 
 
 
 
Figure 5.3.2: Visible light (A) and UV (B) image of the single crystal hit obtained when screening the 
Mtb GyrB24 SLD construct. Crystals obtained in the presence of 0.7 mM novobiocin at 7.9 mg/ml in 
2 M sodium chloride and 10% (w/v) PEG6000. Image taken at 9 days. 
 
Multiple screens were set up with the B24 DLD protein at 17.3 mg/ml in an apo form, or in 
the presence of 0.7 mM novobiocin, 0.25 mM Redx03863 or 0.25 mM Redx04739. Only two 
conditions were identified to optimise. The first of these conditions was that of the apo protein 
in 200 mM magnesium chloride, 100 mM Bis-Tris-HCl pH 5.5, 25% (w/v) PEG3350, with 
the second being novobiocin-bound protein in 100 mM Bis-Tris-HCl pH 6.5, 25% (w/v) 
PEG3350. However, after 2 rounds of optimisations no further hits were obtained, and the 
conditions were dropped as they were not reproducible and presumed to be salt. 
 
Due to the lack of crystals being obtained from extensive screening it was decided to perform 
some basic bioinformatics on the constructs, hence, all the current constructs were put through 
the XtalPred-RF database to determine their likelihood of crystallising (Slabinski et al., 2007). 
The results are summarised in (Table 5.3.1) indicating that the constructs being worked with 
were sub-optimal in terms of the Expert-Pool classification of 2, which only suggests them to 
have approximately a 50% chance of crystallisation. Furthermore, the results of the Random 
Forest classifier were in a wider range of classifications, indicating the best construct to be 
attempting crystallisation on was the one missing the last beta-strand, and that the HisGyrB24, 
GyrB24SLD and HisGyrB24DLD constructs were the next best alternatives (Jahandideh et 
al., 2014). 
174 
 
 
Table 5.3.1 
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5.4 Crystallisation trials of M. smegmatis B24 ATPase subdomain 
As the 4 progressive iterations of the Mtb GyrB24 constructs did not yield protein crystals 
after screening 4896 conditions it was decided to move towards the use of a homologue. In 
the past, two structures of M. smegmatis GyrB24 have been published (Shirude et al., 2013, 
Hameed et al., 2014) in the absence of an Mtb structure. Both structures had at least one loop 
deleted, as per the loop deletion constructs designed for the Mtb protein. Based on the 
crystallisation conditions of these constructs and considering the solubility of the Redx 
compounds, it was decided to only clone the double-loop deletion construct, which was 
published to crystallise at a lower pH. The Msm GyrB24 gene was synthesised and codon-
optimised by Invitrogen GeneArt (ThermoFisher Scientific) and subsequently the synthesised 
gene was sub-cloned into the pET28-MHL vector at the BseRI sites. The protein was 
successfully expressed in the transformed E. coli BL21 cell line in 6 L LB induced with 0.4 
mM IPTG at 30°C for 4.5 hours. The protein was purified following the previously published 
procedure (Shirude et al., 2013) to yield more than 160 mg of pure protein at a concentration 
of 17 mg/ml. 
 
Crystallisation screening was carried out at 17 mg/ml in the presence or absence of 1 mM 
novobiocin, Redx03863 or Redx04739. Initially screening was carried out at a range of 
conditions around the published crystallisation conditions (0-30% (w/v) PEG8000, 100 mM 
sodium acetate pH 5.6, 200 mM calcium acetate). Initial crystal hits were obtained within 2 
days in the presence of novobiocin. Crystals grown in 9% (w/v) PEG8000 were harvested in 
50 µl mother liquor and crushed by vortexing for 4 min with 3 mm glass beads to form a seed 
stock. Crystals of Msm GyrB24 supplemented with 1 mM novobiocin were grown in 15% 
(w/v) PEG8000, 100 mM sodium acetate pH 5.6, 200 mM calcium acetate and were harvested 
after 5 days in a cryoprotectant of the mother liquor supplemented with 25% (v/v) ethylene 
glycol, 1 mM novobiocin by Dr Clare Stevenson (Figure 5.4.1). 
 
Extensive co-crystallisation with Redx03863 and Redx04739 was carried out, including using 
the reconcentration method where the compound was added to the protein at a low protein 
concentration and subsequently reconcentrated, no co-crystals were obtained with or without 
the seed stock and subsequent dilutions as described above (Hameed et al., 2014). 
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Figure 5.4.1: Image of crystals of Msm GyrB24 DLD before harvesting from the well for X-ray 
diffraction (left), and in the loop for data collection at the Diamond synchrotron beamline i04 (right). 
Crystals grown in 15% PEG (w/v) PEG8000, 100 mM sodium acetate pH 5.6, 200 mM calcium acetate 
at protein concentration 17 mg/ml supplemented with 1 mM novobiocin. No UV absorbance was 
observed from the crystals. 
 
To try to obtain a crystal structure of the compound-bound structure in the absence of co-
crystallised proteins the decision was made to trial crystal soaks with the compounds. 
However, as the crystals only grew in the presence and not the absence of novobiocin, soaking 
was carried out on novobiocin-bound crystals. Soaking was trialled over time periods greater 
than 6 hours at low compound concentration in DMSO concentrations less than 2% (v/v). 
However, it was found not to be successful as either the crystals dissolved, or the compounds 
did not out soak the novobiocin in the crystals leaving only novobiocin density visible in the 
structure when viewed with DIMPLE (automated refinement and ligand screening software) 
(Figure 5.4.2). 
 
Figure 5.4.2: Example output from DIMPLE autoprocessing showing unmodelled positive density in 
the structure solution. Map shown at an RMSD value of 1.5 (0.4595 electron/Å3). The model used to 
solve the protein backbone was the refined Msm GyrB24 structure with novobiocin but with the ligand 
removed. This indicated that crystals grown in novobiocin and soaked with Redx04739 still contained 
novobiocin. 
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5.5 X-ray diffraction and structure solution of M. smegmatis B24 ATPase 
subdomain 
Data from the novobiocin-containing crystals was collected on the i04 beamline at the 
Diamond light source. From this data the structure of the Msm B24 sub-ATPase domain was 
solved by molecular replacement using the published structure of the Msm B24 sub-ATPase 
domain (PDB entry 4B6C) as the model for phasing. To remove gaps in the mainchain 
BUCCANEER was utilised. This was followed by iterative rounds of automated and manual 
refinement in REFMAC and COOT respectively until the structure gave optimal density fit 
and conformation (Table 5.5.1). 
 
Overall the crystal structure presented here is highly similar to the published 4B6C structure 
of the same construct bound to a different compound in the A crystallographic copy. However, 
there are some clear differences observable of which the first is the presence of a different unit 
cell where this new structure crystallised in the C2 space group compared to C2221 space 
group in the published structure. Both structures contain two crystallographic copies in the 
asymmetric unit cell, however the interfaces between the two structures are distinct (Figure 
5.5.1). 
 
The 4B6C structure was solved to a lower resolution and there are less visible amino acids at 
the N-termini with 18 extra amino acids being visible at the N-terminus of the A-copy, and 17 
in the B-copy in the new structure presented here. Hence, we propose that this new crystal 
structure is an improvement over the previously published structure. As the crystallisation 
conditions were analogous it is not surprising that there are several similar features in both 
structures, one in particular is the presence of sodium ions within the structure. This is most 
noticeable as there is what appears to be a common sodium ion site which is present in both 
of the crystallographic copies where T167, G81 and D80 appear to coordinate to this sodium 
ion alongside one or two water molecules (Figure 5.5.2). This sodium ion site is similar to the 
one presented in the 4B6C structure (Shirude et al., 2013), and was confirmed by the 
CheckMyMetal server (Zheng et al., 2014, Zheng et al., 2017). 
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Table 5.5.1: Data collection and refinement statistics of the Msm B24 sub-ATPase domain structure. 
 Novobiocin 
Data collection  
Space group C2 
Cell Dimensions  
a, b, c (Å) 157.08, 56.12, 50.71 
α, β, γ (°) 90.00, 90.63, 90.00 
Resolution (Å) a 24.55-1.60 (1.63-1.60) 
Number of Observations a 391119 (19736) 
Unique Observations a 58313 (2855) 
Multiplicity a 6.7 (6.9) 
Rmerge (%) a 0.108 (2.075) 
I/σ (I) a 10.4 (0.9) 
CC(1/2) a 0.999 (0.529) 
Completeness (%) a 99.9 (100) 
Refinement  
Limiting Resolution (Å) 1.60 
No. of reflections 58312 
Rwork/Rfree (%) 13.8, 20.1 
Mean B-values (Å2)  
Protein 27.06 
Ligands 30.47 
Ions 33.72 
Waters 39.35 
R. m. s. deviations  
Bond length (Å) 0.0121 
Bond angles (°) 1.655 
Ramachandran Plot (%)   
Favoured region 97.5 
Allowed region 2.5 
Outlier region 0 
Novobiocin occupancy (chain A/chain B)  
Occupancy 0.96/1.00 
RSCC 0.93/0.93 
a Values in parentheses refer to the outer shell 
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Figure 5.5.1: Comparison of the crystallographic subunit interfaces of the published 4B6C structure 
(gold) and the new structure of the Msm GyrB24 ATP sub-domain double loop deletion construct 
(blue). These structures have a high-degree of structural homology, including a shared sodium ion site. 
 
 
Figure 5.5.2: Visualisation of the differences in the sodium ion sites of the A and B chains within the 
Msm GyrB24 ATPase sub-domain structure. Interactions shown are of 2-3 Å. A) shows the interactions 
in the A chain that only involves the mainchain of T167, G81, D80 and the side chain of T167 and a 
single water molecule, in a square planar geometry. Whereas B) shows the interactions to the B chain 
that also a second water molecule, changing the geometry of this binding site to octahedral. 
180 
 
 
The overall protein backbone is in general agreement between the published 4B6C structure 
and the new structure presented here. There are several amino acids that appear to fall in 
alternative conformations throughout the protein, including one surrounding the ligand 
binding site E48, suggesting the orientation of this residue may be based on the ligand bound. 
The only major significant difference in the protein backbone is the modelling of a section of 
an alternative conformation between residues 97-127 which is around one of the loop deletions 
(103-122) suggesting some flexibility in this area.  
 
In addition to the common sodium ion found in the 4B6C structure, there are two additional 
possible sodium ions found within the B-chain but not within the A-chain. These appear to 
coordinate to 5 and 6 atoms respectively at distances between 2-3 Å, with a high degree of 
hydrogen bonding to water molecules, involving just one amino acid each (Figure 5.5.3). The 
interactions are with the carboxylic acid functional group of glutamic acid 46 and the 
mainchain of threonine 33 respectively. Although, it has not been assigned as such, due to the 
proximity of these binding sites, it is possible that this was a single dual conformation sodium 
ion. It is important to note that there is no visible density for either of these sites on the A 
chain and hence this is likely to be an artefact of crystallisation. 
 
 
Figure 5.5.3: Visualisation of the third and fourth possible sodium ion sites on the B chain. All 
interactions shown here are between 2-3 Å in distance. The first of these appears to hydrogen bond to 
the carboxylic acid group of E48 and three water molecules including one of half occupancy, in an 
octahedral coordination. The second sodium forms a hydrogen to the mainchain oxygen of T33 and 
four water molecules, as well as an ethylene glycol in the crystal. The binding geometry is octahedral. 
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As novobiocin was required for crystallisation of the Msm GyrB24 sub-ATPase domain we 
were able to locate significant density to fit most of novobiocin into. This density was 
confirmed by generating an omit map through the use of simulated annealing (Cartesian) in 
the absence of novobiocin on the final refined structure. The omit map clearly demonstrated 
positive electron density in the region of the ligand which novobiocin could clearly be 
modelled into (Figure 5.5.4). Considering the density fit, in the structure presented here we 
observe novobiocin bound in the same binding site as previously observed in previous work 
(Lewis et al., 1996, Holdgate et al., 1997, Tsai et al., 1997). This binding site involves several 
interactions including the key resistance arginine at position 141 (Figure 5.5.5), with a binding 
distance of 2.99 Å. The R141 residue also forms a hydrogen bond of around 2.8 Å to G83 
which has also been implicated in the resistance mechanism of novobiocin through mutation 
to a serine. From examining the structure, the serine side chain substitution at position 83 is 
most likely to be pointing away from the novobiocin ring. Therefore, it is difficult to see why 
this is likely to occur, although it is theorised here that it causes a change in the conformation 
of R141 due to hydrogen bond interactions to the serine destabilising the interaction that R141 
has with novobiocin. 
 
 
Figure 5.5.4: An omit map of the novobiocin within the structure of Msm GyrB24 crystallised in the 
presence of novobiocin. The omit map was made by simulated annealing (Cartesian) of the final refined 
structure with novobiocin removed (phenix) (Adams et al., 2010). The omit map (blue chicken wire) 
was clipped to 5 Å around the novobiocin in the A chain, at a sigma value of 3. The figure was created 
within CCP4MG. 
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Figure 5.5.5: Bonding interactions involved in the interaction of novobiocin with Msm GyrB. Hydrogen 
bonding interactions are represented as dashed lines. The density around novobiocin (grey chicken 
wire) is shown to 1.5 σ on the 2FcFo map. D79, E87 and R141 form direct interactions with novobiocin, 
meanwhile the sat bridge between E56 and R82 is also depicted. 
 
The Aspartate at residue 79 also forms a hydrogen bonding interaction to novobiocin of 2.8 
Å, as does E87 with a distance of 2.45 Å (Figure 5.5.5). Previously N52 has been attributed 
to being involved in the mechanism of binding by novobiocin (Kampranis et al., 1999b). In 
the model shown here we can attribute this through a water bonding network also involving 
D79. Other residues including T169 and T95 also interact with novobiocin through means of 
a hydrogen-bonding network. It should be noted that in the tuberculosis GyrB protein E87 is 
an alanine and hence is unlikely to form a binding interaction to novobiocin, meanwhile the 
threonine at position 169 is actually a serine. 
 
A salt bridge is observed between residues of the E56 and R82 (Figure 5.5.5). This has also 
been previously described to be an essential interaction in the binding of ATP in E. coli, with 
mutants at these locations losing the ability to supercoil DNA, and presenting with very low 
ATPase activity (Gross et al., 2003). Although neither of these molecules appears to form 
direct interactions with the novobiocin, it is very plausible that this interaction stabilised the 
tertiary structure of the protein and disruption of the salt bridge would disrupt the folding of 
the protein. Although, we are not interested in finding further resistance mutations in the scope 
of this work, it would be interesting to see if the ATPase activity, supercoiling activity and 
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subsequently the novobiocin binding were maintained if the amino acids and hence the charges 
were reversed. 
 
Analysing the positions of the bacterial mutants isolated in E. coli, S. aureus, S. pneumoniae, 
and Halophilic archaebacterium against novobiocin (Table 1.8.1) only the interactions of 
R141 and E87 can explain the resistance phenotype of their corresponding mutations observed 
in whole cells (Figure 5.5.6). Additionally, the S128L S. aureus and S. pneumoniae mutations 
(Munoz et al., 1995, Stieger et al., 1996) can likely be explained through unfavourable steric 
interactions preventing the favourability of the binding of novobiocin when replacing the 
corresponding V125 residue with the larger leucine (Figure 5.5.6). 
 
 
Figure 5.5.6: Visualisation of all the novobiocin mutants isolated from bacterial strains including 
potential hydrogen bonds. Many of the single point mutations do not appear to directly interact with 
novobiocin. 
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Many of the other mutations that have been observed in bacteria do not give obvious direct 
interactions with novobiocin (Figure 5.5.6). These interactions are most likely explained 
through hydrogen bonding networks formed from the presence of ordered water molecules, 
and more long-range conformational changes that prevent novobiocin binding that do not 
influence the binding of ATP. 
 
5.6 Crystallisation trials of M. thermoresistibile B24 ATPase subdomain 
Due to the difficulties with crystallising the Mtb GyrB24 sub-ATPase domain with either of 
the two Redx compounds or novobiocin and due to the additional characterisation work that 
we have carried out on M. thermoresistibile in previous chapters, it was decided to design a 
Mth construct of the sub-ATPase domain. This novel construct of the Mth homologue was 
designed to be comparable to the Msm construct and therefore this construct also had the two 
flexible loops deleted. Furthermore, as mycobacteria have high GC content in their genomes 
(Wayne and Gross, 1968), it was decided to use a codon-optimised construct which was 
synthesised by Invitrogen GeneArt (ThermoFisher Scientific). The coding sequencing was 
subsequently sub-cloned into the pET28-MHL vector at the BseRI sites. The protein was 
successfully expressed in the transformed E. coli BL21 cell line in 6 L LB induced with 0.4 
mM IPTG at 30°C for 4.5 hours. The protein was purified to the same method as the Msm 
protein yielding 250 mg purified protein. 
 
Initially, the protein was screened against the JCSG-plusTM, KISS and SG1TM HT-96 screens 
in the presence and absence of 1 mM novobiocin. Three initial conditions were obtained 
yielding crystals which were further optimised, two of which were subsequently determined 
to be salt by X-ray diffraction. Meanwhile as the third could not be reproduced it was decided 
to rescreen against the Morpheus®, the BCS screen and the PGA screenTM 96-well sparse 
matrix screens. Three further hits were obtained (Table 5.6.1), two of which were optimised 
and found to produce crystals within 12 hours. These crystals were found to be highly 
reproducible but not UV fluorescent although they were confirmed to contain protein by 
harvesting and washing crystals before performing SDS-PAGE (Figure 5.6.1).  
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Table 5.6.1: Crystal screening conditions yielding suspected protein crystals from the second iterative 
round of screening of the Mth GyrB24 DLD construct at 22 mg/ml. 
Screen Sub-well Well conditions 
The BCS screen 1 mM novobiocin 100 mM zinc acetate 
100 mM zinc chloride 
100 mM Bis-Tris pH 7.5 
20% (w/v) PEG smear 
medium* 
The BCS screen 1 mM novobiocin 100 mM ammonium acetate 
100 mM zinc chloride 
100 mM Bis-Tris pH 7.2 
15% (w/v) PEG smear high^ 
The PGA screenTM 1 mM novobiocin 100 mM sodium acetate 
5% (w/v) ɣ-PGA (Na+ form) 
8% (W/V) PEG20000 
*PEG Smear medium refers to a combination of 1:1:1:1 mix of PEG2000: PEG3350: PEG4000: 
PEG5000MME 
^PEG Smear high refers to a combination of a 1:1:1 mix of PEG6000: PEG8000: PEG10000 
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Figure 5.6.1: SDS-PAGE gel run with pure Mth GyrB24 DLD protein and crystals washed four times 
with well solution before adding loading dye, boiling solutions and loading onto 12% Bis-Tris SDS-
PAGE. +ve refers to a pure protein sample of 20.8 kDa. Single zinc refers to crystals grown in 
conditions optimised from the BCS screen condition 100 mM ammonium acetate, 100 mM zinc 
chloride, 100 mM Bis-Tris pH 7.2, 15% (w/v) PEG smear high. Double zinc refers to crystals grown in 
conditions optimised from the BCS screen condition 100 mM zinc acetate 199 mM zinc chloride 199 
mM Bis-Tris pH 7.5, 20% (w/v) PEG smear medium. Unambiguous evidence is observed for the 
crystals to contain protein. 
 
Optimised crystals grown in 100 mM zinc chloride, 100 mM ammonium acetate, 14% (w/v) 
PEG smear high (1:1:1 mix of PEG6000:PEG8000:PEG10000) and 100 mM Bis-Tris pH 7.0 
were harvested and flash frozen with the assistance of CS in the crystallisation solution 
supplemented with 25% (v/v) ethylene glycol and 1 mM novobiocin (Figure 5.6.2). 
 
To obtain the crystal structure bound to Redx03863 further novobiocin crystals grown in 100 
mM zinc chloride, 100 mM ammonium acetate, 15% (w/v) PEG smear high, 100 mM Bis-
Tris pH 7.5 were harvested in 50 µl of well solution and vortexed at maximum power with 
one to three 1 mm glass beads (Sigma-Aldrich) for 4 min to crush the crystals. Redx03863 
was added to the seeding stock to a final concentration of 0.24 mM. Screening was repeated 
over the pH range 7-7.5 and 10-20% (w/v) PEG smear high, with drops containing 300 nl of 
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22 mg/ml Mth GyrB24 DLD supplemented with 0.24 mM Redx03863, 200 nl well solution 
and 100 nl seed stock supplemented with 0.24 mM Redx03863.  Crystals grew optimally in 
11% (w/v) PEG smear high and Bis-Tris pH 7.3 were harvested and flash frozen in mother 
liquor supplemented with 25% ethylene glycol and 0.24 mM Redx03863 with the assistance 
of CS (Figure 5.6.3). 
 
 
Figure 5.6.2: Image of crystals of Mth GyrB24 DLD co-crystallised with novobiocin before harvesting 
from the well for X-ray diffraction (left), and in the loop for crystal screening at the Diamond 
synchrotron beamline i03 (right). Crystals grown in 100 mM zinc chloride, 100 mM ammonium acetate, 
14% (w/v) PEG smear high, 100 mM Bis-Tris pH 7.0 at protein concentration 22 mg/ml supplemented 
with 1 mM novobiocin. No UV absorbance was observed from the crystals. 
 
 
Figure 5.6.3: Image of crystals of Mth GyrB24 DLD co-crystallised with Redx03863 before harvesting 
from the well for X-ray diffraction. Crystals grown in 100 mM zinc chloride, 100 mM ammonium 
acetate, 11% (w/v) PEG smear high, 100 mM Bis-Tris pH 7.3 at protein concentration 22 mg/ml 
supplemented with 0.24 mM Redx03863. No UV absorbance was observed from the crystals. 
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Equivalent screening was performed with Redx04739 to attempt to obtain the crystal structure 
bound to Redx04739, however, no crystals were obtained when Redx04739 was supplemented 
at 0.29 mM to the protein solution and seeding solution. When an apo protein solution was 
crystallised with a seeding supplemented with 0.29 mM Redx04739 small crystals were 
obtained, but when the diffraction data was analysed they were found to only contain 
novobiocin and not Redx04739. Further optimisations were attempted using a seed stock that 
was washed prior to crushing the crystals but no crystals were obtained using this method. 
Overall, unfortunately it was determined that the solubility of this compound was too low at 
the crystallisation conditions to obtain crystals with Redx04739. 
 
5.7 X-ray diffraction and structure resolution of M. thermoresistibile B24 
ATPase subdomain 
Data from the Mth GyrB24 ATPase domain crystals were collected on the i03 beamline at the 
Diamond light source. From the collected data the structures of Mth B24 sub-ATPase domain 
were solved using a preliminary Msm B24 sub-ATPase domain as the model for molecular 
replacement. Subsequent rounds of manual and automated refinement using COOT and 
REFMAC were completed until the structures gave optimal density fit and conformation 
(Table 5.7.1). Both structures were found to contain unit cells of similar parameters and were 
assigned to the same space group P1211. 
 
The overall structure of the Mth domain presented as two copies of the protein present within 
the unit cell forming a non-biological dimer connected by two zinc binding sites (D51, D55 
from one chain and H44 from the other) (Figure 5.7.1). Two further zinc-binding sites were 
observed in the structure bound to novobiocin, each of which appeared to be of split 
conformation likely depending on the conformation of a single histidine residue (61) (Figure 
5.7.2). In the structure containing Redx03863 an additional zinc binding site was observed 
binding to H257 (Chain B). The zinc sites were confirmed by collecting data at the zinc edge 
wavelength 1.2782 Å. None of the zinc-binding sites found here contain a sodium ion in the 
Msm previously presented in this chapter. 
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Table 5.7.1: Table of crystallographic statistics for the structures of Mth GyrB24 sub-ATPase domain 
bound to novobiocin and Redx03863. 
 Novobiocin Redx03863 
Data collection   
Space group P 1 21 1 P 1 21 1 
Cell Dimension   
a, b, c (Å) 43.99, 51.12, 83.22 43.77, 51.67, 82.91 
α, β, γ (°) 90.00, 100.32, 90.00 90.00, 100.25, 90.00 
Resolution (Å) a 51.12-1.4 (1.42-1.4) 51.67-1.50 (1.53-1.50) 
Number of Observations a 472775 (22964) 374605 (18170) 
Unique Observations a 71674 (3549) 58503 (2863) 
Multiplicity a 6.6 (6.5) 6.4 (6.3) 
Rmerge (%) a 0.048 (1.405) 0.060 (1.455) 
I/σ (I) a 16.6 (1.3) 12.6 (1.2) 
CC(1/2) a 0.999 (0.665) 0.999 (0.675) 
Completeness (%) a 99.9 (100) 100 (99.9) 
Refinement   
Limiting Resolution (Å) 1.4 1.5 
No. of reflections 64550 58485 
Rwork/Rfree (%) 14.0, 19.0 14.5, 20.2 
Mean B-values (Å2)   
Protein 30.5 26.5 
Ligands 32.3 26.5 
Ions 29.8 35.3 
Waters 41.6 39.1 
R. m. s. deviations   
Bond length (Å)  0.011 0.010 
Bond angles (°) 1.56 1.54 
Ramachandran Plot (%)    
Favoured region 97.7 96.5 
Allowed region 2.3 3.5 
Outlier region 0 0 
Ligand Occupancy (chain A/chain B)  
Occupancy 1.00/0.94 0.99/0.92 
RSCC 0.96/0.95 0.91/0.94 
a Values in parentheses refer to the outer shell 
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Figure 5.7.1: Overview of the Mth GyrB24 sub-ATPase domain structure bound in the crystallographic 
dimer bound to 4 zinc ions including two bound between the non-biological dimer interface, and 
additionally two novobiocin molecules (one per chain of GyrB). 
 
 
Figure 5.7.2: The dual conformation zinc binding site at Histidine 61 in the A chain of the novobiocin-
bound Mth GyrB24 sub-ATPase domain structure. The histidine binds to half occupancy zinc ions in 
two different conformations. The binding sites in the B chain are also dual conformation although the 
histidine is in a single conformation. A similar arrangement is present in the Redx03863 bound 
structure. 
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The protein backbone of the two structures is in very strong agreement with only 3 amino acid 
sidechains being modelled in alternative conformations across the A chain, and 6 alternative 
conformations in the B chain. Interestingly, N52 was seen to be in a different confirmation in 
the two structures like the Msm structures, suggesting that the orientation of this ligand may 
be dependent on the ligand bound.  
 
As both crystal structures were crystallised in the presence of ligands we confirmed the 
presence of the ligands in their respective structures though the use of simulated annealing 
(Cartesian) on the final structure in the absence of the ligand. The resulting electron density 
map showed positive density in the region of the ligands matching novobiocin and Redx03863 
respectively (Figure 5.7.3). This suggested that our mapping of the ligands was correct. 
 
 
Figure 5.7.3: An omit map of the ligands within the structures of Mth GyrB24 crystallised in the 
presence of A) novobiocin and B) Redx03863. The omit maps were made by simulated annealing 
(Cartesian) of the final refined structure the respective ligand removed (phenix) (Adams et al., 2010). 
The omit maps (blue chicken wire) were clipped to 5 Å around the ligands on the A chain, at a sigma 
value of 3. The figure was created within CCP4MG. 
 
Analysing the novobiocin-binding structure, the key binding interaction of R141 that has been 
identified in many studies in many different species as giving resistance to novobiocin (del 
Castillo et al., 1991, Holmes and Dyallsmith, 1991, Contreras and Maxwell, 1992, Stieger et 
al., 1996, Kampranis et al., 1999b) is again clearly shown to be forming hydrogen bonding 
interactions with the novobiocin in this structure at a distance of 3.07 Å. Additionally D79 has 
also been identified to be involved in the binding interactions of novobiocin and again in this 
new structure there is evidence that a hydrogen bond exists (2.9 Å) between the carboxylic 
head group of the aspartic acid and the amide functional group on the novobiocin (Figure 
5.7.4). Other amino acids that give rise to resistance mutants (Table 1.8.1) are also shown in 
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Figure 5.7.4, although many of them do not appear to give direct binding interactions in the 
Mth structure including H89, V99, V125, and S126. There is no clear evidence as to how N52, 
G83, G168, and V171 influence the binding of novobiocin from this structure, however, they 
do appear to be in close proximity to the novobiocin binding site and inserting a bulky amino 
acid into many of these groups may cause a steric clash preventing novobiocin from binding 
especially in the case of both of the glycine residues. The biological mutant of G168 was found 
to be a valine (Contreras and Maxwell, 1992) meanwhile the G83S mutant was discovered in 
resistant S. aureus (Stieger et al., 1996). Likewise, the V171 mutant was also raised against S. 
aureus where the biological mutant was I175T which could easily cause electrostatic repulsion 
to novobiocin in its current conformation. Finally N52 was a mutant that was examined in 
binding studies by SPR and there are suggestions that altering the charge state at this amino 
acid could alter binding interactions and the tertiary structure preventing binding, although it 
is important to consider that in E. coli this mutant was not found to be biologically relevant as 
mutations resulted in an enzyme that was unable to supercoil DNA (Kampranis et al., 1999b). 
 
 
Figure 5.7.4: Visualisation of the novobiocin-binding site in the Mth GyrB24 sub-ATPase domain 
structure. Electron density is shown for the 2FcFo map at 1.5 σ (grey chicken wire). Hydrogen bonds 
are displayed as dashed lines, including hydrogen bonds between D79, T95 and R141 with novobiocin. 
The salt bridge between E56 and R82 is also shown. 
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Overall the structure of the Mth GyrB24 sub-ATPase domain is similar to the others already 
published within the PDB. Additionally, the binding site presented here is in reasonable 
agreement with previously published binding sites of novobiocin in both the E. coli and S. 
aureus crystal structures implying the correct site has been previously identified (Lewis et al., 
1996, Holdgate et al., 1997, Tsai et al., 1997) and that this structure was an appropriate 
structure to utilise for identification of the binding sites of the two Redx compounds.  
 
Analysis of the structure containing Redx03863 indicated that there were significantly 
different binding interactions between novobiocin and Redx03863, with G83 and N52 forming 
closer binding interactions with Redx03863 of around 4 Å (Figure 5.7.5). Like novobiocin 
D79 appears to form a binding interaction of around 2.8 Å to Redx03863 but in contrast the 
key R141 amino acid does not appear to play a significant role in the binding of Redx03863 
(Figure 5.7.5). Other possible interactions include those of E56, and T169 like within the 
published structure of another TriBE compound in E. faecalis GyrB with hydrogen bond 
distances of around 3.3-3.8 Å (Figure 5.7.5) (Tari et al., 2013a). However, T169 is a serine 
within the tuberculosis protein. Additionally, R82 is likely to coordinate through salt bridge 
that is observed with E56 to Redx03863 (Figure 5.7.5). 
 
One interesting interaction that has been observed within the crystal structure is that of the 
glycine at position 83. This residue has been previously observed to cause resistance to 
novobiocin when mutated to a serine (Stieger et al., 1996, Gross et al., 2003, Fujimoto-
Nakamura et al., 2005), and cross-resistance to novobiocin was obtained in a strain presenting 
with the G83S mutation (Chapter 4). Analysis of the structure presented here demonstrates a 
possibility that the mainchain amino group of this residue could interact with the ether group 
in Redx03863, meanwhile the carboxyl oxygen may interact with one of the nitrogen atoms 
on the terminal pyrimidine group (Figure 5.7.6). In addition, the alpha carbon is located 
between 4-5.5 Å away from several atoms within Redx03863 indicating that there is the 
potential for further interactions. Although, it is unclear what orientation the serine group 
would take in mutated versions of GyrB, there is good scope to alter several interactions 
directly or indirectly with Redx03863 by mutating the glycine to a serine. There are similar 
interactions in the 4KSG structure containing C4 from the original TriBE series by Trius 
Therapeutics (Figure 5.7.6b) (Tari et al., 2013a). Overall, there is considerable evidence from 
the crystallographic structures presented here that the G83 residue could be involved in the 
binding of Redx03863 and other compounds within the series including Redx04739. 
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Figure 5.7.5: Binding site of Redx03863 within the Mth structure. Electron density is shown for 
Redx03863 at a sigma level σ = 1.5 for the 2FcFo map. Hydrogen bonding interaction are indicated by 
dashed lines, as is the salt bridge between E56 and R82. Direct interactions are indicated for G31 and 
D79 but not R141. 
 
 
Figure 5.7.6: Detailed interactions of A) N52, D79 and G83 in Redx03863 bound structure of Mth GyrB 
(sub-ATPase domain) and B) N48, D75 and G79 in the C4 bound structure of E. faecalis GyrB24 
(4KSG). All amino acid residues are labelled to the native proteins. 
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5.8 Site-directed mutagenesis of Mtb DNA gyrase based on the structure 
of M. thermoresistibile B24 ATPase subdomain bound to Redx03863 
To confirm the binding pocket of Redx03863 and likely Redx04739 we sought to find a mutant 
that inhibited the action of the compounds. Based on the crystal structure of Mth GyrB24 DLD 
bound to Redx03863, and the published crystal structures of TriBE compounds co-crystallised 
with GyrB from E. faecalis, several residues were identified to test to confirm this binding 
pocket (Figure 5.7.5) (Tari et al., 2013a). As the G83S mutation had already been tested in the 
scope of the previous chapter and showed insufficient supercoiling activity, it was decided not 
to test this residue further. However, seven mutants were successfully made using SDM of the 
GyrB plasmid, all of which expressed and were purified via the protocol for GyrB. Five of 
these mutants were found to be inactive in the ATP-dependent supercoiling reaction (Figure 
5.8.1). This is understandable due to the proximity to the ATP binding pocket. The R141A 
and R141Q mutants were found to have limited activity which after optimisation was deemed 
suitable to test against the compounds (Figure 5.8.2). This residue has been previously 
demonstrated to be important in novobiocin binding and results in resistance to novobiocin 
(del Castillo et al., 1991, Contreras and Maxwell, 1992, Stieger et al., 1996) which was 
confirmed to be the case in Mtb (Figure 5.8.3). On the other hand, it was found that no 
resistance was obtained from the R141A/Q mutants when tested against either Redx03863 or 
Redx04739 (Figure 5.8.4); this was not an unexpected result as in the crystal structure this 
residue is around 4-5 Å away from Redx03863 (Figure 5.7.5). 
 
As the crystal structure of Redx03863 appeared to have many common interactions with those 
of novobiocin and because many of the mutants made were deficient in supercoiling (and 
hence ATPase activity) we directly compared the crystal structures of the two Mth structures 
presented here with the known Mtb crystal structure of 3ZKB containing the non-hydrolysable 
ATP analogue AMP-PNP. From comparing the inhibitor binding sites to that of ATP, there is 
a significant degree of overlap between the two inhibitor binding sites with that of ATP, 
although they all have distinct binding pockets (Figure 5.8.5). This clearly indicates that the 
planar structure of Redx03863 interacts differently with GyrB than either novobiocin or ATP. 
However, there is partial overlap with the ATP-binding pocket meaning that both ATP and 
Redx03863 cannot bind to DNA gyrase at the same time, and as Redx03863 binds with high 
affinity to GyrB it is likely to outcompete ATP within the cell. 
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Figure 5.8.1: Activity testing of five of the seven mutants made in the GyrB subunit of Mtb DNA gyrase 
suggested by X-ray crystallography to be the binding location of Redx03863. Activity tested with equal 
concentration of GyrA and GyrB mutants over 30 minutes at 37°C. A mutant was declared inactive if 
it displayed no ATP-dependent supercoiling activity at 200 nM concentration under these conditions. 
 
 
Figure 5.8.2: Time course of the activity of the Mtb GyrBWT, GyrBR141A and GyrBR141Q mutants assayed 
at 74 nM with equal amounts of Mtb GyrA to optimise the supercoiling activity for compound testing. 
Optimal supercoiling was observed at 30 minutes GyrBWT, 75 minutes GyrBR141A and 60 minutes for 
GyrBR141Q. 
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Figure 5.8.3: Inhibition of ATP-dependent supercoiling activity of 78 nM GyrBWT (30 min incubation), 
GyrBR141Q (60 min incubation), and GyrBR141A (75 min incubation) with 78 nM GyrA by novobiocin at 
a concentration range of 0.1-10 µM. 
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Figure 5.8.4: Inhibition of ATP-dependent supercoiling activity of 78 nM GyrBWT (30 minute 
incubation), GyrBR141Q (60 minute incubation), and GyrBR141A (75 minute incubation) with 78 nM GyrA 
by Redx03863 at a concentration range of 3-300 nM and Redx04739 at a concentration range of 10-
1000 nM. No resistance was observed in response to the R141A/Q mutations. 
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Figure 5.8.5: Structural alignment of the Mth structures containing novobiocin (gold) and Redx03863 
(blue) and the published 3ZKB crystal structure of the Mtb GyrB ATPase domain containing AMP-
PNP (grey). The overall structural alignments are in good agreement and indicate that there is partial 
overlap in the binding pockets of all three molecules. 
 
5.9 Structural comparison of M. thermoresistibile B24 ATPase 
subdomain bound to Redx03863 with the human topo IIα ATPase 
domain 
As all type IIA topoisomerases share a common mechanism of action and similar structural 
features (Berger et al., 1996, Roca et al., 1996) it was decided to perform structural 
comparisons of the binding site of Redx03863 to that of ATP in a eukaryotic topo II. For this 
purpose, we chose the re-refined structure of human DNA topo IIα containing ADP (4R1F) 
(Wei et al., 2005, Stanger et al., 2014). At present there is not a structure of the ATPase domain 
from the human topo IIβ orthologue preventing this analysis from occurring. 
 
In aligning the ATPase domains from Mth GyrB and human topo IIα it is evident that there is 
a high degree of similarity in these structures although there are some differences in some of 
the structural elements, such as the loop of the amino acids 36-39 in the Mth structure that 
forms a large anti-parallel beta sheet arrangement of residues 54-78 in the human structure. 
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Furthermore, a long flexible loop region is visible in the structure of human topo IIα (146-
166) where a similar flexible loop structure was deleted out of the Mth structure (103-125) 
which is not seen in many other bacterial DNA gyrases. Likewise, several of the secondary 
structure elements are in slightly different orientations, although this can likely be attributed 
to the binding of a nucleotide in the full-length ATPase domain as crystallised in the human 
structure resulting in slight conformational changes to the domain (Figure 5.9.1). 
 
Figure 5.9.1: Structural alignment of the Mth sub-ATPase domain bound to Redx03863 (blue) with the 
first 267 amino acids of Human topo IIα (4R1F) (gold). An enlargement of the ligand interactions is 
displayed indicating an overlap in the binding site of Redx03863 with the ATP-binding site of Human 
topo IIα and possible space for binding of Redx03863 in human topo IIα. 
 
More specifically in analysing the ATP-binding position as in the Mtb structure the location 
of the ATP-binding site overlaps with that of Redx03863 (Figure 5.9.1). This unfortunately 
suggests that there is space and hence a possibility for Redx03863 to inhibit human topo IIα 
although this was not analysed in the scope of this project. Several of the key binding 
interactions indicated previously are conserved within the human structure with amino acids 
in the key locations for binding, these include N52 where an asparagine is conserved in a 
similar structural location (N91); likewise, with the threonine at position 169 (T215) and the 
glycine at 83 (G124) (Figure 5.9.2). However, the key binding interaction of the aspartic acid 
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at position 79 is not conserved in the human structure with an asparagine (N120) being present 
at this location. This is unlikely to interact with Redx03863 directly and may be a significant 
enough interaction to provide resistance to human topo IIα although this needs to be further 
tested in the future (Figure 5.9.2).  
 
 
Figure 5.9.2: A structural comparison of the key binding interactions of Redx03863 in the Mth sub-
ATPase domain (blue)  aligned with the ATPase domain of Human topo IIα (4R1F) (Stanger et al., 
2014) (gold). There is conservation at three of the four binding interactions indicated here but crucially 
the key binding interaction of the aspartic acid D79 is not conserved with an asparagine (N120) being 
present at this position in Human topo IIα. 
 
5.10 Discussion 
5.10.1 Previously known structures 
Previously, the N-terminal domain of DNA gyrase has been solved in several iterations from 
several different species including the M. tuberculosis 43 kDa full ATPase domain in the 
presence of non-hydrolysable ATP analogues (Agrawal et al., 2013), but there is only one 
structure of this full domain within the PDB (1JIK) which was crystallised with novobiocin in 
the absence of an ATP analogue (T. thermophilus) (Lamour et al., 2002). On the other hand, 
there are many more structures available within the PDB of the GyrB24 fragment from a wider 
species range, but more critically contain a wide range of compounds bound including the 
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aminocoumarins and TriBE antibiotics. Here we report three new structures, two of these are 
bound to novobiocin of which there are two other GyrB24 structures in the PDB: 1AJ6 
(Holdgate et al., 1997) and 4URO (Lu et al., 2014) from E. coli (R136H mutant) and S. aureus 
respectively. The resolution of these two novobiocin-bound structures from M. smegmatis and 
M. thermoresistibile are a significant enhancement in resolution with the previous best 
resolution being 2.3 Å, with the new structures reported here being at better than 2 Å 
resolution. Likewise, the previous structure of the M. smegmatis GyrB ATPase subdomain 
was solved to 2.2 Å (Shirude et al., 2013), meaning that our new structure has been solved at 
superior resolution. On the other hand, the previous structures containing the TriBE antibiotics 
from Trius Therapeutics were solved in the E. faecalis GyrB24 construct and include the 
4KSG structure containing C4 with the highest similarity to Redx03863 which was solved to 
1.75 Å (Tari et al., 2013a). However, C1-4 from the compound series were solved at 
comparable resolutions in the same E. faecalis construct to our new Mth Redx03863-bound 
structure presented here. In addition, the structure of C3 from the Trius Therapeutics series 
has also been solved within E. coli GyrB and F. tularensis ParE subunits at good resolutions 
(Tari et al., 2013a). 
 
5.10.2 A future structure of Redx04739? 
During the experiments carried out within this project no crystals containing Redx04739 were 
successfully co-crystallised. Instead the crystals that formed in the presence of Redx04739 
were found to contain novobiocin from the seed stock made with novobiocin-containing 
crystals. Soaking experiments were also trialled, in these experiments it was chosen to use the 
crystals grown in the presence of novobiocin as from the experiments carried out in section 
5.4 it was determined that Redx03863 had a lower IC50 value and hence was likely to be a 
tighter binding inhibitor than Redx04739, whereas novobiocin had a more comparable IC50 
value to Redx04739. In these soaking experiments various time points were trialled between 
3 hours to 3 days, however, for the most part the crystals chosen were dissolved in the presence 
of the compound containing soaking solution and where the crystals remained it was found 
that only novobiocin was observed within these structures. 
 
It is suggested that one of the major factors affecting the lack of crystals that were obtained 
was down to the poor solubility of Redx04739 especially in neutral and basic solutions. It was 
therefore hoped that as the crystallisation conditions for the M. smegmatis were more acidic 
than those for the M. thermoresistibile fragment that the compound may co-crystallise under 
these conditions, however it was found that the compound would drop out of solution when 
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added to the protein solution. Adding the drug at lower protein concentrations and co-
concentration with the drug bound was also trialled in a similar method to that used by Hameed 
et al. (2014), however a significant amount of precipitation of the compounds was still 
observed regardless of the temperature and time incubation before concentration. Although 
the same issue was found with Redx03863 the solubility was greater so when the compound 
was added to the protein solution at 1% DMSO it was able to remain in solution and crystallise. 
We suggest that future crystallisation trials with Redx04739 should be carried out with 
increased concentrations of DMSO to increase its solubility. Additionally, it is suggested that 
use of a seed stock that has decreased concentrations of novobiocin (e.g. by washing the 
crystals) should be used to decrease the availability of novobiocin to decrease the chance of 
obtaining novobiocin containing crystals. 
 
5.10.3 Use of homologues and loop deletion constructs 
In the scope of this work it was not possible to crystallise the GyrB sub-ATPase domain from 
M. tuberculosis, although it is possible with further screening and construct alterations with 
novobiocin that in the future a structure may be obtained. This is especially true as it has now 
been demonstrated that protein crystals bound to novobiocin and Redx03863 do not give UV 
fluorescence, and hence it is possible that previous positive hits were discarded (Figure 5.3.2). 
However, as there are no crystal structures of this domain available in the PDB it is plausible 
that, like the work presented here, crystal hits were not obtained when using Mtb constructs. 
Regardless, the crystal structure that we obtained here has a strong similarity to its 
corresponding section of the full ATPase domain (3ZKB) previously published (Agrawal et 
al., 2013) suggesting that the Msm and Mth homologues presented here were appropriate 
choices. Furthermore, as the Msm homologue has previously been used for the inhibitor co-
crystal structures (4B6C, 4BAE) it has likely been previously found that the equivalent Mtb 
fragment was difficult to crystallise (Shirude et al., 2013, Hameed et al., 2014). 
 
All three of the crystal structures presented here have two loops regions deleted from the 
constructs to aid with crystallisation (Figure 5.3.1). Previously this strategy has been utilised 
to obtain crystals of the M. smegmatis sub-ATPase domain (Shirude et al., 2013, Hameed et 
al., 2014), although on the full-length ATPase domain from M. tuberculosis this was not 
performed, but these chains are not visible within the structure suggesting them to be flexible 
(Agrawal et al., 2013, Roue et al., 2013). After extensive crystallisation trials with the Mtb 
sub-ATPase domain no crystals were obtained and hence it was decided to progress towards 
loop deletion constructs, which although they do not contain the full biological relevance, the 
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loops in question do not appear to alter the binding of either novobiocin or Redx03863, nor 
does the second longer loop appear in other species such as E. coli and S. aureus.  
 
5.10.4 Understanding the binding site of novobiocin through crystallographic analysis 
The binding pockets presented in the two crystal structures of novobiocin presented here have 
close similarities to those previously presented for novobiocin and like many people before us 
we have demonstrated the involvement of R141 (R136 in E. coli) in the binding (Table 5.10.1). 
Our enzymatic studies have further confirmed this showing that no inhibition was seen at 3 
µM novobiocin in comparison to full inhibition of the wild type at this concentration (Figure 
5.8.3). Through our crystal structures presented here we have been able to further rationalise 
the involvement of E87 and D79 through direct hydrogen bonding (Table 5.10.1), as well as, 
V125 through steric hindrance. In the limited amount of time we had we were unable to 
confirm the exact mechanism of several of the other reported resistance mutations such as 
G168 and S169 (Table 5.10.1), although we suggest that they must act through long range 
interactions such as altering a stable hydrogen bonding network or a conformational change.  
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Table 5.10.1 
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5.10.5 Understanding the binding site of Redx03863 through crystallographic analysis 
and mutagenesis of GyrB 
From analysing the solved crystal structure containing Redx03863 and, in comparison with 
the published structure of 4KSG containing the TriBE compound C4 we made several mutants 
(Tari et al., 2013a). However, these mutants appeared inactive in supercoiling when assayed 
at a concentration of 200 nM for 30 mins at 37°C. On comparison to the 3ZKB Mtb crystal 
structure with AMP-PNP it appears that the mutants made may also have important 
interactions with ATP causing them to be inactive in supercoiling (Agrawal et al., 2013). 
Additionally, a comprehensive study of the ATP-binding site through mutagenesis has 
indicated that supercoiling was not permissive in mutating the N46, E50, D73 or R76 residues 
of E. coli DNA gyrase, which correspond to the residues of N52, E56, D79 and R82 which 
were mutated in this study (Table 5.10.1) (Gross et al., 2003). However, several of the residues 
had low-level ATPase activity and hence they were able to confirm that the E50A, D73E and 
R76A all resulted in a significant increase in the apparent IC50 value of novobiocin within the 
ATPase reaction. Initially, it was attempted to perform the SDM in the GyrBA plasmid, 
unfortunately this was unsuccessful, and as the ATPase reaction was problematic giving very 
low ATP turnover when using the individual wild-type Mtb subunits before mutagenesis it 
was decided not to carry out these experiments. On the other hand, from analysing the crystal 
structure it indicated that the G83S mutant obtained from bacterial mutagenesis may result in 
significant resistance to Redx03863 and likely Redx04739 (Table 5.10.1). The carbonyl group 
on the glycine is 4.3 Å away from the compound, meanwhile the amino group is 3.9 Å from 
the ether oxygen. In the published structure of E. faecalis GyrB24 the same interactions with 
C4 of the original TriBE series are 3.9 Å and 4.3 Å suggesting that these could be important 
interactions (Tari et al., 2013a). It is unlikely that the serine side chain would directly interact 
with the compounds as it is likely to point away from the compound, however, it is possible 
that it would alter other surrounding interactions that would directly change the binding 
interactions of the main chain with these compounds. Overall, it is suggested that the G83S 
mutant protein should be further optimised to try and obtain better levels of supercoiling that 
would be possible to be used within an inhibition of supercoiling reaction to determine if there 
is any increase in the IC50 value in the presence of this individual mutant. 
 
The novobiocin binding residue of R141 appears not to interact with Redx03863 or 
Redx04739 in binding. This has been confirmed using inhibition of supercoiling reactions 
with the R141A/Q mutants which do not give resistance to either compound. Likewise, the 
structure presented here of Redx03863 bound to the Mth domain suggests that the distance 
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between this residue and Redx03863 would be too large for a hydrogen bonding interaction 
such as the one seen in the novobiocin bound structures (Table 5.10.1). 
 
5.10.6 Implications of the binding sites  
The binding site of novobiocin has previously been crystallised in other species agreeing with 
the novobiocin-binding site presented here (Holdgate et al., 1997, Lamour et al., 2002, Lu et 
al., 2014). Additionally, the mutagenesis results presented here confirm that this is the correct 
binding site as previously presented in the literature (del Castillo et al., 1991, Contreras and 
Maxwell, 1992, Munoz et al., 1995, Stieger et al., 1996, Fujimoto-Nakamura et al., 2005). 
The crystal structure presented appears to support the idea that R141 is not involved in the 
binding of Redx03863 as the distance between the two species is greater than 4 Å and no 
resistance was obtained when the mutant proteins were analysed. However, the likely binding 
pocket of Redx03863 has a degree of overlap with those of ATP and novobiocin. Overall, this 
leaves compelling evidence for the crystallographic binding site which unfortunately we have 
been unable to confirm via site directed mutagenesis due to the high degree of sensitivity of 
the mutants in this area due to interactions with ATP.  
 
The structural alignments also show that there is the potential for Redx03863 to inhibit human 
topo IIα in addition to the bacterial topoisomerases DNA gyrase and topo IV. However, one 
of the key binding interactions - the aspartic acid (D79) in the Mth structure is presented as an 
asparagine (N120) in the human structure, hence there is a strong possibility that the binding 
and inhibition of Redx03863 may be weaker against human topo IIα. However, this does raise 
significant concerns over the safety of the use of this compound series clinically in humans. 
To confirm this in the future it would be important to test the inhibition of these compounds 
against both Human topo IIα and topo IIβ. Furthermore, additional toxicity tests should be 
utilised to determine the safety of these compounds before further optimisation and hopefully 
developing in pre-clinical testing. 
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6. Discussion 
The work presented in this thesis has used three interlinked areas of study in the form of 
mechanistic, inhibition and structural studies to further our knowledge of DNA gyrase from 
mycobacteria. These studies have built upon the previous studies of Mtb DNA gyrase in terms 
of mechanistic and inhibition studies, meanwhile, although we were unable in the scope of 
this work to advance our structural knowledge of Mtb DNA gyrase, we have instead worked 
towards a place where we may be able to in the future by investigating the structures of other 
mycobacterial species. 
 
6.1 Mechanistic studies of DNA gyrase from M. tuberculosis 
From a mechanistic point of view, we sought to confirm the previous characterisations of 
DNA gyrase (Aubry et al., 2006a), and advance this in terms of using the Mtb DNA gyrase 
fusion protein. From these studies it is clear that our enzymes behaved similarly to previous 
results, with a single omission coming from the results of the ATPase assay. Formerly, it was 
believed that the ATPase activity of Mtb DNA gyrase was very low and unsuitable for 
inhibition studies (Agrawal et al., 2013, Karkare et al., 2013b, Shirude et al., 2013). We 
however, have made an interesting discovery that using a stock of concentrated pure protein 
it is possible to obtain a detectable ATP turnover significantly greater than previously 
determined. In addition, when the reaction was carried out with the fusion protein with a 
topologically unconstrained substrate this rate was determined to be consistently high enough 
to be used for inhibition studies. It is unclear at the current time as to why we observe a 
difference in the ATP turnover from the reconstituted subunits and the fusion protein, however 
we suggest two preliminary explanations for this. The first of these arises from the possibility 
that the fusion proteins are purified to a greater level and hence a greater portion of the ATPase 
rate can be inhibited by novobiocin and hence it makes it appear artificially more active. On 
the other hand, it is also possible that by fusing the two subunits it is also possible that this has 
altered the dynamics of the reaction cycle making it more favourable to carry out the 
supercoiling, and hence the ATPase reaction. At this point in time neither of these explanations 
can be discarded, however, it can be considered that this is the first study to our knowledge of 
the ATPase activity of a DNA gyrase fusion protein. 
 
Whilst determining the ATPase activity from M. tuberculosis DNA gyrase it became apparent 
to us that both the presence and the topological state of DNA were important in stimulating 
this reaction. Previously it has been implied that this is also the case in E. coli DNA gyrase 
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with the presence of either topologically unconstrained double stranded DNA or a relaxed 
plasmid being suggested as the optimal substrates for inducing the ATPase activity (Sugino 
and Cozzarelli, 1980). Our results suggest that the best substrate for Mtb DNA gyrase is 
topologically unconstrained double-stranded DNA. Constrained plasmids appear to be rapidly 
converted into negatively-supercoiled DNA which is a poor stimulator of Mtb DNA gyrase 
and gives a background rate only marginally greater than the enzyme in the absence of DNA. 
Hence, we suggest that future ATPase inhibition studies should be carried out in the presence 
of linearised or nicked plasmid DNA with the fusion protein. Overall, we suggest that this 
means that the ATPase reaction of Mtb DNA gyrase is highly coupled to the presence of 
relaxed or positively supercoiled DNA, suggesting that the enzyme requires an appropriate 
substrate to be active. 
 
It is known that mycobacteria only encode for two topoisomerases within their genomes (DNA 
gyrase and topo I) (Cole et al., 1998). This has caused many previous researchers to question 
if DNA gyrase is able to compensate for the lost functions of topo IV. Topo IV functions in 
the most part to decatenate and relax DNA in an ATP-dependent manner (Kato et al., 1990). 
Although within the scope of the work presented here and previously it has been shown that 
Mtb DNA gyrase can decatenate DNA, it does not appear that it does this to the same level as 
it is able to negatively supercoil a relaxed plasmid (Aubry et al., 2006a). Likewise, although 
Mtb DNA gyrase can relax negatively supercoiled DNA in an ATP-independent fashion 
(Gellert et al., 1977, Sugino et al., 1977), this reaction is slow and can be rapidly reversed 
through the addition of ATP. It is therefore suggested that Mtb DNA gyrase preferentially 
relaxes positively supercoiled DNA, and may be unable to fully compensate for topo IV in 
terms of relaxing negatively supercoiled DNA. 
 
6.2 DNA gyrase from M. thermoresistibile 
One of the key features of this work was the development of DNA gyrase from the 
thermostable M. thermoresistibile, based on the rationale of Edwards et al. (2012), suggesting 
this to be a strong alternative to Mtb as a source of proteins for structural studies. We have 
demonstrated this clearly to be the case as by using the Mth sub-ATPase domain we were able 
to gain a crystal structure bound to Redx03863, which we were unable to with the Mtb and 
Msm homologues. We suggest that this might also be the case with the true aim of this project 
in solving the full-length structure of mycobacterial DNA gyrase. In addition, the Mth fusion 
protein is an ideal candidate to further exploit in future structural studies using both X-ray 
crystallography and cryoEM. 
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On the other hand, we found that the Mth proteins were marginally more difficult to work with 
in terms of enzymatic assays, as the DNA was found to be difficult to remove from the protein 
under the commonly used assay conditions. Regardless of this, we were able to confirm that 
DNA gyrase from Mth is active with the activity being moderately optimised in terms of 
enzyme concentrations, time, and potassium glutamate concentrations. Additionally, we also 
determined that, like the Mtb proteins, there was no significant difference in the enzymatic 
activity by fusing the subunits together. At this stage we cannot confirm if the ATPase rate 
from the Mth enzyme is reliable and reproducible. 
 
6.3 Inhibition of mycobacterial DNA gyrase 
Possibly the most important section of work presented here comes in the form of inhibition 
studies performed on Mtb DNA gyrase. In the period between 2000-2015 an estimated 49 
million people were saved with antibiotics against M. tuberculosis, however, in 2016 alone 
1.3 million people could not be saved and died of tuberculosis (WHO, 2017). This figure 
combined with rising levels of drug resistant-infections being reported, means that we urgently 
need to develop new antimycobacterial agents. Hence, in the scope of the work presented here 
we compared the clinically used second line fluoroquinolone of moxifloxacin (Gillespie, 
2016), and the formally clinically used aminocoumarin novobiocin (Food and Drug 
Administration, 2011) to the novel compound classes of the naphthoquinones (Lall et al., 
2005, Karkare et al., 2013b) and the TriBE antibiotics optimised by Redx AntiInfectives (Tari 
et al., 2013a). 
 
6.3.1 Prospects for the naphthoquinone antibiotic class 
From the work presented here it is clear that the naphthoquinone 7-methyljuglone is not a 
viable option for development into a novel antibiotic. Previous work suggests that these 
compounds are highly unstable in a range of solvents, which we were able to confirm through 
enzymatic assays (van der Kooy, 2007). We therefore suggest that the compound that is active 
against DNA gyrase is not 7-methyljuglone but a resulting derivative or breakdown product. 
As in the scope of this work we were unable to confirm the exact composition of the active 
fraction we therefore propose that this is not a viable option to be taken forwards for further 
investigations. Furthermore, we were unable to confirm the binding pocket of these 
compounds by mutagenesis as we could not obtain a stable and active compound to test the 
model against. 
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6.3.2 The TriBE antibiotics optimised by Redx AntiInfectives 
A substantial proportion of the inhibition studies conducted here used the novel TriBE 
antibiotics of Redx03863 and Redx04739. These have potent activity against whole cell 
mycobacteria as well as against mycobacterial DNA gyrase in both the ATPase and 
supercoiling reactions but not the ATP-independent relaxation reaction. Of the compounds 
tested these compounds present the best opportunity to develop a new clinical 
antimycobacterial compound. These compounds are highly efficient at killing both whole cells 
in MIC testing on agar and in broth as well as having significant activity in killing established 
biofilms. However, there are additional issues with these compounds going forwards, 
including the uncomfortably high frequency of resistance values, suggesting that resistance is 
highly likely to develop, and a non-optimal mechanism of action. These compounds are 
ATPase inhibitors like the aminocoumarin novobiocin, which was withdrawn from clinical 
use against methicillin-resistant S. aureus based on toxicity issues (David and Burgner, 1956, 
Maxwell, 1993, Food and Drug Administration, 2011, Chopra et al., 2012). As DNA gyrase 
is a member of the GHKL ATPase family there is a significant likelihood that any ATPase 
inhibitors of DNA gyrase will have activity against other members of this family (Dutta and 
Inouye, 2000). Likewise, as a type IIA topoisomerase DNA gyrase has significant structural 
homology to eukaryotic topo II enzyme including human topo IIα and β there is a strong 
chance of inhibition of these enzymes causing adverse effects (Wei et al., 2005). Furthermore, 
the structural analysis carried out on the Redx03863 structure suggests that cross susceptibility 
could be an issue with human topo IIα, which should be tested in the future. 
 
One of the biggest challenges of this section of work has been to elucidate the binding pocket 
of both Redx03863 and Redx04739. From combining the proposed mechanism of action of 
competitive inhibition of the ATPase reaction, the preliminary SPR results indicating that 
Redx04739 binds to the sub-ATPase domain of Mtb GyrB, and the crystal structure of 
Redx03863 bound to the sub-ATPase domain of Mth GyrB we believe that we have likely 
determined the binding site of these compounds. However, using bacterial mutagenesis we 
have only determined one mutation in the proposed binding site (G83S) which appears to be 
almost completely inactive in supercoiling. Additionally, all the mutants identified through 
analysis of the crystal structure are inactive in both ATPase and supercoiling activity, hence 
we were unable to definitively confirm the binding site at this time. Despite this, we believe 
it probably has incomplete overlap with the aminocoumarin binding pocket. We suggest that 
in the future it would be important to optimise the little supercoiling activity the G83S mutant 
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presents with to confirm the binding site. Previously this mutant in E. coli (G77S) was 
described to have ATPase activity of 10% of the wild type enzyme, and supercoiling activity 
requiring a 10x increase in protein concentration, as well as, weak complementation of a 
temperature sensitive mutation (Gross et al., 2003). Overall, this suggests that it is likely that 
we should be able to confirm the binding site in the future. Due to the challenges we faced 
with the SPR experiments we do not propose to use this method to confirm the binding site in 
the future. 
 
Overall, we suggest that these compounds are unlikely to advance towards clinical trials in the 
future due to concerns with toxicity, spontaneous resistance due to the mechanism of action, 
and their poor solubility. Regardless of these concerns, these compounds show some promise 
and it may be possible to optimise them further to alleviate some of these problems. 
Additionally, if this is not possible there may be potential to develop these compounds for 
alternative uses in the future instead, such as anticancer drugs targeting human topo IIα if it 
was proved that they also inhibit this enzyme. Likewise, with the presence of DNA gyrase in 
plants these compounds may be useful as herbicides in the future (Wall et al., 2004). 
 
6.4 Structural studies on mycobacterial DNA gyrase 
In the scope of the work presented here, we were unable to solve the full-length high-
resolution structure of mycobacterial DNA gyrase as we were unable to determine conditions 
that enabled the growth of protein crystals. Furthermore, due to the lack of availability we 
were unable to perform cryoEM studies on these proteins either. From the limited 
crystallisation attempts that were made with both the Mtb and Mth fusion proteins it is clear 
that there are many variables of which only a few have been fully explored and that another 
ten years could easily be spent attempting to generate a crystal. Therefore, we propose that 
with the recent improvements to cryoEM technology in recent years (reviewed in (Renaud et 
al., 2018)), that although DNA gyrase is relatively small and likely only has a two-fold 
symmetry axis, it is an exciting candidate for use within this growing technique. However, it 
has already been shown that DNA gyrase is not an optimal candidate for cryoEM and that the 
addition of DNA is important in stabilising the enzyme (Papillon et al., 2013). This leads us 
to suggest that in future structural studies (crystallography and cryoEM) that a DNA fragment 
capable of wrapping the C-terminal domains and a non-hydrolysable ATP analogue such as 
AMP-PNP should be included in the conditions. Overall, we acknowledge that the 
crystallisation conditions trialled in the scope of this project were not extensive, and that 
further trials should be investigated in an attempt to determine the full-length high-resolution 
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structure of mycobacterial DNA gyrase via X-ray crystallography alongside optimisations 
using cryoEM. 
 
In contrast with the unsuccessful structural studies of the full-length enzyme, we had increased 
success in generating new structures of the ATPase domain of mycobacterial DNA gyrase. 
Two of these structures were bound to the known inhibitor of novobiocin, which were solved 
at superior resolution to the previously available structures (Lewis et al., 1996, Holdgate et 
al., 1997, Tsai et al., 1997). These structures confirmed our current knowledge of the sub-
ATPase domain and the novobiocin binding site. In addition, we solved the structure of the 
sub-ATPase domain bound to the novel compound Redx03863 confirming the 
crystallographic binding site of the TriBE compounds (Tari et al., 2013a), however, in the 
absence of an active resistance mutant we are unable to confirm this model. Unfortunately, 
we were unable to co-crystallise Redx04739 in either of the GyrB24 sub-ATPase domain 
constructs due to its low solubility, confirming it to be unlikely to progress further towards 
clinical trials. 
 
6.5 Are we closer to a new antimycobacterial drug? 
The biggest goal of this project was to head closer to generating a new antimycobacterial agent 
that will help to save millions more patients with the goal of ending epidemic tuberculosis by 
2030, which forms part of goal 3 of the sustainable development goals (WHO, 2017). 
However, we acknowledge that our part in this long-term goal is very small and has not yielded 
a new drug. We have however, ventured into lesser explored chemistries including those from 
the naphthoquinones and the pyrrolopyrimidine TriBE inhibitors. Although neither of these is 
likely to progress beyond laboratory testing, they have provided useful advancements in our 
knowledge of mycobacterial DNA gyrase beyond the immediate compounds, which can be 
used in future experiments and drug discovery efforts. These include the discovery that 
reliable and measurable ATPase rates can be obtained from M. tuberculosis DNA gyrase using 
the fusion construct; a crystallisable construct that yields reproducible crystals of the sub-
ATPase domain from M. thermoresistibile; and the adaption of several bacteriology 
techniques to determine inhibition of the slow growing M. smegmatis. Finally, we have also 
worked to perform initial characterisations on M. thermoresistibile DNA gyrase which we 
strongly believe will help in the search for a full-length high-resolution structure of DNA 
gyrase in the future. 
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